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Abstract 
 
Acrylamide (AA) has been classified as a probable human carcinogen by IARC. 
Besides being used in numerous industrial applications, AA is also present in a variety 
of starchy cooked foods. This AA exposure scenario raised concerns about risk in 
human health and suggests that the oral consumption of AA is an additional risk factor 
for cancer. A considerable number of findings strongly suggest that the reactive 
metabolite glycidamide (GA), an epoxide generated presumably by cytochrome P450 
2E1, plays a central role in AA carcinogenesis. 
Until now there are a scarcity of results concerning the mechanisms of 
genotoxicity of AA and GA in mammalian cells. In view of that, the study described in 
this thesis aims to unveil the genetic consequences of AA and GA exposure using 
mammalian cells as a model system. 
With this aim we evaluated the cytotoxicity of AA and GA using the MTT assay 
and subsequently performed two cytogenetic end-points: chromosomal aberrations 
(CAs) and sister chromatid exchanges (SCEs), in order to evaluate DNA damage 
induced by these compounds in V79 Chinese hamster cell line. The results showed that 
GA was more cytotoxic and clastogenic than AA. 
Within the scope of this thesis the quantification of specific DNA adducts were 
also performed, namely N7-(2-carbamoyl-2-hydroxyethyl)guanine (N7-GA-Gua) and 
N3-(2-carbamoyl-2-hydroxyethyl)adenine (N3-GA-Ade). Interestingly, the GA 
concentration and the levels of N7-GA-Gua presented a linear dose-response 
relationship. Further, a very good correlation between the levels of N7-GA-Gua and the 
extent of SCEs were observed. 
In order to understand the mechanisms of AA-induced toxicity, the modulation 
of reduced glutathione (GSH)-dependent mechanisms were studied, namely the 
evaluation of the effect of buthionine sulfoximine (BSO), an effective inhibitor of GSH 
synthesis, of GSH-monoethyl ester (GSH-EE), a cell permeable compound that is 
intracellularly hydrolysed to GSH and also of GSH endogenously added to culture 
medium,z in V79 cell line. The overall results reinforced the role of GSH in the 
modulation of the cytotoxic and clastogenic effects induced by AA. 
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Complementary to the studies performed in V79 cells, SCEs, specific DNA-
adducts and alkaline comet assay in lymphocytes from healthy donors exposed to AA 
and GA were also evaluated. Both, the frequency of SCE and the quantification of 
specific GA DNA adducts, produced comparable results with those obtained in V79 cell 
line, reinforcing the idea that GA is far more genotoxic than AA. Further, the DNA 
damaging potential of AA and GA in whole blood leukocytes evaluated by the alkaline 
comet assay, showed that GA, but not AA, increases DNA damage.  
Additionally, this study aimed to identify associations between DNA damage 
and biomarkers of susceptibility, concerning individual genetic polymorphisms 
involved in detoxification and DNA repair pathways (BER, NER, HRR and NHEJ) on 
the GA-induced genotoxicity assessed by the SCE assay and by the alkaline comet 
assay. The extent of DNA damage determined by the levels of SCEs induced by GA 
seems to be modulated by GSTP1 (Ile105Val) and GSTA2 (Glu210Ala) genotypes. 
Moreover, the results obtained from the comet assay suggested associations between 
DNA damage and polymorphisms of BER (MUTYH Gln335His and XRCC1 
Gln399Arg) and NER (XPC Ala499Val and Lys939Gln) genes, either alone or in 
combination. 
The overall results from this study contribute to a better understanding of the 
genotoxicity and carcinogenicity of AA and GA in mammalian cells, as well as the 
knowledge about the variability in individual susceptibility involved in detoxification 
and repair of DNA damage due to these dietary xenobiotics.  
 
 
 
 
 
 
 
Keywords: acrylamide; glycidamide; sister chromatid exchange; chromosomal 
aberrations; DNA-adducts; comet assay; SNPs; genotoxicity; carcinogenicity.  
 
iii 
 
Resumo 
 
Em 1994 a acrilamida (AA) foi classificada pela IARC como um provável 
cancerígeno para o homem. Para além da utilização de AA em numerosas aplicações 
industriais, a AA está também presente numa grande variedade de alimentos ricos em 
amido e processados a temperaturas elevadas. Esta exposição através da ingestão de 
produtos alimentares despoletou elevadas preocupações ao nível do risco para a saúde 
pública e poderá implicar um risco adicional para o aparecimento de cancro. A 
glicidamida (GA), o metabolito epóxido formado a partir da oxidação da AA 
provavelmente através do citocromo P450 2E1, é considerada por vários estudos, o 
principal responsável pela carcinogenicidade da AA.  
Actualmente existe uma escassez de resultados relativamente aos mecanismos de 
genotoxicidade da AA e GA em células de mamífero. Por este motivo, o objectivo deste 
estudo centra-se na avaliação das consequências genéticas da exposição à AA e GA, 
recorrendo-se para tal ao uso de células de mamífero como modelo. 
Tendo como base este objectivo avaliou-se a citotoxicidade da AA e GA, através 
do ensaio do MTT, e realizaram-se dois testes citogenéticos, o teste das aberrações 
cromossómicas (CAs) e o teste da troca de cromátides irmãs (SCEs), de modo a avaliar 
as lesões de DNA induzidas por estes compostos em células de hamster Chinês V79. Os 
resultados globalmente mostraram que a GA é mais citotóxica e clastogénica do que a 
AA. 
No âmbito deste trabalho, foi também efectuada a quantificação de aductos 
específicos de DNA, nomeadamente N7-(2-carbamoil-2-hidroxietil)guanina (N7-GA-
Gua) e N3-(2-carbamoil-2-hidroxietil)adenina (N3-GA-Ade). Os resultados obtidos 
permitem afirmar que os níveis de N7-GA-Gua e a concentração de GA apresentam 
uma relação linear dose-resposta. Foi também identificada uma óptima correlação entre 
os níveis de N7-GA-Gua e a frequência de troca de cromátides irmãs. 
Adicionalmente, e de forma a compreender os mecanismos de toxicidade da AA, 
estudaram-se os mecanismos dependentes da modulação do glutationo reduzido (GSH), 
nomeadamente da butionina sulfoximina (BSO), um inibidor da síntese de GSH, do 
GSH-monoetil estér (GSH-EE), um composto permeável nas células e que é intra-
celularmente hidrolisado a GSH e ainda do GSH adicionado exogenamente ao meio de 
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cultura, em células V79. Os resultados obtidos reforçaram o papel da modulação do 
GSH nos efeitos de citotoxicidade e clastogenicidade da AA. 
Para além dos estudos efetuados com células V79, procedeu-se também à 
determinação da frequência de SCEs, à quantificação de aductos específicos de DNA, 
bem como ao ensaio do cometa alcalino em amostras de dadores saudáveis expostos à 
AA e GA. Tanto os resultados obtidos através do ensaio das SCE, como pela 
quantificação de aductos específicos de DNA, ambos efectuados em linfócitos 
estimulados, originaram resultados comparáveis aos obtidos anteriormente para as 
células V79, reforçando a ideia de que a GA é bastante mais genotóxica do que a AA. 
Por outro lado, os resultados obtidos pelo ensaio do cometa para exposição à AA e GA 
mostraram que apenas esta última aumenta o nível das lesões de DNA. 
Outro objectivo deste trabalho, foi a identificação de possíveis associações 
existentes entre as lesões de DNA, quantificadas através do ensaio das SCEs e do 
cometa, e biomarcadores de susceptibilidade, tendo em conta os polimorfismos 
genéticos individuais envolvidos na destoxificação e nas vias de reparação do DNA 
(BER, NER, HRR e NHEJ) em linfócitos expostos à GA. Tal permitiu identificar 
associações entre os níveis de lesão de DNA determinados através do ensaio das SCEs, 
e os polimorfismos genéticos estudados, apontando para uma possível associação entre 
o GSTP1 (Ile105Val) e GSTA2 (Glu210Ala) e a frequência de SCEs. Por outro lado, os 
resultados obtidos através do ensaio do cometa sugerem uma associação entre as lesões 
de DNA e polimorfismos da via BER (MUTYH Gln335His e XRCC1 Gln39Arg) e da 
via NER (XPC Ala499val e Lys939Gln), considerando os genes isoladamente ou 
combinados. 
Estes estudos contribuem para um melhor entendimento da genotoxicidade e 
carcinogenicidade da AA e GA em células de mamífero, bem como da variabilidade da 
susceptibilidade individual na destoxificação e reparação de lesões de DNA provocadas 
pela exposição a estes xenobióticos alimentares. 
Palavras chave: acrilamida; glicidamida; troca de cromátides irmãs; aberrações 
cromossómicas, aductos de DNA; ensaio do cometa; SNPs; genotoxicidade; 
carcinogenicidade.   
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1.1. Causes of Cancer 
 
1.1.1. Principles 
 
Cancer is a leading cause of death all over the world and is characterized by 
uncontrolled cellular growth as a result of changes in the genetic and epigenetic 
information of cells. Each year, tens of millions of people are diagnosed with cancer and 
more than half of the patients eventually die from it. Moreover, cancer rates could 
further increase by 50% to 15 million new cases in the year 2020, according to the 
World Cancer Report [1, 2]. 
It is known that about 5-10% of all cancers are caused by genetic defects, while 
90-95% are caused by environmental factors and lifestyle, including diet (30-35%), 
tobacco smoking (25-30%) and alcohol (4-6%) [1]. Cancer related with genetic defects 
can result directly from inherited mutated genes. However, the majority involves 
alterations or damage accumulation over time of the genetic material within cells [3]. 
This damage can be caused by both endogenous (internal) and exogenous 
(environmental) factors, known as important for cancer development [1]. The 
endogenous causes can be inherited germ line mutation, oxidative stress, generated 
through normal oxidative metabolism and pathophysiologic states, such as 
inflammation [1, 3]. There are also several known exogenous factors including tobacco 
smoking, infectious agents (e.g. viruses, bacteria and parasites), drug intake, radiation, 
that can damage DNA, both directly by causing breaks in DNA strands and indirectly 
by interacting with water molecules and generating reactive oxygen species (ROS), 
industrial chemicals and carcinogenic agents in food and drink that are established as 
carcinogenic by IARC [3].  
Already in 1981 Doll and Peto [4] identified and attempted to quantify the 
causes of cancer. The factors related with cancer and their relation with the proportions 
of cancer deaths are listed in next table.  
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Table I.1-Proportions of cancer deaths attributed to various different factors, according 
to Doll and Peto (from [4]). 
 
Factor or class of factors Percent of all cancer deaths 
Best estimate Range of acceptable estimates 
Tobacco 30 25-40 
Alcohol 3 2-4 
Diet 35 10-70 
Food additives <1 -5-2 
a
 
Reproductive and sexual 
behavior 
7 1-13 
Occupation 4 2-8 
Pollution 2 <1-5 
Industrial products <1 <1-2 
Medicines and medical 
procedures 
1 0.5-3 
Geophysical factors 
b 
3 2-4 
Infection 10? 1-? 
Unknown ? ? 
a 
Allowing for a possibly protective effect of antioxidants and other preservatives. 
b
 Only about 1% could reasonably be described as “avoidable”. Geophysical factors also 
cause a much greater proportion of nonfatal cancers (up to 30% of all cancers, depending on 
ethnic mix and latitude) because of the importance of UV light in causing the relatively nonfatal 
basal cell and squamous cell carcinomas of sunlight-exposed skin. 
 
According to the previous table, the cause of 97% of all human cancers is 
explainable and it was estimated that 35% of cancer deaths might be avoidable through 
changes in diet [4-6]. Diet has long been recognized as potentially important modifiers 
of cancer risk, beyond that, human beings are often being exposed to carcinogenic 
factors during their life, some of which are nutritional factors [1]. It is important to note 
that during their life a human being ingests about 15 tons of dry matter in the form of 
food [7]. Although many foodstuffs contain genotoxic compounds, the majority of these 
only occur at low levels, however, multiple genotoxic substances in the same food may 
result in cumulative or synergistic actions leading to neoplasia in humans [8]. These 
findings moved attention away from environmental factors such as pollution or viruses 
or occupational factors, and turned the focus instead onto dietary factors as a major 
contributor to disease risk [9]. In the same way, through the 1970s and 1980s, many 
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chemicals from various sources (e.g. environment, occupation and diet) were tested for 
mutagenic effects with the Ames test and concluded that natural chemicals, present in 
human diet as complex mixtures may be a more important source of human mutation 
than environmental or occupational exposure [9].  
 
 
1.1.2. Food contaminants 
 
Food contaminants can be classified as genotoxic and non-genotoxic mutagens 
according to the mechanistic view of carcinogenesis. Genotoxic agents begin their 
action at the DNA level, causing DNA damage (gene point mutations, deletions and 
insertions, recombination, rearrangements and amplifications, as well as chromosomal 
aberrations). Non-genotoxic agents presumably affect indirectly the cell through tumor 
promoters, however their modes of action are less defined. These non-genotoxic agents 
are generally macro-components, e.g. high fat [1]. 
Genotoxic mutagens are frequently natural products that can be avoided. For 
instance, through fungal contamination, mycotoxins (e.g. Aflatoxin B1); or 
anthropogenic chemicals produced through cooking or preserving methods, (e.g. 
heterocyclic amines (HCAs), polycyclic aromatic hydrocarbons (PAHs), N-nitroso 
compounds (NOCs) and AA). On the other hand, there are also genotoxic mutagens in 
natural products that can be present in food and are unavoidable (e.g. Ptaquiloside and 
Pyrrolizidine alkaloids (PAs)). Furthermore, there are chemicals intentionally added to 
foods or food coloring, that can act as genotoxic agents, however these cause much less 
concern, since they are added intentionally [1, 5, 9, 10].  
One of the most important genotoxic food carcinogens is aflatoxin B1 (AFB1). 
This mycotoxin is produced by the mold Aspargelius flavus, which grows on poorly 
(hot and humid climate) stored foods including corn, peanuts and rice [1, 9]. Through 
epidemiologic studies, AFB1 has shown to increase carcinogenic risk in humans. These 
toxins proved to be very important liver carcinogens, especially in combination with 
chronic infection with hepatitis B virus [11-17]. AFB1 initiates its action with metabolic 
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activation by cytochrome P450, forming an exo-8,9-epoxide and subsequent adduct 
formation producing DNA damage [18, 19].  
Other important carcinogenic formed within muscle foods (beef, lamb, and 
poultry, but also in fish) cooked at high temperatures (e.g. frying, broiling and 
barbecuing) are the heterocyclic amines [1, 5, 9, 10]. These are formed through a 
pyrolysis process from amino acids, proteins and creatines of the meat. In humans there 
is good epidemiologic evidence correlating the consumption of food containing high 
levels of HCAs and cancer, namely colorectal [14, 20-24], breast [25-27], prostate [14, 
28-30] and pancreatic cancers [31-33]. HCA carcinogenesis mechanism encompasses a 
bioactivation of N-hydroxylation by CYP1A2 and subsequent esterification. The 
nitrenium ion is likely the ultimate carcinogen, capable of binding guanine at position 
C8, causing altered DNA sequences with subsequent base substitution, deletion and 
insertion [1, 34]. 
PAH compounds are also considered food carcinogens formed during 
incomplete combustion of organic matter during food processing (smoking, barbecuing 
and grilling). PAH can also be found in wood fires, automobile exhaust, tobacco smoke 
and occur as environmental contaminants on food plants (e.g., cereals and vegetable) [1, 
9, 35]. In humans there is some evidence of association of dietary PAH exposure with 
colon cancer [36, 37]. Carcinogenesis mechanism of PAHs is conducted through 
benzo(a)pirene (BaP) adduct formation, after being activated by CYP1A and CYP1B 
enzymes. This adduct is associated with site-specific hotspot mutation in p53 tumor 
suppressor gene [1]. 
Another important food carcinogen are N-nitroso compounds which can be 
found in a wide variety of foods, like salted, smoked or dried fish and meat [9]. 
Moreover, NOCs can be formed in vivo during simultaneous ingestion of nitrite or 
nitrogen oxides and a nitrosable substrate such as a secondary amine [38]. Various types 
of cancer (lung, liver, kidney, mammary gland, among others) have been observed and 
related to NOCs in humans [1, 39, 40]. The common carcinogenic mechanism of N-
nitrosamines requires metabolic activation through hydroxylation. This is catalyzed 
mainly by CYP2E1, but other cytochrome P450 isoforms including CYP2A6 have been 
implicated. N-nitrosodimethylamine undergoes enzymatic hydroxylation and 
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subsequent hydrolysis to aldehyde and monoalkylnytrosamine that rearranges and 
releases a carbocation that is reactive toward DNA bases. [1, 38]. 
Acrylamide is another important carcinogen formed through cooking, identified 
in starch-based foods such as potato chips and French fries cooked using high 
temperature deep-frying, grill and baking methods [35]. Acrylamide is clearly an animal 
carcinogen and a neurotoxin. However, extrapolation of effects in cell systems and in 
animals to effects in humans has been controversial [9]. This compound is the main 
focus of the present study and because of its importance in the development of this 
thesis, a more explanatory chapter will be developed ahead (chapter point 1.5.). 
Despite the great importance attributed to the existence of food genotoxic 
agents, the relevance of the absence of some dietary components should also been taken 
into account, especially micronutrients, that can be related with increased cancer risk. 
Folate deficiency is well known as one of the most common vitamin deficiencies, which 
contributes to chromosomal instability and may increase susceptibility to radiation-
induced DNA damage [9, 41]. Folate deficiency may contribute to carcinogenesis by 
causing DNA hypo-methylation and proto-oncogene activation or by inducing uracil 
misincorporation during DNA synthesis [41]. Another, equally important deficiency is 
the lack of selenium, which has been linked with increased cancer risk. Some studies 
reported selenium supplementation as protective against the development of cancer at 
numerous sites including prostate, colon, and lung. Although the mechanisms of 
chemoprevention by selenium remain unclear, enhanced protection against oxidative 
stress may be involved [42, 43].  
As a general conclusion, one can say that conventional epidemiology can show 
association between cancer and some types of food, and/or with cooking process. 
However, these are not constitutive proofs of cause and effect. It is difficult, if not 
impossible, to attribute such results with certainty to any specific compound, since food 
is a complex mixture [9]. Many food components have already genotoxic potential and 
more can be produced endogenously during digestion [5]. There is increasing evidence 
that consumption of some foods, like fresh fruits and vegetables may decrease the risk 
of cancer. In the same way, a number of plant constituents have been shown to have the 
potential to inhibit various stages of the carcinogenic process [5]. Consequently, the risk 
of cancer related with nutrition outcome from an imbalance of carcinogenesis and anti-
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carcinogenesis process [1]. Nevertheless, the role of food and nutrition in the 
modification of the cancer process is very complex [5]. 
 
 
1.2. Biomarkers of genetic DNA damage 
 
1.2.1. Principles 
 
The National Academy of Sciences defines a biomarker as a xenobiotically 
induced alteration in cellular or biochemical components or processes, structures or 
functions that is measurable in a biological system or sample, this means that 
biomarkers are observable endpoints that indicate events in the processes leading to 
disease [44, 45]. 
Biomarkers are becoming increasingly important in toxicology and human 
health and many research groups are carrying out studies to develop biomarkers of 
exposure to chemicals and apply these for human biomonitoring [46]. Biological 
monitoring has advantages over environmental monitoring because it measures the 
internal dose of a compound. However, is important take into account the inter-
individual differences in absorption, bioavailability, excretion and DNA repair [44].  
Biomarkers used in human health studies are typically divided into three classes: 
biomarkers of exposure, effect and susceptibility (Fig. 1.1), depending on their 
toxicological significance, whose concepts will be developed later. 
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Fig. 1.1- Relation of events and biomarker classification (adapted from [46]). 
 
Susceptible individuals could be identified by biomonitoring and molecular 
epidemiology, particularly those suffering a combination of high risk factors, namely a 
high level of exposure to chemicals, inherited cancer predisposing genes and a 
deficiency of protective factors. Individual susceptibility factors can influence all the 
stages between exposure and the onset of disease (Fig. 1.1) [46]. 
 
 
1.2.2. Biomarker of exposure 
 
A biomarker of exposure is a chemical, its metabolite or the product of an 
interaction between a chemical and some target molecule or macromolecule that is 
measured in a compartment or a fluid of an organism [45]. It involves measurements of 
the internal dose by chemical analysis of the parent compound, metabolites or DNA or 
protein adducts in body fluids or excreta such as blood, urine and exhaled air [44, 47]. 
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Biomarkers of exposure can be divided into biomarkers of internal dose and biomarkers 
of biological effective dose [46, 48]. 
 
 
1.2.2.1. Biomarkers of internal dose 
Biomarkers of internal dose are indicative of the occurrence and extent of 
exposure of the organism [48]. These markers indicate the actual exposure to a 
particular compound that occurred by measuring the compound or its metabolite(s) in 
body fluids. However these biomarkers do not reveal to what extent the metabolized 
agent has affected the target tissue or cells [48]. One example is the measurement of the 
excretion of 1-hydroxypyrene, an urinary metabolite that is widely used for 
measurement of exposure of PAHs. The excretion of this metabolite was found to 
correlate well with PAHs exposure. Another example is mercapturic acids in urine that 
have also been used for monitoring exposure to a number of specific chemicals, for 
example epichlorohydrin and styrene [46]. 
 
 
1.2.2.2. Biomarkers of effective dose 
Biomarkers of effective dose are indicative of the extend of exposure of the 
target molecule, structure or cell [48]. These biomarkers included the measurement of 
adducts formed by the reaction products of alkylation of endogenous or exogenous 
chemicals compounds, often called alkylating agents, and cellular macromolecules, such 
as proteins and DNA [49, 50], giving rise to hemoglobin (Hb) and DNA adducts. The 
alkylation occurs between the nucleophilic atoms (nitrogen, oxygen, or sulfur) within 
the biomolecule and an electrophilic atom in the reactive molecule [49]. This is 
especially useful, since represents the dose that has escaped the detoxification process 
and that has reached the macromolecule [46]. 
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DNA adducts 
It is well known that genotoxic carcinogens-like alkylating agents or epoxides 
initiate tumorigenesis by reacting with nucleophilic sites of DNA and by generating 
DNA adducts [51]. Besides the DNA adducts that can be formed from alkylating agents, 
numerous DNA adducts are also formed endogenously, for example from the 
methylating factor S-adenosylmethionine or by oxidative metabolism that produces 
ROS [49]. 
The use of DNA adducts as biomarker have disadvantages, because DNA from 
susceptible human tissues is not readily accessible in large amounts and DNA adducts 
are susceptible to repair and at different rates depending on the tissue, cell type and 
DNA region [44]. Moreover, the stability of DNA adducts is a complex issue in 
investigation, because some adducts are naturally chemically unstable (e.g. guanine N7 
and adenine N3 adducts) generating repairable apurinic sites (AP) on DNA. It is also 
important to note that DNA adducts can suffer enzymatic repair [49]. The formation of 
adducts by the reaction of chemicals with DNA is thought to be the critical step for the 
initiation of carcinogenesis [50, 52, 53]. Up to now DNA adducts do not allow a 
quantitative estimate of cancer risk. However, the occurrence of DNA adducts show at 
least an elevated cancer risk [52]. DNA adducts not only represent an exposure that 
already occurred, but they also imply a potential for significant biological 
consequences, e.g. mutations [53]. 
DNA adducts analysis started in the beginning of the 1980s when Randerath et 
al developed the 
32
P-postlabelling analysis technique [46, 49]. Later, another method of 
analysis of DNA adducts that became popular was the reversed phase HPLC-MS/MS. 
Nowadays, tandem mass spectrometry, particularly if combined with HPLC, is currently 
the recommended detection technique [49]. 
 
Protein adducts 
Protein alkylation products are stable in vivo and thus are excellent targets for 
biomonitoring purposes. The most commonly used molecules are hemoglobin and 
albumin, because these molecules can be obtained in an easy way from blood samples. 
The most commonly studied alkylation site on hemoglobin is the N-terminal valine, 
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however sulfhydryl group of cysteine and nitrogen of histidin are also preferred sites of 
binding [49, 52]. 
Protein adducts can be regarded as an integrative exposure methods. One good 
example is that hemoglobin adducts are considered good biomarkers to measure the 
cumulative internal dose due to repeated exposures, since red blood cells live for as long 
as 4 months in humans [46, 49, 54]. These type of adducts are chemically stable and 
they are not prone to repair mechanisms [46, 49, 52]. In contrast, albumin adducts have 
a shorter lifetime in blood of about 20 days and therefore reflect a more limited period 
of exposure [46]. 
The important role of protein adducts were highlighted in 2002 by a study were 
high levels of acrylamide protein adducts were found in occupational settings [49]. 
However, there are several compounds including PAHs, HCAs, aromatic amines, 
micotoxins and chemotherapeutic agents, among others that forms Hb-adducts [44]. 
The protein adducts analysis was developed by Enrenberg’s group in Stockholm 
based on the hemoglobin molecule [46]. The most widely applied and most successful 
procedure is through the modified Edman degradation of globin protein. In this method, 
globin is precipitated from red blood cells and the valine terminal of hemoglobin is 
cleaved. Subsequently, adducts are analyzed by GC-MS [46, 49, 52].  
 
 
1.2.3. Biomarkers of effects 
 
A biomarker of effect is a measurable biochemical, structural, functional, 
behavioral or any other kind of alteration in an organism that, according to its 
magnitude, can be associated with an established or potential health impairment or 
disease [45]. These include well-established biomarkers for chromosome damage 
measured by micronuclei, chromosome aberrations, sister chromatid exchanges and 
comet assay. 
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1.2.3.1. Micronuclei (MN) 
Measurement of micronuclei frequency in human lymphocytes is one of the 
most commonly used methods for measuring DNA damage in human populations 
exposed to genotoxic agents [55, 56]. This assay has been also successfully applied to 
identify occupational, dietary and genetic factors that have a significant impact on 
genome stability [55].  
Micronucleus is originated from chromosome fragments or whole chromosomes 
that fail to engage with the mitotic spindle and therefore lag behind when the cell 
divides [56]. The formation of MN in dividing cells is the result of chromosome 
breakage (clastogenesis) due to unrepaired or mis-repaired DNA lesions, or 
chromosome mal-segregation (aneugenesis) due to mitotic malfunction [55, 57]. The 
most widely used test for the detection of MN is based on the use of cytochalasin B, a 
fungal metabolite that inhibits cytokinesis, being this assay named the cytokinesis-block 
micronucleus (CBMN) test [57].  
Compared to other cytogenetic assays, quantification of MN, using the CBMN 
assay, confer several advantages, including high reliability and low cost of the 
technique, no requirement for metaphase cells and reliable identification of cells that 
have completed only one nuclear division, which prevents confounding effects [55, 56].  
According to Bonassi et al [55] there is an association between MN induction 
and cancer development. This association was also evident in a cohort study done by the 
Human MicroNucleus project, where there are significant evidences in all cohorts for all 
major cancer sites, especially urogenital and gastrointestinal cancers. This study 
provided valuable evidence that MN frequency in PBL is predictive of cancer risk, 
suggesting that increased MN formation is associated with early events in 
carcinogenesis [58]. 
 
1.2.3.2. Chromosomal aberrations (CAs) 
CAs has been used as a biomarker of chromosomal damage and genome 
instability and represent the most extensively used and validated biomarker in 
populations exposed to genotoxic agents [56, 57, 59].  
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Chromosomal aberrations are changes in normal chromosome structure 
(structural aberrations) or number (numerical aberrations) that can occur spontaneously 
or as a result of chemical/radiation treatment. Structural CAs may be induced by direct 
DNA breakage, by replication on a damaged DNA template, by inhibition of DNA 
synthesis and by other mechanisms (e.g. topoisomerase II inhibitors) [60]. Numerical 
CAs refers to changes in normal chromosome number (i.e. aneuploidy, polyploidy) 
which occur due to abnormal chromosome segregation; they may arise either 
spontaneously or as a result of aneugen treatment [60]. CAs are evaluated in stimulated 
peripheral blood lymphocytes arrested at metaphase and stained, usually by the Giemsa 
band technique [57].  
An increased frequency of CAs in circulating lymphocytes is generally 
considered indicative of increased cancer risk for those exposed to DNA damaging 
agents [56, 61]. Moreover data obtained from both studies carried out by Hagmar et al. 
[62] and Bonassi and Abbondandolo [63], indicated that the frequency of CAs in 
peripheral blood lymphocytes is a relevant biomarker for cancer risk in humans, 
reflecting both early biological effects of exposure to genotoxic carcinogens and 
individual cancer susceptibility [56]. In spite of the excellent sensibility of this 
technique and proved predictive value regarding cancer risk, the detection of 
chromosomal aberrations is technically demanding and a slow process [57].  
 
 
1.2.3.3. Sister chromatid exchange (SCE) 
SCE is the process whereby the sister chromatid effectively break and rejoin 
with one another, physically exchanging regions. SCEs are formed during the S phase 
of the cell cycle and can be induced by UV light and a large number of genotoxic 
chemicals, especially those chemicals that are S-phase-dependent clastogens [64, 65]. 
They can be visualized in cultured cells when division is induced in the presence of 5-
bromodeoxyuridine (BrdU) [57]. 
According to Suspiro and Prista [57] there is some uncertainty regarding the 
significance of increased SCE frequency with regard to cancer risk. Norppa et al (2006) 
reviewed some of the results of the European collaborative project (Cancer Risk 
Biomarkers) and suggest that the association between frequencies of SCEs and cancer 
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risk may be difficult to predict [66]. They also observed that the frequencies of SCEs 
are heavily affected by technical variation, which makes it difficult to define a high SCE 
level when data from a number of studies are combined. However, SCEs are known to 
be increased by exposure to various genotoxic carcinogens and seem to reflect the repair 
of DNA lesions by homologous recombination [66]. SCE assay is well-known for its 
sensitivity to detect DNA damage induced by chemical genotoxicants. 
 
1.2.3.4. Comet assay  
The comet assay, also known as single cell gel electrophoresis, is a versatile and 
sensitive method for measuring DNA damage. This technique has become very popular 
for the assessment of DNA damage with applications in genotoxicity testing, human 
biomonitoring and molecular epidemiology, ecotoxicology, as well as in research in 
DNA damage and repair [67]. Under alkaline (pH>13) conditions, the assay can detect 
single and double stranded breaks, incomplete labile sites, alkali labile sites, and also 
possibly both DNA-protein and DNA-DNA cross-links in eukaryotic cells [68-70].  
The comet assay consists of a single cell suspension embedded in agarose and 
layered onto a microscope slide, after lysis to deliberate DNA content and 
electrophoresed under alkaline conditions. The product can be visualized after staining 
with a suitable dye [52, 57, 71]. This type of test as many advantages, namely high 
sensitivity for detecting low levels of DNA damage, requirement of small number of 
viable cells per sample, the simplicity, low cost and short time of test performance [57, 
71]. However is important to note that there is a wide variability of the comet data since 
the basal level of DNA damage is influenced by a variety of factors such as lifestyle, 
diet, infections, medication, air pollution, season, climate or exercise [52].  
The significance of comet assay as a marker of increased cancer risk remains 
unclear [57]. Comet assay can be considered, for the time being, a biomarker of 
exposure rather than a biomarker of effect, due to the lack of prospective studies 
demonstrating an increased cancer risk [57, 71]. It should however been mentioned that 
the comet assay is actually an emerging tool to properly assess primary DNA damage 
either in vitro or in vivo. 
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1.2.4. Biomarker of susceptibility 
 
A biomarker of susceptibility may be defined as an indicator of an inherent or 
acquired ability of an organism to respond to the challenge of exposure to a chemical 
[45]. They serve as indicators of particular sensitivity of individuals to the effect of a 
xenobiotic or to the effects of a group of such compounds. They can be genetic markers 
that include alterations in chromosomal structures, genetic polymorphisms, among 
others [44].  
It is generally agreed that genetic polymorphisms (GP) are associated with most 
common disorders with a genetic component such as cancer. However, the complex 
metabolism of these compounds involving different polymorphic genes and also 
different DNA repair polymorphic genes could in association modulate the individual 
risk factor for this kind of disease [61]. 
It is normally accepted that the biotransformation of xenobiotic compounds 
including drugs involved mainly two Phases I and II. Phase I reaction include 
transformation of a parent compound to more polar metabolite(s). For example, phase I 
reactions includes N- and O-dealkylation, aliphatic and aromatic hydrolylation, N- and 
S-oxidation and deamination. The main enzymes in this phase are cytochrome P450 
(CYPs) performing mainly hydroxylations and hence acting as monooxygenases, 
dioxygenases and hydrolases [72].  
Phase II enzymes play also an important role in the biotransformation of 
endogenous compounds as xenobiotics to more easily excretable forms. The purpose of 
phase II biotransformation is to perform conjugating reactions. These include 
glucuronidation, sulfation, methylation, acetylation, glutathione and amino acid 
conjugation. In general, the respective conjugates are more hydrophilic than the parent 
compounds. Phase II drug metabolizing enzymes are mostly transferases and include: 
UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), N-acetyltransferases 
(NATs), glutathione S-transferases (GSTs) and epoxide hydrolase (EPHX) [44, 72-74].  
In general the actions of phase I and phase II enzymes render susceptible 
compounds more soluble and more readily excreted and ought to reduce genetic damage 
and cancer risk with several exceptions. It is important to note that some authors 
 
17 
 
consider epoxide hydrolase as a phase II enzyme [73, 74] while others consider the 
same as a phase I enzyme [72]. 
 
 
1.2.4.1. Main Metabolism/Detoxification polymorphisms 
 
Cytochrome P450 family (CYPs) 
The family of CYPs is involved in the metabolism of several xenobiotics, 
biosynthesis of steroids, lipids, vitamins and natural products. [44, 75]. The CYPs are 
enzymes which catalyze the insertion of one atom of molecular oxygen into a substrate 
[61]. The liver generally expresses the highest CYP activity, but all tissues express the 
enzymes in a tissue-specific manner [76]. Some of the enzymes of CYP family will be 
discussed below. 
CYP1A is one of the major Phase I enzymes responsible for the metabolic 
activation of PAHs (e.g. benzo[a]pyrene), one of the main carcinogens found in 
cigarette smoke and environmental pollution [61, 77, 78]. Previous studies have 
described several polymorphisms in the CYP1A1 gene (CYP1A1*2A and CYP1A1*2C 
for example) [79, 80]. In relation to CYP1A1 an association between this polymorphism 
and cancer risk, namely lung cancer [81], susceptibility in childhood acute 
lymphoblastic leukemia [82] and colorectal cancer [83] was found. On the other hand, 
no association was found, specifically with renal cell carcinoma [79, 84] and esophageal 
cancer [85].  
Another example is CYP2E1 that plays an important role in the activation of a 
variety of carcinogens, including nitrosamines, some components of tobacco smoke, 
and many organic chloride and non-chloride solvents, including benzene and also AA 
[61, 78]. This enzyme may be induced by ethanol, and thus alcohol intake may 
influence carcinogenesis by exposure to carcinogens activated by CYP2E1 [61]. This 
enzyme is constitutively expressed in the liver and in many other tissues and is of 
clinical and toxicological importance [86].  
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Concerning the correlation of CYP2E1 and cancer risk, some studies observed 
that CYP2E1 polymorphism may affect the susceptibility to lung cancer [87] and of 
esophageal squamous cell carcinoma [78].  
 
Microsomal epoxide hydrolase polymorphisms 
The EPHX1catalyzes the hydrolysis of reactive epoxides to their corresponding 
dihydrodriols, playing an important role in detoxification of epoxides [78, 88]. This 
irreversible reaction produces metabolites, which are more water soluble, less reactive, 
and readily conjugated and excreted [61]. Although EPHX is considered a detoxifying 
enzyme, the dihydrodiol deriving from PAHs may be further transformed by CYP into 
more reactive species, an example is dihidrodiol epoxides, that are the most mutagenic 
and carcinogenic of PAHs metabolites [61]. EPHX1 is expressed in all tissues studied, 
including white blood cells [88]. 
For EPHX1 SNP and like an example of cancer risk association, in white 
populations, the high-activity (variant) genotype of EPHX1 polymorphism at exon 4 
was associated with a modest increase in risk of lung cancer, while the low-activity of 
EPHX1 polymorphism at exon 3 was associated with decreased risk of lung cancer [89, 
90].  
 
Glutathione S-transferases (GSTs) polymorphisms 
GSTs, one of the major phase II detoxification enzymes are involved in the 
metabolism of xenobiotics and play an important role in cellular process against 
oxidative stress [72]. 
GSTs play a major role in the detoxification of epoxides derived from PAHs and 
alfa-beta unsaturated ketones. Moreover, a number of endogenous compounds such as 
prostaglandins and steroids are metabolized via glutathione conjugation [72-74, 91].  
Human GST enzymes belong to five different classes designated by Alpha, 
Gamma, Mu, Pi and Theta, with their isoenzyme type designed by Arabic numerals. 
Several types of allelic variations have been identified in the class Alpha, Mu, Pi and 
Tetha gene families [73, 74]. Overall, individuals lacking GSTM1, GSTT1 and GSTP1 
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genes have a higher incidence of bladder, breast, colorectal, head/neck and lung cancer. 
Loss of these genes has also been found to increase susceptibility to asthma and 
allergies, atherosclerosis and rheumatoid arthritis [72]. 
GSTT1 enzyme is expressed mainly in the liver and kidney, but also in red blood 
cells and is involved in the metabolism of several important epoxides, such as 
methylene chloride and ethylene oxide [74]. Overall, epidemiologic studies do not show 
any clear association between the GSTT1 null genotype and cancer development [73, 
74, 76]. 
GSTM1 enzyme is expressed in many organs including liver, testis, adrenals and 
white blood cells and metabolizes epoxides such as styrene 7,8-oxide and the ultimate 
form of aflatoxin B1 [74, 76]. GSTM1 null genotype was not associated with risk of oral 
and lung cancer in Caucasians [92, 93], however it was associated with an increased risk 
of sporadic colorectal cancer [94].  
The GSTP1 is widely expressed in tissues and is the major enzyme in the blood 
(white and red cells). Polymorphisms in GSTP1 have been associated with a reduction 
in enzymatic activity toward several substrates, including both chemotherapy agents 
(such as cisplatin, a common agent used in lung cancer treatment) and carcinogens 
found in tobacco smoke [95]. The association between GSTP1 and lung cancer risk was 
examined by Cote et al that found no significant association between this type of cancer 
and the GSTP1 exon 5 polymorphism [95]. However, GSTP1 Ile105Val appears to be 
associated with a modest increase in the risk of bladder cancer [96]. Moreover, Ramos 
et al [97] suggested a possible role of GSTP1 on the modulation of the genotoxicity 
induced by Doxorubicin. 
GSTA2 belongs to the Alpha class of GSTs that are strongly expressed in liver, 
kidney and adrenal tissue. The Alpha class has commonly been described as one of the 
most versatile GST families, since it is responsible for GSH conjugation of compounds 
such as bilirubin, bile acids and penicillin, thyroid and steroid hormones, allowing their 
solubilisation and storage in the liver [98, 99]. Since the Alpha family is involved in a 
wide range of roles that include steroid biosynthesis and providing protection against 
alkylating agents, polymorphic variations in these genes could be responsible for 
physiological consequences that could alter the susceptibility to disease and drug 
response [91, 99]. Two members of this class, GSTA1 and GSTA2 catalyze the GSH 
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conjugation of a wide variety of electrophiles, possess glutathione-dependent steroid 
isomerase activity, and glutathione-dependent peroxidase activity [100]. The GSTA2 
gene is believed to represent a major line of defence against oxidative stress [99]. No 
association was observed between individual GSTA2 polymorphisms and individual 
susceptibility, namely to breast [98, 101], colorectal and prostate cancer [102]. 
However, the variant allele of this polymorphism seems to be associated with an 
increased risk of lung cancer [103]. 
 
 
1.2.4.2. DNA repair enzymes polymorphisms 
As abovementioned, a wide variety of DNA damage may be induced by normal 
endogenous metabolic processes or by environmental carcinogens. If not repaired, such 
damage can lead to gene mutations and genomic instability, which in turn may cause 
malignant transformation of cells. The individual response to DNA damage induced by 
xenobiotics depends largely on the efficiency of DNA repair mechanisms. Normal 
function of DNA repair enzymes is essential for the removal of damage. It has been 
shown that reduced DNA repair is associated with increased risk of cancer. 
These repair mechanisms and respective enzymes, due to their importance in the 
present work, will be discussed in the next section entitled DNA damage. 
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1.3. DNA Damage 
 
1.3.1. Principles 
 
DNA damage is a relatively common event in the life of a cell and may lead to 
mutation, cancer and cellular or organismic death [104]. The genome is inherently 
unstable due to spontaneous chemical reactions, and its fidelity is compromised due to 
very low but significant replication errors [105]. Moreover, the genomes of all 
organisms are continuously exposed to a wide variety of insults, responsible for the 
lesions that arise in DNA (Figure 1.2). The most common insults are environmental 
agents, such as the ultraviolet (UV) component of sunlight, ionizing radiation and 
numerous genotoxic chemicals. Products of normal cellular metabolism that include 
ROS (superoxide anions, hydroxyl radicals and hydrogen peroxide) derived from 
oxidative respiration and products of lipid peroxidation cannot be forgotten. Finally, 
under physiological conditions, some chemical bond in DNA tends to spontaneously 
break, leading non-instructive abasic sites from hydrolysis of nucleotide residues [106]. 
The most common types of DNA damage and their sources are summarized in 
Figure 1.2. 
Fig. 1.2– DNA damage, repair mechanisms and consequences (from [106]). 
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These endogenous and exogenous insults promote several DNA lesions, such as 
single and double strand breaks, abasic sites and the formation of DNA adducts 
(Fig.1.2). These DNA lesions need to be repaired in order to a proper functioning of the 
cell, by DNA repair systems discussed in next section point.  
 
 
1.3.2. DNA Damage Repair System 
 
The cells need a multiple DNA repair pathways to avoid the broad DNA 
damaging agents which are responsible for different types of DNA lesions. These 
pathways include: (a) direct repair of alkyl adducts by O
6
-alkylguanine DNA 
alkyltransferase, (b) repair of base damage and single strand breaks by base-excision 
repair (BER), (c) repair of bulky adducts by nucleotide-excision repair (NER), (d) repair 
of double strand breaks by homologous recombination repair (HRR) and non-
homologous end joining (NHEJ) and (f) repair of mismatches and insertion/deletion 
loops by DNA mismatch repair (MMR) [106, 107]. 
 
 
1.3.2.1. Direct repair (DR) 
Direct repair is involved in DNA damage repair due to alkylating agents. There 
are two different mechanisms of direct repair in the majority of organisms: the 
photoreversal of UV-induced pyrimidine dimmers and the removal of the O
6
-methyl 
group from O
6
-methylguanine (O
6
MeGua) in DNA [104]. In mammals, the only known 
DR pathway is the last one, that is comprised of a single protein (and thus a single 
gene), termed O
6
-methylguanine (O
6
-MeGua) DNA methyltransferase (MGMT). This 
protein transfers the alkyl group at the O
6
 position of guanine to a cysteine residue 
within its active site, leading to the direct restoration of the natural chemical 
composition of DNA without the need for genomic “reconstruction”. However, this 
repair event leads to the irreversible inactivation of the MGMT protein and thus has 
often been referred to as a “suicide” reaction [104, 108]. Deficiencies in MGMT can 
 
23 
 
lead to an increase in mutations, in part because O
6
-MeG mispairs with thymine during 
DNA replication [108]. 
 
1.3.2.2. Base excision repair (BER) 
Base excision repair commonly deals with small chemical alterations of bases 
that may or may not block the transcription and replication, although they frequently 
miscode. BER is particularly important for preventing mutagenesis and the main lesions 
subjected to BER are oxidized DNA bases, arising spontaneously within the cell during 
inflammatory responses, or from exposure to endogenous agents, including ionizing 
radiation and long-wave UV light [106, 109]. Lesions for this repair process affect only 
one of the DNA strands. BER is known as the main guardian against DNA damage, 
commonly due to cellular metabolism, including that resulting from reactive oxygen 
species, methylation, deamination and hydroxylation [106] and is responsible for 
removing DNA-damaged bases, which can be recognized by specific enzymes, the 
DNA glycosylases [109]. 
BER presents two optional repair patches depending on the initial events in base 
removal, the short patch, the dominant mode, when one single nucleotide is removed 
and the long patch when 2-10 nucleotides are removed [104]. 
Base excision repair is initiated by a DNA glycosylase which catalyzes the 
hydrolysis of the N-glycosyl bond between the base and the sugar phosphate backbone 
forming an abasic site (AP) in the DNA [106, 110]. The resulting abasic site can also 
occur spontaneously by hydrolysis [106] . 
There are different DNA glycosylases that recognize oxidized/reduced bases, 
alkylated (usually methylated) bases, deaminated bases (e.g. uracil, xanthine), or bases 
mismatches. In BER, the damaged base is removed by different DNA glycosylases 
(depending on the damage) and APE1 endonuclease [111]. Two classes of DNA 
glycosylases have been identified, some DNA glycosylases catalyses only the 
hydrolytic removal of the base to form apurinic/apyrimidinic (AP) site, whereas others 
remove the base and subsequently cleave off the base by a lyase mechanism and 
catalyze a subsequent AP lyase reaction [104]. The initiating glycosylase dictates the 
downstream repair events.  
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When excision is done by a glycosylase without associated AP lyase, a free base 
is released and an AP site is formed in DNA. The AP site is cleaved by a 5’ AP 
endonuclease (APE1), generating a 3’-hydroxyl group and a 5’-deoxyribose phosphate 
moiety [110]. The later one can be removed by DNA polymerase β (Pol β), leaving a 
one-nucleotide gap in DNA, which will be filled by DNA Pol β (short patch BER). 
Alternatively, when the AP site is formed by spontaneous hydrolysis, the 5’-
deoxyribose phosphate can be displaced from its complementary DNA which may 
involve Pol δ/ε (DNA polymerase δ/ε) and PCNA (proliferating cell nuclear antigen) for 
repair synthesis (2-10 bases) as well as the FEN1 endonuclease to remove the displaced 
DNA flap [106, 110]. If BER is initiated by a glycosylase/ AP lyase the resulting AP 
site is cleaved at its 3’ by the glycosylase-associated AP lyase activity immediately after 
the base excision. The 3’ baseless sugar phosphate at the DNA nick can subsequently be 
removed by the 5’ AP endonuclease, generating one nucleotide gap [110]. BER is 
completed by a DNA ligation step, involving DNA ligase III-XRCC1 complex and 
DNA ligase I [106, 110]. 
Up to now a mutation in germ line gene MUTYH (MYH) is associated with a 
predisposition to multiple colorectal adenomas, known as MYH polyps and is described 
as an autosomal recessive [112-114] 
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Fig. 1.3–Base excision repair mechanisms in mammalian cells (from [104]). 
 
 
1.3.2.3. Nucleotide excision repair (NER) 
Nucleotide excision repair deals with the wide class of helix-distorting lesions 
that interfere with base pairing and generally obstruct transcription and normal 
replication. Most NER lesions arise from exogenous sources [106]. NER is the most 
important repair system to remove bulky DNA lesions that can be caused by UV 
radiation and large chemical adducts generated from exposure to aflatoxine, 
benzo[a]pyrene and other genotoxic agents [109, 111]. Of all repair systems, NER is the 
most versatile in terms of lesion recognition. Two NER sub-pathways exist with partly 
distinct substrate specificity: global genome NER (GG-NER) and transcriptional-
coupled repair (TCR). GG-NER scans genome constantly and removes lesions from the 
non-transcribed domains of the genome and the non-transcribed strand of transcribed 
regions. TCR removes different RNA-polymerase-blocking lesions from the transcribed 
strand of active genes and is thought to be focuses on damage that blocks elongating 
RNA polymerases [106, 109, 111]. 
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NER is mechanistically complex, involving more than 20 proteins in the repair 
pathway (Figure 1.4) and can be divided into five distinct steps: (a) damage recognition, 
(b) dual incisions bracketing the lesion, (c) excision, (d) repair synthesis to fill in the 
resulting gap and (e) DNA ligation [104, 110]. 
In GG-NER, the DNA lesions are recognized by the XPC-HR23B complex, 
whereas in TCR the lesions are recognized by two specific factors: CSB and CSA [106]. 
The subsequent stages of GG-NER and TCR may be identical. After recognition of the 
lesion, the transcript factor TFIIH, consisting of seven different proteins, is recruited to 
the site of DNA damage and is the responsible for unwinding DNA around the lesion 
[109]. After the formation of an open complex the excision of the lesion is carried out 
by dual incisions at defined positions flanking the DNA damage. XPG and XPF-ERCC1 
are respectively responsible for the cleavage in 3’ and 5´ of the borders of the opened 
stretch only in the damage strand, generating a 24-32 base oligonucleotide containing 
the injury [106, 109]. The arising DNA gap is filled in by Polδ and Polε with the aid of 
replication accessory proteins PCNA and RFC and sealed by DNA ligase I [104, 109]. 
Cells defective in NER belong to different complementation groups and UV-
hypersensitive disorders, such as Xeroderma Pigmentosum, Cockayne syndrome, 
trichothiodystrophy (TTD) and UV-sensitive syndrome (UVSS), all characterized by 
photosensitivity, predisposition to cancer and neurological degeneration in some cases 
[106, 109, 110]. The Cockayne syndrome is thought to be directly related with defects 
in TCR [109]. 
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Fig. 1.4- Mechanism of nucleotide excision repair (NER). A- global genome repair and 
B- transcription-coupled repair (from [106]). 
 
 
1.3.2.4. Double strand breaks  
Double strand breaks (DSBs) are highly potent inducers of genotoxic effects and 
cell death [109]. In DSBs both strands are affected and the cell has to know which ends 
belongs together what is a very difficult task given the size of the mammalian genome 
[106]. Because both strand of the DNA helix are broken, chromosomal fragmentation, 
translocations and deletions can easily occur and rapid repair is crucial [111]. DNA 
DSBs can be caused by ionizing radiation, ROS and chemotherapeutic drugs and can 
arise during replication of a single strand break [106, 111]. 
There are two possible pathways for the repair of DNA double strand breaks, the 
homologous recombination repair (HRR) and non homologous end joining (NHEJ). The 
two main differences between these pathways are the requirement for extensive DNA 
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homology on the sister chromatid in HRR and the accuracy of repair [111]. When after 
replication, a second identical copy is available, homologous recombination seems to be 
preferred, otherwise cells rely on end joining, which is more error-prone [106]. The 
usage of NHEJ and HRR also depends on the phase of the cell cycle. NHEJ occurs 
mainly in G0 and G1 or terminally differentiated cells, whereas HRR occurs during the 
late S or G2 phase [109, 111]. 
The NHEJ system is initiated by the biding of a heterodimeric complex 
consisting of the Ku70 and Ku80 proteins to the damaged DNA. Following DNA 
biding, the Ku-heterodimer associates with the catalytic subunit of DNA-PK, which is 
activated by interaction with single strand DNA at the site of DSB and display Ser/Thr 
kinase activity. The XRCC4-ligase IV complex is the responsible for the link of duplex 
DNA molecules with complementary but non ligatable ends [104, 109]. The HRR is 
more complex, since DSBs generated by mutagenic agents needs to be processed first. 
This process (Figure 1.5) has three steps: (a) strand invasion, (b) branch migration and 
(c) Holliday junction formation. This repair process is initiated by a nucleolytic 
resection of the DSB in the 5’-3’ direction by the MRE11-Rad50-NBS1 complex which 
displaysexonuclease, endonuclease and helicase activity. The resulting 3’ single-
stranded DNA is thereafter bound by a heptameric ring complex formed by Rad 52 
proteins. After DSB recognition and strand exchange performed by Rad proteins, the 
resulting structures are resolved according to the model of Holliday [104, 109]. 
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Fig. 1.5-Double strand break/recombinational repair. A- Homologous recombination 
and B- Nonhomologous end-joining (from [104]). 
 
 
1.3.2.5. Mismatch Repair (MMR) 
Mismatch repair pathway is involved in the repair of specific types of errors that 
occur during new DNA synthesis. The loss of this system accelerates the accumulation 
of potential mutations and predisposes to certain types of hereditary and sporadic 
cancers [115]. 
MMR system is responsible for removal base mismatches caused by 
spontaneous and induced base deamination, oxidation, methylation and replication 
errors and is also involved in the repair of DNA lesions induced by a variety of 
cytotoxic agents [107, 109].  
The steps (presented in Figure 1.6) by which MMR proceeds are: (a) recognition 
of DNA lesions, (b) recruitment of additional MMR factors, (c) search for a signal that 
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identifies the wrong (newly synthesized) strand followed by degradation past the 
mismatch and (d) resynthesis of the excited tract [106, 115].  
The recognition of mismatches or chemically modified bases is performed by a 
complex composed by the homologous proteins MSH2 and MSH6 called MutSα 
complex that is able to recognize base/base mismatches and short insertion/deletion 
loops. MSH2 can also form another complex with the mismatch repair protein MSH3, 
that is designated MutSβ complex that is only capable of biding to larger 
insertion/deletion loops [109, 115]. Upon biding to the mismatch, MutSα associates 
with MutLα, a complex that consist of the MutL homologous mismatch repair proteins 
MLH1 and PMS2. After that the excision of DNA strand containing the mispaired base 
is performed by exonuclease I and the new synthesis by DNA polymerase δ (polδ) 
[109]. 
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Fig. 1.6 – Mismatch repair pathway. A- repair of a single nucleotide mismatch in S 
phase and B- repair of insertion/deletion errors at microsatellites sequences (from 
[115]). 
 
Defects in MMR can lead to microsatellite instability, consequently 
heterozygotic defects in MLH1, MSH2 or PMS2 genes predispose humans to hereditary 
nonpolyposis colorectal cancer [110]. 
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1.4. Reactive Oxygen Species  
 
1.4.1. Principles 
 
Oxidative stress by definition is an imbalance between oxidants and 
antioxidants, potentially leading to damage [116-118]. Oxidants are produced by an 
increased generation of oxygen free radicals, i.e. species containing one or more 
unpaired electrons, and non-radical derivatives [119]. ROS as well as reactive nitrogen 
species (RNS) overcomes cellular antioxidants, producing a disturbance in the 
equilibrium status of pro-oxidant/antioxidant reaction in living organism [117, 119].  
Oxidative stress has been implicated in a various pathological processes, 
including cancer, inflammatory disorders, cardiovascular disease, pulmonary disease 
and neurodegenerative disease, as well as in ageing process [117, 120-122]. These 
major chronic diseases increase rapidly in both incidence and mortality as a function of 
age [122].  
In respect to cancer, is important to note that ROS are tumorigenic due to their 
ability to increase cell proliferation, migration and survival, and by inducing DNA 
damage, all contributing to tumor initiation, promotion and metastasis [122, 123]. 
ROS and RNS are produced during normal cellular function, as a consequence 
of endogenous sources as aerobic respiration and substrate oxidation [117, 119, 122]. 
Besides the endogenous sources of reactive species (RS) there are several external 
agents that can trigger RS production. This include different types of radiation, such as 
ionizing and UV radiations, alcohol, tobacco smoking, diet and some environmental 
carcinogens, as well as viral infections [122, 124]. Figure 1.7 represents the sources and 
cellular responses to reactive oxygen species [125]. 
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Fig. 1.7- The sources and cellular responses to reactive oxygen species (from [125]). 
 
ROS include superoxide anion (O2˙
-
), hydroxyl radicals (HO˙), hydrogen 
peroxide (H2O2), singlet oxygen (
1
O2), alkoxyl radicals (RO˙), and peroxyl radicals 
(ROO˙) [119, 126]. RNS include nitric oxide (NO˙) and peroxynitrite anion (ONOO
-
) 
[119, 126]. Some ROS, especially O2˙
-
 and HO˙ are extremely unstable and reactive. On 
the other hand, other ROS like H2O2 or ROO˙ are relatively stable, with half-lives in the 
range of seconds. These species may diffuse away from their site of generation, 
transporting the radical or the oxidant function to other target sites [116, 125]. 
Superoxide anion and H2O2 are formed in biological system by the partial reduction of 
molecular oxygen. O2˙
-
 is produced from one electron reduction of molecular oxygen 
and H2O2 is produced from a reduction of O2˙
-
 with a second electron or by two electron 
reduction of molecular oxygen. Formation of hydroxyl radical (HO˙) is thought to occur 
through the one electron reduction of H2O2, a reaction that is facilitated by transitions 
metals (e.g. Cu(I) and Fe(II)), that are in reduced valence state, this is called Fenton 
reaction. Alternatively, hydrogen peroxide may be converted into water by the enzymes 
catalase or glutathione peroxidase [116, 121, 127]. Four electrons and two protons are 
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required to reduce molecular oxygen to water. Additionally, ROS can react with other 
molecules (e.g. polyunsaturated lipids, thiols and nitric oxide) producing other reactive 
species, such as ROO˙ [116, 121].  
ROS are transient due to their high chemical reactivity that leads to lipid 
peroxidation and oxidation of DNA and proteins [119]. The formation of 8-
hydroxyguanine is a common DNA lesion, and this is one of the most extensively 
studied DNA lesions in humans [52]. Upon oxidation of guanine, a hydroxyl group is 
added to the 8
th
 position of the molecule and the modified product 8-hydrox-2’-
deoxyguanosine (8-OHdG) is one of the predominant forms of free radical induced 
lesions of DNA. The presence of 8-OHdG reveals a lower fidelity in the replication 
process and enhances the probability of adenine incorporation into the complementary 
strand, giving rise to G-T transversions [49, 52]. Agents that increase levels of 8-OHdG 
should thus increase the risk of cancer development [52]. 
The oxidative DNA damage leads to alterations in purine and pyrimidine bases 
and deoxyribose sugar as well as cleaving the phosphodiester DNA backbone to create 
DNA strand breaks [122]. 
The production of ROS that are generated as a result of normal intracellular 
metabolism occurs mostly within the mitochondria of the cell [117, 125]. Low levels of 
ROS are beneficial and even indispensable in many biochemical processes, including in 
cellular response to noxia (e.g. defense against infectious agents and in function of 
signaling systems). However, the excess of ROS can cause severe metabolic 
malfunctions and cellular damage in lipids and membranes, proteins and DNA, 
inhibiting their normal function [117, 120, 123]. 
 
1.4.2. Antioxidant defenses 
 
Antioxidants are substances that prevent or delay oxidation of cellular oxidizable 
substrates and involve several strategies, both enzymatic and non-enzymatic [116, 119]. 
Antioxidants exert their effect by scavenging reactive species or by activating 
detoxifying/defensive proteins [119]. Under normal conditions, antioxidant systems of 
the cell minimize the perturbations caused by ROS [119]. Moreover, several biological 
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compounds have been reported to have antioxidant functions. Enzymatic antioxidant 
defenses include superoxide dismutase (SOD), glutathione peroxidase (GPX) and 
catalase (CAT). Non-enzymatic antioxidants are represented by vitamin C (ascorbic 
acid), vitamin E (α-tocopherol), pyruvate, glutathione (GSH), carotenoids, flavonoids 
among other [117, 119, 122, 127]. 
 
 
1.5. Acrylamide 
 
1.5.1. Acrylamide: production, uses and sources of exposure 
 
Acrylamide (CH2=CHCONH2) is an important industrial monomer produced by 
hydration of acrylonitrile with commercial availability since the mid-1950s. It is mainly 
used to produce water-soluble polyacrilamides, used as flocculents for clarifying 
drinking-water, for treating municipal and industrial waste waters and as flow control 
agents in oil-well operations. It was also used in soil stabilization and in grouting for 
repairing sewers and manhole. The monomer itself is also handled in many molecular 
biology and genetic engineering laboratories for the preparation of electrophoresis gels 
[54, 128-130]. In the workplace the major routes of exposure appear to be dermal 
absorption of acrylamide monomer from solution and inhalation of dry monomer or 
aerosols of acrylamide solution. Additionally, AA has other uses such as cosmetic 
additives (e.g. creams, body lotions, shampoos) and is also a component of tobacco 
smoke (1-2 µg/cigarette) [54].  
Besides the industrial and laboratory uses the general population is exposed to 
varying amounts of AA via diet. In fact, recently, it was discovered that AA can be 
formed in significant amounts and measured at significant concentrations in many 
common human foods during high-temperature frying, roasting or baking. However this 
compound is not typically found in boiled or micro-waved food [128, 129, 131, 132]. 
Moreover, the general population is exposed to small quantities of AA in drinking 
water, refined with poliacrylamide [133]. 
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Acrylamide can be generated from food components during heat treatment as a 
result of the Maillard reaction between an amino acid, primarily asparagine (the major 
amino acid in potatoes and cereals) and reducing sugars, such as glucose [134, 135]. AA 
formation begins at temperatures between 160 and 180ºC [132] and the products of 
Maillard reaction are responsible for much of the flavor and color generated during 
baking and roasting [129, 134, 135]. Figure 1.8 represents the proposed pathway for the 
formation of acrylamide by Heatox 2007 [136]. 
 
Fig. 1.8- Proposed pathway for the formation of AA after thermal processing (from 
[136]). 
 
The proposed mechanism for AA formation (see Figure 1.8) involves the 
formation of a Schiff base from the reaction of a carbonyl compound with asparagine. 
Decarboxylation of the Schiff base, in a Strecker-type reaction, gives an unstable 
intermediate that can hydrolyze to 3-aminopropamide, which on elimination of 
ammonia yields AA. Alternatively, the decarboxylated Schiff base could form AA via 
elimination of an imine [136]. In addition to the Maillard reaction, alternative routes for 
the formation of AA have been proposed [137]. 
AA is very soluble in water, to the extent of 215.5 g/100ml at 30ºC [131], but is 
equally well soluble in some organic solvents including methanol and ethanol [138]. 
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Acrylamide was evaluated by the International Agency for Research on Cancer 
in 1994 as “probably carcinogenic to humans” (IARC, Group 2A) on the basis of the 
positive bioassay results in mice and rats, supported by evidence that AA is 
biotransformed in mammalian tissues to a chemically reactive genotoxic metabolite 
named glycidamide (GA). In the European Union classification system it is classified as 
a category 2 carcinogen, a category 2 mutagen and as toxic to reproduction in category 
3 [54, 130, 131, 133]. 
 
 
1.5.2. Acrylamide dietary exposure 
 
More than one-third of the calories we consume in each day come from foods 
with detectable levels of AA [132]. Average daily intake was estimated to be ranged 
from 0.3 to 2.0 μg/kg bw in the general population. For high percentiles consumers 
(90th to 97.5th) intake estimates ranged from 0.6 to 3.5 μg/kg bw per day, and up to 5.1 
μg/kg bw per day for the 99th percentile consumer [139]. Children would generally 
have exposures 2-3 times higher and therefore they are at higher risk than adults [54, 
140]. This may be due to a combination of children’s higher caloric intake relative to 
body weight as well as their higher consumption of certain AA-rich foods, such as 
French fries and potato crisps, but butter biscuits and sweet biscuits are also important 
sources. [132], these products contribute to approximately 55-65% of the total mean 
intake [141]. 
Studies conducted in Sweden in 2002 showed that high levels of AA were 
formed during the frying or baking of a variety of foods and this finding was quickly 
confirmed by authorities in Europe and in United States [142]. Due to the high concerns 
about the possible public health risks from dietary exposure to AA several reports were 
performed with the purpose to reduce dietary AA intake. This requires that dietary 
levels of AA should be further reduced by appropriate technology in food processing 
and that AA levels should be monitored regularly in commercially distributed food 
items. Moreover, the consumers must be instructed and follow appropriate rules of food 
preparation, especially for home-made food [129]. 
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In 2005 and according to Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) a report showed that the major contributing foods to total exposure to AA, for 
most countries were potato chips (French fries) (16-30%), potato crisps (Chips) (6-
46%), coffee (13-39%), pastry and sweet biscuits (Cookies) (10-20%) and bread and 
rolls/toasts (10-30%). Conversely others foods items contributed less than 10% of the 
total exposure. Given that, it can be said that foods rich in AA precursors are largely 
derived from vegetable sources, such as potatoes and cereals, but apparently not from 
animal sources [139, 143]. 
The more recent results on AA levels in certain foodstuffs were reported by the 
European Food Safety Authority (EFSA) in 2010. This report describes the results of 
the monitoring exercise in the period from 2007 to 2009 from a total of 23 Member 
States, plus Norway submitted 10366 results to EFSA for the three-year period [144]. 
Portugal was one of the countries that did not provide results of AA levels in food 
items, therefore not contributing for this EFSA report. However, a study is currently 
being performed in young adult Portuguese population and the overall results obtained 
in this study showed that the estimation of the amount of AA consumed in the large 
group of participants was approximately 0.35, 0.56, 0.87, 1.35 and 1.74 µg/kg wt/ day 
for 25, 50, 75, 90 e 95 percentiles respectively. 
The 3728 results from 2008 were compared with the 3281 results collected in 
2007 (Table I.2). The product categories potato crisps, instant coffee and substitute 
coffee showed statistically significantly higher levels of AA in 2008 compared to 2007. 
On the other hand, French fries and fried potato products for home cooking, soft bread, 
bread not specified, infant biscuit, biscuit not specified, muesli and porridge and other 
products not specified showed statistically significantly lower levels of AA in 2008 
compared to 2007. There were no statistically significant differences in AA level for the 
other food groups [144]. This report suggests lower AA values in 2008 compared to 
2007. 
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Table I.2 - Acrylamide levels in various food reported by the Member States of 
European Union and Norway in 2007 and 2008 (Adapted from [144]).  
Food 2007 2008 
 Median 
(μg/kg) 
Maximum 
(μg/kg) 
Median 
(μg/kg) 
Maximum 
(μg/kg) 
Biscuits  
Crackers  
Infant  
Not specified  
Wafers 
 
195 
100 
173 
118 
 
1526 
2300 
4200 
1378 
 
185 
64 
126 
109 
 
1042 
1200 
1940 
2553 
Bread 
Bread crisp 
Bread soft  
Non specified 
 
116 
30 
58 
 
2430 
910 
2565 
 
107 
30 
19 
 
1538 
528 
86 
Breakfast cereals 100 1600 75 2072 
Cereal-based baby food 38 353 25 660 
Coffee  
Instant  
Not specified 
Roasted 
 
188 
183 
197 
 
1047 
1158 
958 
 
482 
210 
164 
 
1373 
734 
1524 
French fries 246 2668 220 2466 
Jarred baby food 30 162 25 297 
Other products 
Gingerbread  
Muesli and porridge  
Not specified  
Substitute coffee 
 
226 
156 
134 
334 
 
3615 
805 
2529 
4700 
 
227 
30 
60 
702 
 
3307 
112 
2592 
7095 
Potato crisps 413 4180 436 4382 
Home-cooked potato 
products 
Deep fried  
Not specified  
Oven fried 
 
 
182 
150 
260 
 
 
1661 
2175 
941 
 
 
152 
75 
172 
 
 
1220 
3025 
1439 
Note: Median values are upper bound values. 
 
According to this EFSA report, the area of potato products has drawn much 
attention because of their important contribution to the AA exposure based both on a 
high consumption of the products and on a relatively high content of AA. Potato crisps 
were identified as a food product with potential for high levels of AA formation [145]. 
Given their popularity as a snack food, particularly among younger age groups, it is 
important to reduce its AA content [144]. 
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Moreover, there are a second large group of products contributing to AA 
exposure which are cereals. From the comparison of AA data between 2007 and 2008 it 
was observed that the overall trend in cereal products tends towards lower AA content 
showing a statistically significant decrease in soft bread, infant biscuit and muesli and 
porridge. However, no statistical difference in AA content between 2007 and 2008 was 
found for the other cereal products [144]. 
On the other hand, coffee is also an important contributor to AA exposure. The 
results of laboratory scale experiments have led to the conclusion that only limited 
process options are available to reduce AA levels without affecting the quality in 
respect to the consumer acceptance of a product. Other conclusion in studies at pilot 
scale showed that asparagine content of dried chicory was correlated to the formation of 
AA [144]. 
The wide variations in levels of AA in different food categories as well as in 
different brands of the same food category (e.g. French fries, potato chips) appears to 
result from the variation in processing conditions (temperature; time; nature of frying 
oil; nature of food matrix) [128, 129]. Large variations are also to be expected during 
home cooking, although this aspect has been less well documented. Additionally, the 
composition of the food also has an influence, crucially the content of free asparagine 
and reducing sugars. Storage and seasonal variations can also occur and other important 
factors could be pH and water content [139].  
In order to confirm whether the AA levels tend indeed towards a decrease over 
time more food samples need to be collected and analyzed in coming years [144]. 
 
 
1.5.3. Acrylamide toxicokinetics 
 
Acrylamide is reactive in three different ways. First, it can undergo radical-
mediated polymerization. Secondly, AA has an alpha, beta unsaturated double bond, 
that reacts with nucleophile, including amino and thiol groups in amino acids and 
proteins by Michael additions. This alpha, beta double bond is responsible for much of 
its activity. The thiol addition represents a detoxification pathway by yielding primarily 
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AA-glutathione conjugates as urinary excreteable compounds. On the other hand it can 
also result in alkylation of proteins and can also bind to DNA in a similar “Michael 
type” addition, however with low reactivity [54, 131, 146]. Thirdly, AA can be 
metabolized to glycidamide (GA) an epoxide derivative, presumably by cytochrome 
P4502E1 (Fig. 1.9), being readily reactive toward DNA and other molecules [146]. 
 
 
 
 
 
 
Fig. 1.9 - CYP2E1 mediated biotransformation of AA to GA. 
 
For several decades is known that AA is metabolized to GA, but only in 1993 
Bergmark et al showed the first evidences for formation for GA in humans. These 
evidences have been shown indirectly in the hemoglobin workers exposed to relatively 
high levels of AA, through the detection of Hb-adducts of GA [147]. 
Glycidamide is an epoxide metabolite which is genotoxic in a variety of in vitro 
and in vivo test system [131, 138]. GA has an epoxide group that appears generally 
more reactive with hemoglobin that the double bond of AA, and GA has been reported 
to be 100-1000 times more reactive with DNA than AA [131]. Due to this, the 
genotoxic effect of AA is mostly attributed to GA, focuses much of the toxicological 
interest of this compound in its metabolite and making it the objective of a large number 
of studies. However, the role of GA in the toxicity of AA is not fully understood and 
continues to be worthy of attention by the scientific community. 
After oral administration, AA is rapidly absorbed by the gastrointestinal tract in 
all species, including rats, mice and human. On the other hand, dermic absorption and 
inhalation is much less efficient [148, 149]. AA passes in the blood and is widely 
distributed in the body, including breast tissue, due to hydrosolubility, in all animal 
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species so far investigated (rats, mice, dogs and mini-pigs) [54, 138, 150, 151]. 
Additionally, it has been shown that AA could cross the blood/placenta barrier in a 
human placenta in vitro model as well as the blood/breast milk barrier in vivo of 
lactating mothers [152]. 
Ingested AA is taken up into circulation and metabolism of AA can proceed 
according to Figure 1.10. As already previously seen, AA is largely oxidized in mice, 
rats and humans to GA, being cytochrome P450 2E1 the more plausible candidate for its 
oxidation. This enzyme also oxidizes alcohol and is induced by ethanol [54, 153-156]. 
Secondly both AA and GA can be conjugated with GSH yielding excreatable 
mercapturic acids conjugates, which can be eliminated via the urine [86]. The 
conjugation of AA with GSH yield N-acetyl-S-(3-amino-3- oxopropyl)cysteine and 
when GA reacts with GSH yield N-acetyl-S-(3-amino-2-hydroxy-3-oxopropyl)cysteine 
and N-acetyl-S-(carbamoyl-2-hydroxyethyl)cysteine [54, 129, 153]. Thirdly GA 
hydrolysis can occur via epoxide hydrolase (EH) forming 2,3-dihydroxypropionamide 
[153, 155].  
 
Fig 1.10 - Proposed mammalian metabolic pathway for AA. GSH, glutathione; EH, 
epoxide hydrolase (from [153]). 
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Except for the differences related to the metabolism of AA and its metabolites, 
few quantitative differences are expected between rats and humans with respect to 
absorption, distribution and excretion, in part due to the high hydrosolubility [153]. In 
what concerns the expected differences between humans and rats it is important to note 
that human metabolizes much less AA to GA compared to rats in similar doses, and the 
GA produced in rats is conjugated by GSH to a much larger extent than in humans. This 
is very important with respect to risk assessment [129, 153]. Humans, on the other hand, 
detoxify and eliminate GA via hydrolysis almost exclusively, while rats only hydrolyze 
GA to a limited extent. In view of this, humans will have a much lower blood level of 
GA than rats, for a given dose of AA [153]. Presently, one can say that in humans, at 
relatively low doses GA is formed at higher extent than in rats, most likely because of 
the higher levels of CYP2E1 [54]. 
Several studies on the toxicokinetics of AA were carried out [148, 149, 153, 
156]. The overall results suggest conjugation of AA with GSH exceeds the formation of 
reactive metabolite GA, having a bioavailability of AA in humans of about 20-49%. It 
is metabolized to GA, than for your turn is detoxified by conjugation with GSH [148]. 
Both AA and GA are equally distributed among the tissues and have half-lives 
of about 5 h in rats. The conversion of AA to GA is saturable, ranging from 50% of 
very low doses to 13 % at 100 mg/Kg bw in rats [54]. 
It is also important to note that there are several exogenous factors that are very 
important in the formation of GA in humans that should be taken into account, such as 
alcohol consumption, smoking habits, age and sex [157, 158]. Two studies by Vikström 
et al [158] and Vesper et al [157] investigated whether alcohol (ethanol) consumption 
might have an influence on the metabolism of AA to GA in humans exposed to AA 
through foods. In these studies a decrease of GA adducts associated with alcohol 
consumption was observed. This can be explained due to a competitive effect between 
ethanol and AA as both are substrates for cytochrome P4502E1. These results strongly 
indicate that ethanol influence metabolism of AA to GA. 
The thorough knowledge of AA metabolism is very important, since only the 
knowledge of these mechanisms will allow us to dissipate any doubts regarding the 
toxicology of this compound. 
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1.5.4. Adducts of AA and GA 
 
1.5.4.1. Hemoglobin adducts 
An important reaction of AA with protein is the formation of hemoglobin (Hb) 
adducts. These adducts are formed at the site of sulfhydryl (SH) groups and on the 
amino groups of the N-terminal aminoacids (α-NH2), and have been widely used to 
estimate internal exposures in human biomonitoring studies [54, 138]. Hemoglobin 
adducts from direct reaction of AA and from reaction with GA have been detected in 
rodents administered AA, in exposed humans, and in cigarette smokers [141]. Data 
showed that Hb adduct formation was linear in a dose response manner when the 
epoxide GA was administrated in experimental animals [138]. Moreover, preliminary 
studies that measured concentrations of AA- and GA-haemoglobin adducts in rodents 
and humans with background exposure to AA through the diet suggested that there may 
be species differences in the relative formation of GA with mouse > rat >human. 
However, the formation of GA and AA adducts with Hb is directly proportional in man 
and rat [54]. Additionally, the detection of Hb-adducts for GA in both rodents and 
humans confirms the formation of GA in vivo in humans [54]. 
Smoking is one example of an exogenous factor that has been studied by 
correlating exposure of tobacco smoking and Hb-AA and Hb-GA adducts. These 
studies revealed levels of hemoglobin adducts significantly higher in smokers than in 
non-smokers [159, 160]. 
Hb-adducts are not used as an indicator of toxicity. However, they are used as a 
measure of human exposure to electrophilic compounds, for example as a marker of in 
vivo exposure to AA [54]. Some studies have used hemoglobin adducts of AA and GA 
as biomarkers of AA exposure to determine the internal exposure dose [147, 159, 161, 
162]. Hemoglobin adducts were also correlated with neurotoxicity, but there has been 
no systematic standardization of hemoglobin adducts with dose [163]. 
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1.5.4.2. DNA adducts 
Acrylamide adduct formation with DNA has also been reported, although the 
reaction is very slow. AA itself is of low DNA reactivity under in vitro conditions but 
after metabolic activation specific DNA adducts on the basis of GA were observed 
[164]. Due to this, the genotoxicity of AA has been mainly attributed to the epoxide 
metabolite GA [146]. 
AA is proposed to interact with DNA, giving rise to promutagenic AA DNA-
adducts. The structural analysis of reaction products of AA with DNA in vitro revealed 
the formation of the following adducts in descending order of abundance, N1-(2-
carboxyethyl)-adenine, N3-(2-carboxyethyl)-cytosine, N7-(carbamoylethyl)-guanine, 
N6-(2-carboxyethyl)-adenine and N1-(carboxyethyl)-guanine (Figure 1.11) [146, 165]. 
 
Fig. 1.11 - Chemical structures of major DNA adducts of AA and GA (from [146]). 
 
On the other hand GA forms adducts with DNA in vivo and in vitro in 
considerable amounts [164]. The predominant adduct detected in mice and rats has been 
a GA-guanine adduct the N-7-(2carbamoyl-2-hydroxyethyl)guanine (N7-GA-Gua), 
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formed by reaction of the DNA with the epoxide metabolite GA. N3-(2-carbamoyl-2-
hydroxyethyl)adenine (N3-GA-Ade) and N1-(2-carboxy-2-hydroxyiethyl)-2’-adenine 
(N1-GA-Ade) were also identified as additional GA-derived DNA adducts, (Figure 
1.11) [164, 166]. Both N7-GA-Gua and N3-GA-Ade are promutagenic, because they 
can undergo spontaneous depurination, producing an apurinic (AP) sites [146, 167]. It 
has been suggested that the abasic sites that are produced by depurination of N7-GA-
Gua are likely to promote incorporation of deoxyadenosine during DNA replication 
leading to G-T transversions [146, 167]. The N3-GA-Ade also can block transcription, 
which can lead to sister chromatid exchange, S-phase arrest, chromosomal aberration 
and cytotoxicity [164]. N1-GA-Ade is also highly promutagenic, because of its 
impaired base-pairing potential [146, 168]. 
DNA adducts have been found in liver, lung, testis, leukocytes, and kidney of 
mice and in liver, thyroid, testis, mammary gland, bone marrow, leukocytes, and brain 
of rats treated with either AA or GA [139]. These adducts, formed in rodents, showed 
the formation of higher amounts of DNA adducts by treatment with GA than after AA 
treatment, at all doses tested [131, 146]. DNA adducts formation from AA was 
saturable, while formation of most DNA adducts from GA was dose-dependent at the 
doses tested [131, 146]. 
In mice higher levels of DNA adducts were detected when compared to rats. 
This is already expected due the correlation with the greater metabolic conversion of 
AA to GA in mice compared to rats [54, 138]. According to Maniére et al [51] the N7-
GA-Gua was detected in similar levels in brain and liver and at lower levels in testes of 
rats treated with a single oral dose of AA. The overall DNA adducts in adult mice 
treated with GA were 1.2-1.5 fold higher than those in their AA treated counterparts 
[146]. DNA adducts formation after AA exposure in humans is still lacking [54, 138]. 
 
 
1.5.5. Genotoxicity of acrylamide and glycidamide 
 
The genotoxicity of AA as well as of its reactive metabolite epoxide GA, has 
been extensively studied. AA is both clastogenic and mutagenic in mammalian cells in 
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vitro and in vivo. In addition, dominant lethality studies have showed that AA is a germ 
cell mutagen in male rodents. Additionally, the mutational spectra produced by AA and 
GA in transgenic mouse cells are consistent with formation of promutagenic purine 
DNA adducts in vivo [131]. Furthermore, there is some evidence of the involvement of 
free radicals in AA genotoxicity, leading to oxidative modification of pyrimidines 
[169]. 
 
1.5.5.1. Genotoxicity in Prokaryotes  
AA was not mutagenic in bacterial systems, since did not induce gene mutations 
in different strains of Salmonella typhimurium (Ames test), in the presence or in the 
absence of an exogenous activating system. In contrast, GA was mutagenic in bacterial 
system, since it induces gene mutations in S. typhimurium strains TA1535 and TA100 
with and without metabolic activation [54, 129, 138]. The fact of AA did not induce 
gene mutations may be related with the scarce presence or lack in the S9 mix of the 
specific isozyme (as been already seen the most plausible is P4502E1) capable of 
metabolizing small molecules [54]. Moreover, a study in vitro demonstrated that AA is 
not activated in presence of the most common exogenous system of metabolic 
activation (rat liver S9 mix) [170]. 
 
1.5.5.2. Genotoxicity in mammalian cells 
In vitro, AA generated positive results for mutagenicity even without metabolic 
activation. These positive results showed mutations thymidine kinase (TK) locus in 
mouse lymphoma cells [171] and in human lymphoblastoid TK6 cells [170] but only for 
high concentrations (>10 mM). However, in V79 cells AA was inactive up to 
concentration of 10 mM in hypoxanthine-guanine phosphoribosyl transferase (Hprt) 
mutagenicity test [172]. On the other hand, GA was mutagenic in relatively low 
concentrations in both TK and Hprt assays [170-172]. Furthermore, molecular analysis 
of the TK mutants revealed that AA predominantly induced loss of heterozygosity 
mutation like spontaneous one while GA-induced primarily point mutations [170]. 
In vivo, both AA and GA originated dominant lethal mutations in rodents [173]. 
In Big Blue rats, both compounds significantly increased lymphocyte Hprt mutant 
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frequency [174, 175]. However, neither compound increased the cII mutants in testis, 
mammary gland and liver, while both compounds induced weak positive increases in 
bone marrow and thyroid [174]. Opposing results were observed by Majanatha et al in 
relation to cII mutants frequencies that were increased in liver for high doses of AA and 
GA. Moreover, molecular analysis of the mutants indicated that AA and GA produced 
similar mutations spectra, of which, the predominant were G to C tranversions and 
frameshifts [175]. 
Previously in another in vitro study, GA showed to be more mutagenic than AA 
at any given dose. The spectrum of GA-induced cII mutations was statistically 
significant different from the spectrum of spontaneously occurring mutations in control-
treated cells. Further cells treated with GA or AA had more A→G transitions and G→C 
tranversions and moreover cells treated with GA had more G→T transversions [53]. 
This last mutation is compatible with in vivo studies and the authors concluded that 
although both AA and GA are mutagenic in mice, the mutagenicity of AA is based on 
the capacity of its epoxide metabolite GA to form DNA adducts [53, 175], pointing out 
that the mutation spectrum been totally compatible with adducts of adenine and guanine 
previously identified [164]. 
Several studies showed pronounced evidence about the role of GA mutagenicity 
in vivo and in vitro. On the contrary, in relation to AA only a weak in vitro mutagenic 
potential was attributed, showed possible clastogenic effects. AA is clearly a direct-
acting clastogen in mammalian cells in which it also induces, at lower extent, 
aneuploidy, polyploidy and other mitotic disturbances [54]. In fact the clastogenicity of 
AA have been reported in several studies, namely cytogenetic studies [176-178].  
The in vivo exposure to AA induced positive results in chromosomal alterations 
in mouse bone marrow cells but negative in spermatoigonia [179]. 
On the other hand, in vitro studies reported that AA induced sister chromatid 
exchanges and chromosomal aberrations in V79 cells [176, 178]. AA also showed to be 
clastogenic in micronucleus assay and presented DNA strand breaks (comet assay) in 
HepG2 cells [180]. However, significant micronucleus inductions were only found in 
human blood cells [172] and TK6 cells [170]. Others authors also found DNA damage 
in V79 and in Caco-2 cells but for AA high concentrations (6 mM) [181]. 
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In relation to GA a significant level of DNA damage was reported in vitro in 
testicular cells of mice and human peripheral blood lymphocytes [182]. Also the 
induction of micronuclei in human TK6 cells [170] and in human blood [172] has been 
reported. Other studies observed an increase in micronuclei in peripheral blood [175, 
183, 184] and in bone marrow of mice [179] but not in rats [174, 184] when 
administered with AA. Paulsson et al (2003) showed that mice suffer a dose-dependent 
increase in micronucleus when exposed to GA [185]. These genotoxicity differences 
may be related with the different metabolism between rats and mice [186]. Overall, the 
studies in vitro of DNA damage confirmed the major mutagenic potential for GA in 
relation to AA, not only for the significant increases of DNA damage with low doses of 
compound, but also the positive results obtained in all cell lines studied [170, 181, 182]. 
Additionally studies with CYP2E1 in mice also suggest strong evidences about 
genotoxicity of AA trough GA in germ cells [187] and in somatic cells [168]. 
Overall in cytogenetic studies both AA and GA has demonstrated being 
clastogenic, however the reactive metabolite GA showed a greater potent to induce 
CAs, MN, SCEs and DNA strand breaks [170, 176, 188]. 
 
 
1.5.6. Animal carcinogenicity 
 
Acrylamide is carcinogenic to experimental mice and rats, causing tumors at 
multiple organ sites, in both species given in drinking water or by others means. AA 
was tested for carcinogenicity in two experiments in Fischer 344 rats by oral 
administration [189, 190]. In these studies an increase of the incidence of peritesticular 
mesotheliomas and folicular adenomas of the thyroid was observed in males and of 
thyroid follicular tumors, mammary tumors, glial tumors of the central nervous system, 
oral cavity papillomas, uterine adenocarcinomas and clitoral gland adenomas in females 
[189, 190]. These positive biosassays of AA carcinogenicity in experimental animals 
establish that AA is a multiorgan carcinogen in both rats and mice. This is of high 
importance, since they indicate that AA presents a potential carcinogenic hazard to 
humans [131].  
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1.5.7. Epidemiologic studies 
 
Epidemiology is the study of the distribution and determinants of disease in a 
population that can suggest association but not causation, between exposure to an agent 
and an outcome, e.g., disease [53, 132]. Several epidemiologic studies were conducted 
with the aim of assess the association between AA intake and the risk of cancer in many 
sites, however, there are some conflicting results. 
In the 1980’s, two studies investigating the correlation between occupational AA 
exposure and cancer mortality, were carried out by Sobel et al [191] and Collins et al 
[192]. In these studies occupational AA exposure was evaluated in two cohorts of 
industrial workers who were exposed in the monomer production and polymerization 
industries. After the analysis of cancer incidence in those workers, no consistent effect 
of AA exposure on cancer incidence at any site was identified [131, 138].  
In 1999, an extended and updated investigation of the mortality experience of 
part of the cohort originally studied by Collins et al [192] was undertaken by March et 
al [193]. In an exploratory exposure-response analysis of rectal, oesophageal, 
pancreatic, and kidney cancer, increased standardized mortality ratios for some 
categories of exposure to AA were observed but little evidence of an exposure-relation 
was found. These results corroborated the original cohort study findings [193]. An 
updated follow up done by the same authors [194] concluded the same results, since AA 
exposure at the level present in the study sites was not associated with elevated cancer 
mortality risks. 
In recent years, due to the high concern of AA exposure, several studies 
evaluated the carcinogenicity of AA/GA in relation to dietary intake in various 
European countries, including Sweden, Switzerland, Netherlands, Norway and Italy and 
also in American population were carried out and are summarized in Table I.3. Several 
sites of cancer risk were assessed and the AA intake was carried out for estimative with 
bases in food frequencies questionnaires (FFQs) to assess diet. It is, however, not well-
known, whether FFQs can accurately measure AA [172] intake in the diet. AA content 
in a particular food varies with specific cooking and processing methods for both 
homemade and commercially prepared foods, which makes measuring individual intake 
difficult [195]. Only recently case-control studies have examined the relationship 
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between the AA-Hb and GA-Hb adducts and breast and prostate [195] cancer risk. They 
analyzed N-terminal hemoglobin adduct levels of AA and its genotoxic metabolite, GA 
in blood samples [195, 196]. 
As shown in Table I.3 most of the results of the case-control and cohort studies 
done revealed no significant correlation between frequent consumption of foods with 
high levels of AA and the increase of cancer risk in various sites, like bowel, bladder, 
kidney, prostate, among others. However, positive results have also been found, 
particularly in relation to breast, ovarian, endometrial, lung, renal and esophageal 
tissues.   
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Table I.3 - Epidemiological studies of dietary AA intake and cancer risk (adapted from 
[197]). 
Cancer site Design Population Sample size Cancer risk Published 
Colon, rectum, 
Bladder 
kidney 
case-control Swedish men and 
women 
591 cases; 538 controls 
263 
133 
- 
- 
- 
[198] 
Renal case-control Swedish men and 
women 
379 cases; 353 controls - [199] 
Breast cohort Swedish women 43404 
667 cases 
- [200] 
Colon, rectum cohort Swedish women 504/237 cases(colon/rectal) 
823072 person-years 
- [201] 
Breast Case-control American women 582 cases; 1569 controls + [202] 
Oral/pharynx 
Esopgagus 
Large bowel 
Larynx 
Breast 
Ovary 
Prostate 
Case-control Italian and Swiss 
men and women 
749 cases; 1772 controls 
395 cases; 1066 controls 
2280 cases; 4765 controls 
527 cases; 1297 controls 
2900 cases; 3122 controls 
1031 cases; 2411 controls 
1294 cases; 1451 controls 
- 
- 
- 
- 
- 
- 
- 
[203] 
Endometrial 
Ovarian 
Breast 
Sub-cohort Dutch women 2589; 327 cases 
300 cases 
1835 cases 
+ 
+ 
- 
[204] 
Breast Case-control Danish women 374 cases; 374 controls + 
a 
[196] 
Renal cells 
Bladder 
Prostate 
Sub-cohort Dutch men and 
women 
5000; 339 cases 
1210 cases 
2246 cases 
+ 
- 
- 
[205] 
Lung cohort Dutch men and 
women 
58279 men; 62573 women 
2649 cases 
- [206] 
Brain cohort Dutch men and 
women 
5000; 216 - [207] 
Breast cohort Swedish women 61433; 2952 cases - [208] 
Ovarian cohort Swedish women 61057; 368 cases - [209] 
Endometrial cohort Swedish women 61226; 687 cases - [210] 
Colorectal cohort Swedish men 45306; 676 cases - [211] 
Prostate cohort Swedish men 45306; 2696 cases - [212] 
Oral cavity 
Oro-hypopharynx 
Larynx 
Thyroid 
cohort Dutch men and 
women 
120852; 101 cases 
83 cases 
180 cases 
66 cases 
+ 
b 
- 
- 
- 
[213] 
Prostate Case-control Swedish men 1499 cases; 1118 controls 
170 cases; 161 controls 
-(FFQ) 
-(AA-Hb) 
[195] 
Breast cohort American women 90628; 1179 cases 
 
- [214] 
Breast cohort English women 33731; 1084 cases + 
c 
[215] 
Breast cohort Dutch women 62573; 2225 cases + 
d 
[216] 
Endometrial 
Ovarian 
Breast 
cohort American women 69019; 484 cases 
80011; 416 cases 
88672; 6301 cases 
+ 
+ 
 
- 
[217] 
Lung 
Prostate 
Urotherial 
Colorectal 
Stomach 
Pancreatic 
Renal 
Lymphomas 
cohort Finnish men 27111; 1703 cases 
799 cases 
365 cases 
316 cases 
224 cases 
192 cases 
184 cases 
175 cases 
+ 
- 
- 
- 
- 
- 
- 
- 
[218] 
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Table I.3 (continued) 
Cancer site Design Population Sample size Cancer risk Published 
Esophageal Case-control Swedish men and 
women 
618 cases; 820 controls +
e 
[219] 
Prostate cohort American men 47896; 5025 cases - [220] 
 
 (+) significant association between AA intake and cancer risk; (-) absence of a positive 
association. 
a
 Association with hormonal receptor status; 
b 
positive association for female non-smokers; 
c
 weak association with premenopausal breast cancer; 
d
 association with hormonal receptor 
status in postmenopausal never smoking women; 
e
 stronger association among overweight or 
obese persons was indicated. 
 
In 2007, Hogervorst et al [204] investigate the association between AA intake 
and endometrial, ovarian and breast cancer risk. In this study the risk of breast cancer 
was not associated with AA intake. However, an increased risk of postmenopausal 
endometrial and ovarian cancer with increasing dietary AA intake was observed [204]. 
The same authors examined the association between AA intake and renal cell, bladder 
and prostate cancer and found some associations between dietary AA intake and renal 
cell cancer risk. However, it was a slight association that was noted only after the 
authors attempted to adjust for smoking, hypertension, body mass index, and fruit and 
vegetable consumption [205]. Negative results were also obtained by other authors in 
relation to prostate and breast cancer [195, 217]. On the other hand, there are other 
studies that correlate positively the dietary intake of AA and breast cancer risk. For 
example, Michels et al (2006), correlate diet during preschool age and risk of breast 
cancer and observed a possible association between diet before puberty and the 
subsequent risk of this type of cancer [202]. Furthermore, Olesen et al [196] used AA-
Hb and GA-Hb adducts as biomarkers of acrylamide exposure founded a weak 
association between GA hemoglobin levels and incidence of estrogen receptor positive 
breast cancer after adjustment for smoker behavior. This was the first epidemiologic 
study done using AA-Hb and GA-Hb adducts as biomarkers. Later Wilson et al [195] 
using the same type of biomarkers (AA-Hb) found no association between AA-Hb 
adducts with risk of prostate cancer. Another study done by Pedersen et al [216] also 
showed some indications of a positive association between dietary acrylamide intake 
and receptor positive of breast cancer risk in postmenopausal never smoking women. 
Burley et al [215] showed a weak association of premenopausal breast cancer, however 
requires further investigation. Lastly Shouten et al [213] founded some association 
 
54 
 
between dietary AA intake and oral cavity cancer risk for female nonsmokers and Lin et 
al [219] found that dietary intake of AA might be a risk exposure for esophageal cancer, 
mainly among overweight or obese persons. Furthermore, dietary AA intake was 
positively associated with the risk of lung cancer by Hirvonen et al [218] in a Finnish 
male smoker’s population. 
The results obtained concerning animal and human data on AA risk diverge. 
This should be analyzed in light of the strengths and limitations of epidemiologic 
studies. One possible explanation for this disparity is that the adverse effects of AA are 
present in the cohort studies, but cannot be observed in the study populations due to 
limitations in statistical power to detect pathological events. Alternatively, the disparity 
may be due to invalid assumptions made in risk assessments [132]. Two common 
assumptions in human health risk assessment include (1) extrapolation in a systematic 
manner to predict response rates in humans according to tumor or other pathology 
response rates in a test species and (2) tumor and other pathology response rates 
observed following high dose exposures can be extrapolate to predict response rates 
following low-dose exposure [153]. It is important to note that the level of conversion 
of AA to GA may be different at very low versus high doses, and cellular protective 
mechanisms such as DNA repair may effectively lower the deleterious effects of AA 
and GA at the lower doses. AA exposure may also produce different effects when 
delivered with a multitude of nutrients and other compounds in foods rather than as a 
single additive in water, since the bioavailability of AA is also different according to the 
source of AA exposure [132, 153]. In addition, the tumors observed in rodents and the 
increased risk observed in some studies suggests that AA can influence the hormonal 
systems, for which rodents could not be a good model [221]. 
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2.1. Problem and Method 
 
In 1997, an incident involving tunnel workers in southern Sweden led to a 
toxicological contamination in which fish died, cows became paralyzed and workers 
presented reversible mild neurotoxicity [1]. Acrylamide (AA) a component of the grout 
used to seal the tunnel seemed to be implicated in this toxicological accident, due to its 
known potential neurotoxicity. However, analysis of samples derived from exposed and 
non-exposed workers revealed the presence of AA-hemoglobin adducts in non-exposed 
workers [1]. In addition, and although tobacco smoke can be a possible source of AA 
background, Bermark [2] has reported that nonsmoker´s samples also contained 
background levels of the protein adduct of AA. In view of this, the possibility that AA 
was present in food became a real and worrying consideration. Subsequently, the 
analysis of a number of foodstuffs were performed and AA was identified has being 
formed during heat processing of starch-rich foods [3]. According to some authors, AA 
is formed by the Maillard reduction of the amino acid asparagine with reducing sugars 
such as fructose or glucose upon heating at temperatures above 120 ºC [4, 5]. This 
compound is found at relatively high concentrations (µg to mg/Kg) in common food 
items such as French fries, potato crisps, crisp bread, bread, coffee and biscuits [3, 6, 7]. 
Based on food contents, the estimated average daily intake of AA in US and Europe 
through food consumption is about 0.5 µg/Kg body weight, but the intake is often 
higher in children and adolescents [6]. AA is classified by the International Agency for 
Research on Cancer [8] as potentially carcinogenic to humans (class 2A) based on 
animal experiment data. The discovery of AA in many common cooked starchy foods 
triggered significant challenges to toxicologists, food scientists, national regulatory and 
public health organizations due to the potential risks of neurotoxicity and cancer. In 
fact, these findings have raised a great concern in general public health in recent years. 
AA is metabolized to glycidamide (GA) in both human and experimental 
animals. This step seems to be determinant for the formation of several AA-induced 
DNA adducts observed in rodents [9, 10] as well for the induction of bacterial 
mutagenicity [11], micronuclei [12] and dominant lethality in mouse spermatids [13].  
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As abovementioned, AA possesses a range of hazardous properties, being the 
key effects carcinogenesis, genotoxicity and reproductive toxicity [14]. AA has been 
shown to cause neurotoxicity in laboratory animals and humans, as well as to induce 
various types of tumors, including mammary gland [15, 16]. Different epidemiologic 
studies have reported lack of association between intake of food containing AA and 
various types of human cancer [17, 18]. However, other epidemiological studies also 
reported positive associations. In this context, recent reports from Hogervorst et al. [17, 
19] described an increased risk of ovarian, endometrial and renal cancer in humans with 
high AA dietary intake. Moreover, Olesen et al [20], have recently reported a positive 
association between AA-hemoglobin adducts concentrations, as a biomarker of AA 
exposure and estrogen receptor-positive breast cancer. Overall, it is important to 
highlight that there is a growing concern about the intake of food containing AA and the 
possible association with several types of cancer.  
In view of the importance of AA and GA it is crucial to increase our knowledge 
on the deleterious effects induced by these agents in mammalian cells. In this context, 
different biomarkers (exposure, effect and susceptibility) were used in the present study, 
for the determination of AA and GA genotoxicity and individual susceptibility 
associated with these chemical compounds. The use of mechanistic biomarkers is 
important in toxicology and human health. In fact, the relation between different 
biomarkers is capable to give us valuable insights about the mode of action of these 
compounds. In this work, chromosomal aberrations (CAs), sister chromatid exchanges 
(SCEs), comet assay, specific GA-DNA adducts and individual genetic polymorphisms 
were selected as key biomarkers.  
Complementary approaches were used throughout this work. In order to assess 
genotoxicity of AA and GA-induced, CAs, SCEs and DNA-adducts in V79 Chinese 
hamster cells, a mammalian cell line essentially devoid of CYP2E1 activity were first 
evaluated (Chapter 3). Later, and with the knowledge that GSH is a key factor for 
mammalian cell homeostasis, a study of the effect of the GSH modulators, namely 
evaluation of the effect of buthionine sulfoximine (BSO), an effective inhibitor of GSH 
synthesis, of GSH-monoethyl ester (GSH-EE), a cell permeable compound that is 
intracellularly hydrolysed to GSH and also of GSH endogenously added to culture 
medium in the same cell line were performed using cytotoxicity and clastogenicity 
endpoints (Chapter 4).  
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With the aim of expanding the previous results obtained in the first chapters to 
human cells, the quantification of AA and GA-induced SCEs and DNA-adducts in 
stimulated human lymphocytes was also performed, and the results presented in 
Chapter 5. Moreover, DNA damage accumulation measured by comet assay in whole 
blood leucocytes from healthy individuals was evaluated and described in Chapter 6. 
Genes encoding the enzymes involved in the metabolism and repair of xenobiotics 
substances are often polymorphic in humans. Such genetic polymorphisms may result in 
inter-individual differences in detoxification and clearance of certain chemicals, as well 
in the repair of certain DNA damage, possibly affecting health-risk assessments. In 
view of this, the present thesis also addressed the role of individual genetic 
polymorphisms that can affect metabolism and DNA repair pathways (BER, NER, HRR 
and NHEJ) on GA-induced genotoxicity assessed by the SCE (Chapter 5) and by the 
alkaline comet assay (Chapter 6) in order to evaluate individual susceptibility to GA 
induced genotoxic effects.  
The results obtained in the context of this thesis may help to predict the impact 
of the genotoxic effects of AA and of its metabolite GA in human health. Moreover, the 
association of the previously described methods with a food frequency questionnaire 
can provide valuable information to future epidemiologic studies. 
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Chapter 3 
 
 
 
 
 
 
Cytogenetic damage induced by acrylamide and glycidamide in 
mammalian cells: correlation with specific glycidamide-DNA adducts. 
 
 
 
 
 
This chapter was adapted from: 
 
“Cytogenetic damage induced by acrylamide and glycidamide in mammalian cells: 
correlation with specific glycidamide-DNA adducts.” Martins C, Oliveira NG, 
Pingarilho M, Costa GG, Martins V, Marques MM, Beland FA, Churchwell MI, Doerge 
DR, Rueff J and Gaspar JF. Toxicology Science (2007) 95: 383-90. 
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Abstract  
 
Acrylamide (AA) is a suspected human carcinogen generated in carbohydrate-
rich foodstuffs upon heating. Glycidamide (GA), formed via epoxidation, presumably 
mediated by cytochrome P450 2E1, is thought to be the active metabolite playing a 
central role in AA genotoxicity. In this work we investigated DNA damage induced by 
AA and GA in mammalian cells, using V79 Chinese hamster cells. For this purpose, we 
evaluated two cytogenetic end-points, chromosomal aberrations (CAs) and sister-
chromatid exchanges (SCEs), as well as the levels of specific GA-DNA adducts, 
namely N7-(2-carbamoyl-2-hydroxyethyl)guanine (N7-GA-Gua) and N3-(2-carbamoyl-
2-hydroxyethyl)adenine (N3-GA-Ade) using high-performance liquid chromatography 
coupled with tandem mass spectrometry. GA was more cytotoxic and clastogenic than 
AA. Both AA and GA induced CAs (breaks and gaps) and decreased the mitotic index. 
GA induced SCEs in a dose-responsive manner; with AA, SCEs were increased at only 
the highest dose tested (2 mM). A linear dose-response relationship was observed 
between the GA concentration and the levels of N7-GA-Gua. This adduct was detected 
for concentrations as low as 1 µM GA. N3-GA-Ade was also detected, but only at very 
high GA concentrations (≥ 250 µM). There was a very strong correlation between the 
levels of N7-Gua-GA in the GA- and AA-treated cells and the extent of SCE induction. 
Such correlation was not apparent for CAs. These data suggest that the induction of 
SCEs by AA is associated with the metabolism of AA to GA and subsequent formation 
of depurinating DNA adducts; however, other mechanisms must be involved in the 
induction of CAs. 
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3.1. Introduction 
 
Acrylamide (AA; Fig. 3.1) is an important industrial chemical that has been 
produced for about 50 years in Europe, Japan, and the United States. AA has numerous 
applications; it has been used as starting material for the synthesis of polyacrylamide 
polymers, which are employed mainly as flocculating agents in water treatment 
(drinking and waste waters), as flow control agents in oil well operations, in pulp and 
paper processing, and in mining and mineral processing. AA is also used as an 
ingredient in several cosmetic formulations and in molecular biology research 
laboratories [1, 2]. 
AA was recently found to be generated during the heating of carbohydrate-rich 
foodstuffs, predominantly from the precursor asparagine [3]. This finding has refocused 
the interest in this genotoxicant, especially because appreciable amounts of AA are 
present in Western diets. In fact, some foods (e.g. French fries, potato crisps, bread and 
breakfast cereals, and coffee) may contain up to 3 ppm of AA [4]. The average daily 
intake of AA has been estimated at about 0.5-1.0 µg/kg bw in adults and up to twofold 
higher in 13-year-old children consuming a normal Western diet [4]. Until 2002, AA 
was mainly regarded as an industrial or occupational toxicant, and the foremost routes 
of exposure were considered to be dermal absorption and inhalation of aerosols in the 
workplace; the new data suggest that oral consumption of AA may be a key element for 
global risk assessment.  
In addition to its well-known neurotoxicity [5], the toxicological hazards 
associated with AA exposure include germ cell mutagenicity [6] and cancer [7] in 
rodents. AA has been classified as a probable human carcinogen by IARC (group 2A) 
[1]. This classification is based on experimental rodent models that have shown AA to 
be carcinogenic, causing tumours at multiple organ sites in both male and female mice 
and rats, including follicular thyroid tumours, adrenal pheochromocytomas, scrotal 
mesotheliomas, mammary gland tumours, lung adenomas and carcinomas, glial brain 
tumours, oral cavity papillomas, and uterine adenocarcinomas (reviewed in [1, 7]). 
Evidence for the induction of malignant neoplasia by AA in humans is inadequate, 
mainly because it is quite difficult to associate dietary consumption of AA with a 
specific cancer outcome. Moreover, occupational studies have failed to show that AA is 
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carcinogenic to industrial workers. It is therefore extremely important to obtain data on 
the mechanisms of action of AA, in order to understand how this genotoxicant may 
affect the human genome.  
 
 
 
Fig. 3.1. CYP2E1-mediated biotransformation of acrylamide to glycidamide and 
chemical structures of the depurinating adducts (N7-GA-Gua and N3-GA-Ade) 
mentioned in the text. 
 
AA is metabolized to glycidamide (GA; Fig 3.1) by an epoxidation reaction, 
presumably mediated by cytochrome P450 (CYP) 2E1 [8-10]. This metabolic 
conversion appears to be critical for the genotoxicity of AA because when the 
mutagenicity of AA and GA have been compared, GA has typically been more potent 
[11-14]. Recently, a number of DNA adducts have been characterized from the 
interaction of GA with DNA. These adducts include N7-(2-carbamoyl-2-
hydroxyethyl)guanine (N7-GA-Gua, Fig. 3.1), N3-(2-carbamoyl-2-
hydroxyethyl)adenine (N3-GA-Ade; Fig. 3.1), and N1-(2-carboxy-2-hydroxyethyl)-2’-
deoxyadenosine (N1-GA-dA) [15, 16]. In this work we have compared the extent of 
GA-DNA adduct formation induced by AA and GA with the genotoxicity of AA and 
GA using two different mechanistically based cytogenetic assays: the induction of 
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chromosomal aberrations (CA) assay and the sister chromatid exchanges (SCE) assay. 
These assays were performed in V79 Chinese hamster cells, a widely used non-
transformed mammalian cell line devoid of cytochrome P450 activity [10, 17]. 
 
 
3.2. Materials and methods 
 
3.2.1. Chemicals 
5-Bromo-2’-deoxyuridine (BrdU), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT), trypsin, Ham´s F-10 medium, Hoechst 33258, 30% 
hydrogen peroxide (w/w),  newborn calf serum, mitomycin C, phosphate buffered saline 
pH 7.4 (PBS), ribonuclease A, and penicillin-streptomycin solution were purchased 
from Sigma-Aldrich (St. Louis, MO). Dimethylsulphoxide (DMSO), methanol, acetic 
acid, potassium chloride, sodium chloride, and Giemsa dye were obtained from Merck 
(Darmstadt, Germany). Colchicine and AA (CAS Registry Number 79-06-1,  99.5 % 
pure) were purchased from Fluka (Buchs, Switzerland). GA (CAS Registry Number 
5694-00-8, >98.5% pure, containing approximately 1% AA) was obtained from Toronto 
Research Chemicals (North York, Ontario, Canada).  
 
 
3.2.2. V79 Cells culture 
V79 Chinese Hamster cells (MZ), kindly provided by Prof. H.R. Glatt - German 
Institute of Human Nutrition, Nuthetal, Germany were cultured using Ham’s F10 
medium, supplemented with 10% newborn calf serum and 1% antibiotic solution 
(penicillin-streptomycin). The cells growing up at 37ºC in an atmosphere containing 5% 
CO2. 
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3.2.3. MTT cytotoxicity assay 
The MTT assay is based on the reduction of the yellow MTT tetrazolium by 
mitochondrial desydrogenases to form a blue MTT formazan, in viable cells [18, 19].  
Approximately 5  10
3 
V79 in 96-well plates and incubated at 37 ºC under a 5% 
CO2 atmosphere. The cells were grown for 16 hours and then exposed to different 
concentrations of AA and GA (dissolved in PBS, pH 7.4), ranging from 100 to 10000 
µM, for a 24-h period. Hydrogen peroxide (250 µM) was used as a positive control. The 
cells were washed with culture medium, incubated with MTT (500 µg/ml) for a further 
period of 4 h and then carefully washed with PBS. At the end of the incubation period, 
the media was discarded and DMSO (200 µl) was added to each well. Absorbance was 
read at 595 nm in a Zenyth 3100 microplate reader. Four independent experiments were 
performed and eight individual cultures were used for each GA or AA concentration in 
each independent experiment. 
 
 
3.2.4. Chromosomal aberration assay 
Twenty-four hour cultures (approximately 5 x 10
5
 cells), growing in 25 cm
2
 
culture flasks, were exposed to different concentrations of AA and GA, ranging from 1 
to 2000 µM, for a period of 16 h. Mitomycin C (750 nM) was used as the positive 
control. The cells were subsequently washed with fresh culture medium and colchicine 
was added at a final concentration of 600 ng/ml; the cells were incubated for a further 
period of 2.5 h and then harvested by trypsinization. After 3-min hypotonic treatment 
with KCl (0.56%, w/v) at 37 ºC, the cells were fixed with methanol/acetic acid (3:1), 
and slides were stained with Giemsa 4% [(v/v) in phosphate buffer 0.01 M, pH 6.8] for 
10 min, according to Oliveira et al. (2005) [20] and scored [21, 22].  
For the quantification of the DNA damage induced by both AA and GA, the 
index of percentage of aberrant cells excluding gaps (%ACEG) was used. This index 
represents the frequency of metaphases containing chromosomal aberrations excluding 
gaps and is the standard indicator for the CA assay. The types of aberrations considered 
for this index were breaks (chromatid and chromosome), dicentric chromosomes and 
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rings, chromatid-type rearrangements (triradial, quadriradial), other complex 
rearrangements, and multi-aberrant cells (MA, cells with more than 10 aberrations, 
including heavily damaged pulverized cells). The presence of chromatid and 
chromosome gaps in AA and GA exposed cultures was also evaluated. The index 
percentage of aberrant cells including gaps (%ACIG) was calculated as mentioned for 
the %ACEG, including, however, the metaphases containing gaps.  
The evaluation of cell proliferation was carried out using the mitotic index (MI). 
For this index, 1000 V79 cells were scored for each independent experiment and the 
number of metaphases recorded.  
 
 
3.2.5. Sister chromatid assay 
Twenty-four hour cultures (approximately 5 x 10
5
 cells), growing in 25 cm
2
 
culture flasks, were exposed to different concentrations of AA and GA, ranging from 1 
to 2000 µM. BrdU was also added at a final concentration of 6 µM. Mitomycin C (750 
nM) was used as a positive control. After a period of 27 h, the cells were washed with 
fresh culture medium and colchicine (600 ng/ml) was added. The cells were then 
incubated for a further 2.5-h period and then harvested by trypsinization, as described 
before. 
Differential staining of BrdU-substituted sister-chromatids was performed 
according to the fluorescence-plus-Giemsa (FPG) method [23]. Briefly, the slides were 
stained for 12 min with the fluorescent dye Hoescht 33258 (10 µg/ml) in 2% KCl (w/v), 
exposed to UV (254 nm) for approximately 9 min, and then stained with 4% Giemsa 
[(v/v) in 10 mM phosphate buffer, pH 6.8] for 10 min.  
SCEs per cell were scored in 30 second-metaphases for each dose-level in each 
independent experiment. At least two independent experiments were performed. The 
evaluation of cell proliferation was carried out using the MI, as described above. At 
least 100 metaphases per culture for each dose-level, in each independent experiment, 
were scored for the replication index (RI), calculated according to [24].  
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3.2.6. DNA adducts 
 
3.2.6.1. Chemical exposure and DNA extraction 
Twenty-four hour cultures (approximately 8 x 10
6
 cells), growing in 75 cm
2
 
culture flasks, were exposed to different concentrations of AA (0-2000 µM) and GA (0-
2000 µM) during two different time periods, 18 h (corresponding to parallel cultures of 
the CAs assay) and 29 h (corresponding to parallel cultures of the SCE assay). The cells 
were then harvested by trypsinization as described above, washed with PBS, and the 
cell suspensions were immediately stored at -20 ºC. DNA was extracted from the cell 
suspensions using the QIAamp DNA mini Kit (Qiagen, Hilden, Germany), according to 
the manufacturer’s instructions, with minor modifications done in order to prevent 
depurination of the DNA adducts [25]. Cell suspensions (200-250 µl) were lysed with 
20 µl of proteinase K, provided by Qiagen, and ribonuclease A (200 µg) for 1 h at 37 ºC 
and at the end of the chromatographic process DNA samples were eluted in water (200 
µl), and stored at -20 ºC for subsequent DNA quantification and determination of DNA 
adducts.  
 
3.2.6.2. DNA quantification 
Quantification of DNA was carried out using a PicoGreen dsDNA quantitation 
kit (Molecular Probes, Eugene, OR). λ Phage DNA (100 µg/ml) was used as the 
standard. The DNA concentration in the standard curve ranged from 0 to 300 ng/ml. 
Briefly, 10 µl of final DNA eluate was mixed with 190 µl of Tris-EDTA (10 mM Tris-
HCl, 1 mM EDTA, pH 7.5) diluted with PicoGreen reagent. Fluorescence intensity was 
measured in a Zenyth 3100 microplate reader at excitation and emission wavelengths of 
485 and 535 nm, respectively. The yield of DNA extracted from each cell suspension 
was in the range of 20-40 µg, in accordance with the manufaturer’s standard yields of 
DNA for cultured cells. 
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3.2.6.3. Quantification of DNA adducts 
GA-DNA adducts, specifically N7-GA-Gua and N3-GA-Ade (Fig. 3.1), were 
released from the DNA by neutral thermal hydrolysis and quantified by HPLC coupled 
with tandem mass spectrometry, essentially as described in Gamboa da Costa et al. [16]. 
Briefly, aliquots of DNA solutions (~5 µg), containing the 
15
N-labeled adducts as 
internal standards, were heated at 100 ºC for 15 min and then filtered through a 
prewashed 3-kDa molecular weight cutoff spin filter. The adducts were separated on a 2 
x 150 mm C18 analytical column (Luna C18(2), Phenomenex, Torrance, CA) with 2% 
acetonitrile in water and quantified by tandem mass spectrometry in the multiple 
reaction monitoring mode, using a Quattro Ultima triple quadrupole mass spectrometer 
(Waters, Milford, MA) equipped with an electrospray source. 
 
 
3.2.7. Statistical analyses 
Dose-related effects were assessed using linear regression analysis. One-way 
ANOVA, followed by Dunnett's test, was used to compare specific treatment levels to 
the control group. Two-way ANOVA, followed by Dunnett's test, was used to compare 
AA and GA treatments. Pearson's Product Moment test was used to assess correlations 
between variables.  
 
 
3.3. Results 
 
A wide range of AA and GA concentrations were tested in a 24-hour incubation 
MTT cytotoxicity assay protocol. The average survival values obtained from four 
independent experiments with V79 cells treated with AA and GA are depicted in Figure 
3.2. Previous experiments revealed no changes in the survival frequency of V79 cells 
using a 3-hour incubation period with both compounds (data not shown). It is clear from 
Figure 3.2 that both AA and GA induced dose-dependent cell death, as measured by the 
MTT assay. Moreover, GA was clearly more cytotoxic than AA, causing lower survival 
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rates at all the equimolar concentrations studied. Very low (< 5%) survival values, 
occurred at very high concentrations of GA ( 4 mM) and AA (10 mM). 
 
Fig. 3.2. Cytotoxicity of acrylamide and glycidamide in V79 cells (MTT assay). The 
results are expressed as the average ± SEM from four independent experiments. 
 
Both AA and GA induced CAs (Table III.1) and decreased the MI, evaluated as 
a measure of cell proliferation associated with this cytogenetic end-point. This 
antiproliferative effect was more pronounced in GA exposure, with the MI being zero at 
2000 µM, which prevented the cytogenetic evaluation at this dose level (Table III.1).  
AA and its metabolite GA increased the %ACEG, especially for the higher 
concentrations evaluated (1000 and 2000 µM, for GA and AA, respectively). As 
observed in the survival assays, GA had, as expected, a more pronounced effect than 
AA at equimolar concentrations (Table III.1). 
 
 
 
Table III.1- Induction of chromosomal aberrations in V79 cells by acrylamide and glycidamide. 
Test compound 
 
Chromosomal aberrations per 100 cells
a
 MA Gaps/cell %ACIG
b
 %ACEG
c
 MI (%)
d
 
  Ctg Csg  Ctb Csb Rearr Dic+rings (%)   (Average  S.D.) (Average  S.D.) 
              
Acrylamide (M)              
0  6.5 0.5  0.5 0 0 0 0 0.07  0.03 6.0  1.4 0.5  0.7 9.3  0.1 
250  3.5 0  1.0 0 0 0 0 0.04  0.02 4.5  3.5 1.0  1.4 8.5  0.4 
500  11.5 1.5  2.0 0.5 0 0 0 0.13  0.01 14.5  3.5 2.5  0.7
+
 8.4  0.2 
1000  17.5 0  3.0 0 0 0 0.5 0.18  0.01 18.0  4.2 3.5  2.1 6.9  0.1
+
 
2000  19.0 1.5  8.5 1.5 0.5 0 0 0.21  0.01 27.0  5.7 10.0  4.2 5.2  1.7
+
 
Glycidamide (M)              
0  5.8 0.5  0.5 0 0 0 0 0.06  0.02 5.5  1.3 0.5  0.6 9.2  0.1 
1  3.0 0  1.0 0 0 0 0 0.03  0.01 4.0  2.8 1.0  1.4 8.4  2.0 
2.5  6.0 0  0.5 0 0.5 0 0.5 0.06  0.03 6.5  0.7 1.5  0.7 8.2  0.1 
5  5.5 0  0.5 0 0 0.5 0 0.06  0.04 6.5  3.5 1.0  0.0 8.7  0.3 
10  4.0 0.5  1.5 0 0 0 0 0.05  0.04 5.5  3.5 1.5  0.7 8.0  1.1 
25  8.5 0.5  0.5 0 0 0 0.5 0.09  0.07 9.0  7.1 1.0  0.0 7.5  0.1 
50  7.5 0  1.5 0 0 0 0 0.08  0.02 8.0  1.4 1.5  0.7 8.2  1.0 
100  10.5 0.5  1.0 0 0 0 0 0.11  0.01 10.0  1.4 1.0  1.4 7.2  0.4 
250  12.0 0.5  2.5 0 0 0 0 0.13  0.02 13.5  2.1 2.5  0.7
*
 8.1  0.6 
500  18.5 0.5  5.5 0 0.5 0 0 0.19  0.03 19.5  0.7 6.0  0.0
**
 5.8  0.7 
1000  29.5 1.5  6.5 0 2.0 0 0.5 0.31  0.08 30.0  1.4 9.0  1.4
**
 4.8  0.0 
2000  - -  - - - - - - - - 0.0  0.0 
              
Mitomycin C (nM)              
750  34.3 3.7  26.0 4.3 17.7 0.3 7.0 0.38  0.04 55.0  1.0 40.3  6.7 4.4  1.3 
a
The results are expressed as the average from two independent experiments (100 metaphases analysed per experiment) for all the points, except for negative V79 cell 
controls and mitomycin C. In these cases the results are expressed as the average from four independent experiments (100 metaphases analysed per experiment). Ctg, 
chromatid gap; Csg, chromosome gap; Ctb, chromatid break; Csb, chromosome break; Dic, dicentric chromosome; Rearr, rearrangements (triradial, quadriradial, and 
other complex rearrangements); 
b
%ACIG, percent of aberrant cells including gaps (average  standard deviation); 
c
%ACEG, percent of aberrant cells excluding gaps 
(average  standard deviation); MA, multi-aberrant cells, corresponding to cells with more than 10 aberrations. MA are included in the index %ACEG and %ACIG; 
d
MI, mitotic index. 
*
 P<0.05 when compared with control experiment; 
**
 P<0.001 when compared with control experiment. 
+
 P<0.05 when compared with the same 
concentration of glycidamide. 
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For both AA- and GA-exposed cultures, the CA pattern consisted mainly of 
chromatid breaks, although some few chromatid-type rearrangements (e.g. 
triradial/quadriradial) were also found for GA. Dicentric and ring chromosomes, and 
multi-aberrant cells were nearly absent.  
Gaps are generally considered to be a minor class of aberrations, and their real 
biological significance has been a matter of discussion. These events are usually 
recorded separately from the other aberrations [21, 22]; however, it is clear that both 
AA and GA are very efficient inducers of chromatid gaps, leading to a consistent dose-
response effect (P<0.001) (Table III.1). In view of this, we also calculated the %ACIG 
and the number of gaps per cell (Table III.1). The highest values of %ACIG were about 
30% for both the AA-exposed (2000 µM) and GA-exposed (1000 µM) cultures. 
Moreover, the gaps/cell index revealed a maximum value of 0.2 for AA (2000 µM) and 
0.3 for GA (1000 µM) treatment (Table III.1), showing the importance of these 
aberrations.  
Table III.2 presents data on the two cytogenetic indices associated with the SCE 
assay (SCE/cell and SCE/chromosome), as well as the proliferation indices (mitotic and 
replicative) associated with exposure to AA and GA. A wide range of GA (1-1000 µM) 
and AA (250-2000 µM) concentrations were included in this study. The results clearly 
show that GA consistently induces SCEs for concentrations 10 µM (see Table III.2), 
increasing the background level of SCEs by about 10-fold, to levels of ~60 SCE/cell at 
the highest concentration tested (1000 µM). For AA-exposed cultures, a significant 
increase in SCE/cell was only observed for the highest dose tested (Table III.2) and this 
effect can be considered as mild, since it represents only a ~1.6 fold increase over 
background. 
The levels of N7-GA-Gua and N3-GA-Ade in V79 cell cultures exposed to AA 
and GA for 18 and 29 hours (corresponding to parallel cultures of the CAs and SCE 
assays, respectively) are presented in Table III.3. These data show that GA is a potent 
inducer of N7-GA-Gua, with a linear dose-response dependence (P<0.001). For both 
periods of exposure, the detection of N7-GA-Gua was observed for doses as low as 1 
µM GA. In addition, the levels of N7-GA-Gua did not show any significant differences 
between the two exposure periods tested (Table III.3). In fact, these levels were in the 
same range for all the concentrations tested, except for the highest concentration of GA 
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(2000 µM), which showed an approximately twofold increase in the 29-h exposure 
period when compared to the 18-h period; however, this difference did not reach 
statistical significance.  
 
Table III.2. Sister chromatid exchanges induced by acrylamide and glycidamide in V79 
cells 
Test compound SCE /chromosome
a
 SCE/metaphase
a 
MI (%)
c
 RI
d
  
 (Average  S.D.
b
) (Average  S.D.) (Average  S.D.) (Average  S.D.) 
     
Acrylamide (M)     
0 0.31 ± 0.03     6.83 ± 0.52 4.5 ± 0.4 2.00 ± 0.01 
250 0.35 ± 0.00      7.65 ± 0.02
+
 4.3 ± 0.1 2.00 ± 0.01 
500 0.39 ± 0.01       8.33 ± 0.14
++
 4.0 ± 0.6 2.04 ± 0.06 
1000 0.36 ± 0.04    7.70 ± 0.90 3.9 ± 0.8 1.99 ± 0.00 
2000 0.51 ± 0.01      11.08 ± 0.02
*
 4.1 ± 1.0 1.99 ± 0.01 
     
Glycidamide (M)     
0 0.29 ± 0.02 6.19 ± 0.50 5.2 ± 0.7 1.97 ± 0.04 
1 0.33 ± 0.04 7.05 ± 0.68 6.1 ± 1.3 2.08 ± 0.01 
2.5 0.35 ± 0.05   7.72 ± 1.06 5.7 ± 0.6 2.06 ± 0.02 
5 0.33 ± 0.03 7.12 ± 0.68 5.5 ± 1.1 2.07 ± 0.04 
10 0.49 ± 0.13   10.53 ± 2.64
*
 6.4 ± 0.8 2.00 ± 0.03 
25 0.54 ± 0.07     11.60 ± 1.41
**
 4.5 ± 0.2 2.04 ± 0.02 
50 0.47 ± 0.06    10.26 ± 1.38
**
 5.1 ± 1.2 2.02 ± 0.06 
100 0.72 ± 0.07     15.42 ± 1.26
**
 4.7 ± 1.0 2.02 ± 0.02 
250 1.10 ± 0.10     23.75 ± 2.57
**
 4.3 ± 1.1 2.00 ± 0.00 
500 1.73 ± 0.03     37.98 ± 0.21
**
 2.8 ± 0.3 1.98 ± 0.01 
1000 2.71 ± 0.44     59.02 ± 9.88
**
 1.3 ± 0.5 1.96 ± 0.04 
2000 - - 0.0 ± 0.0 0.00 ± 0.00 
     
Mitomycin C (nM)     
750 4.05 ± 0.62 88.32 ± 13.70 4.4 ± 0.8 1.66 ± 0.37 
a
The results are expressed as the average from at least two independent experiments (30 
metaphases analysed per experiment) for all the points; 
b 
S.D., standard deviation; 
c
MI, 
mitotic index; 
 d
RI, replication Index. 
*
 P<0.01 and 
**
 P<0.001  when compared with the control experiment. 
+
 P<0.05, 
++
 P<0.001 when compared with the same concentration of glycidamide. 
 
N3-GA-Ade was only detected for GA concentrations higher than 250 µM, with 
a dose-response effect. In addition, the levels of this adduct were in all circumstances 
two orders of magnitude lower than those of N7-GA-Gua, which is fully consistent with 
previous data from DNA modifications in vitro and from AA and GA administration to 
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mice [16]. As observed for N7-GA-Gua, the levels of N3-GA-Ade were independent of 
the exposure time period, although a twofold to threefold decrease was apparent at 29 
hours for the highest GA doses tested (1000 and 2000 µM), compared to the 18-h 
incubation period (Table III.3).  
 
Table III.3. Levels of GA-DNA adducts in cell cultures exposed to acrylamide and 
glycidamide. 
Test compound 18 hours exposure
a
 29 hours exposure
a
 
 
N7-GA-Gua/ 
10
6
 nucleotides 
N3-GA-Ade/ 
10
6
 nucleotides 
N7-GA-Gua/ 
10
6
 nucleotides 
N3-GA-Ade/ 
10
6
 nucleotides 
     
Acrylamide (M)     
0 <LOD
b
 <LOD <LOD <LOD 
500 <LOD <LOD <LOD <LOD 
1000 <LOD <LOD <LOD <LOD 
2000 0.2  0.0 <LOD <LOD <LOD 
     
Glycidamide (M)     
0 <LOD <LOD <LOD <LOD 
1 0.2  0.0 <LOD 0.2  0.0 <LOD 
2.5 0.3  0.1 <LOD 0.3  0.0 <LOD 
5 0.6  0.1 <LOD 0.7  0.1 <LOD 
10 1.2  0.3 <LOD 1.6  0.3 <LOD 
25 3.1  0.4 <LOD 3.7  1.6 <LOD 
50 6.4  0.9 <LOD 7.6  2.8 <LOD 
100 13.2  2.8 <LOD 12.8  1.9 <LOD 
250 31.6  3.0 0.3  0.4 34.2  0.5 0.4  0.1 
500 50.2  6.2 0.9  0.1 73.0  9.0 1.0  0.2 
1000 137.6  69.8 2.3  1.3 156.8  17.2 1.1  0.8 
2000 220.4  25.9 3.8  1.2 488.4  149.4 1.3  1.9 
a
The results are expressed as the average  standard deviation  from at least two independent 
experiments; 
b
LOD, limit of detection. 
The LOD for N7-GA-Gua and N3-GA-Ade, when assaying 5 µg of DNA, was 0.1 adducts/10
6
 
nucleotides. 
 
AA exposure led to very low levels of N7-GA-Gua, which were only observed 
for concentrations higher than 1000 µM. The adduct levels detected at 2000 µM AA 
were comparable to those observed for 1 µM GA. N3-GA-Ade was not detected in AA-
exposed cultures at any dose level. Negative controls, corresponding to cells not 
exposed to either AA or GA, did not present any detectable levels of GA-DNA adducts. 
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The levels of N7-GA-Gua were compared with the levels of cytogenetic damage 
in AA- and GA-exposed cultures, at the periods of time corresponding to parallel 
cultures for the SCE and CA assays. A very strong correlation was observed between 
the levels of N7-GA-Gua and SCE/cell (r=0.987; P=1.25 x 10
-12
). 
 
 
3.4. Discussion 
 
AA is metabolized to GA in mice, rats, and humans [25-27]. The conversion of 
AA to GA is apparently saturable in rodents [28] and both compounds are detoxified by 
conjugation with glutathione; in addition, GA can also be detoxified by epoxide 
hydrolase [1].  
The cytotoxic potential of both AA and GA was investigated in this work in 
order to select the range of concentrations to be tested in the subsequent studies using 
different cytogenetic end points (CAs, SCEs). The results show that, with our 
experimental conditions, GA is clearly more cytotoxic than AA for all the 
concentrations evaluated. Additionally, at concentrations up to 4 mM for AA and up to 
1 mM for GA, the cell survival was clearly above 50%, indicating that the cytotoxicity 
of both compounds would not hinder the cytogenetic studies (Fig. 3.2). These results are 
in agreement with data recently reported by other groups, using different cell survival 
end points [11, 12] . 
The genotoxicity of AA has been evaluated in several systems (reviewed in 
[13]). Positive results for the induction of CAs and SCEs in Chinese hamster V79H3 
cells at concentrations in the millimolar range were reported by Tsuda et al. [29]. These 
results are in general agreement with the results reported in the present work. Our data 
showed that AA induced CAs in a dose-response manner, with chromatid gaps and 
breaks being the typical features observed. However, if we exclude the gap-type 
aberrations, the genotoxicity observed at the highest AA concentration tested (2 mM), 
can be considered moderate. Since CYP2E1 activity is not detectable in V79 cells [10, 
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17], the clastogenicity observed, about 10% ACEG, must be related to mechanisms 
other than metabolic conversion to GA. 
AA may undergo Michael-type additions in particular with thiols, thus 
potentially depleting the levels of glutathione, a molecule protecting the cell against 
endogenous oxidants and electrophiles [10]. Michael-type addition reactions, which 
proceed at very low rates, have also been reported between AA and DNA to yield a 
series of depurinating and non-depurinating adducts [30]. Additionally, there is some 
evidence of the involvement of free radicals in AA genotoxicity, leading to oxidative 
modification of pyrimidines [31]. These mechanisms might, to some extent, explain the 
clastogenic activity of AA observed in this study. SCEs were induced at only the 
highest AA dose evaluated (2 mM), which was similar to what was observed for the 
induction of CAs and also consistent with previously reported data [10, 29]. The same 
aforementioned reasons for the results of the chromosomal aberrations assay may 
explain the slight increase in the frequency of SCEs observed in 2 mM AA-treated 
cultures. 
Our results concerning the induction of CAs by GA showed that this compound 
is approximately twofold more clastogenic than AA and, as observed for AA, chromatid 
gaps and breaks were the most common features observed (Table III.1). In addition, the 
induction of chromatid gaps was observed to be dose dependent. Considering that gaps 
might be a consequence of DNA breaks [32], these data are in agreement with the 
results obtained by other authors using the comet assay, where GA induced alkali-labile 
sites [12, 33, 34]. The comparison of the genotoxicity of AA and GA in human 
lymphoblastoid TK6 cells in three different endpoints (comet assay, micronucleus test 
and thymidine kinase assay) also suggested that GA is more genotoxic than AA [12], 
which is in agreement with the data obtained in our cytogenetic end-points. 
There are only a few studies comparing, in the same experimental conditions, 
the genotoxic activity of AA to that of its reactive metabolite, GA. In addition, only 
limited information is available concerning cytogenetic end-points for both compounds. 
To our knowledge, this is the first study reporting data from SCEs and CAs for both 
compounds in the same experimental conditions. Moreover, it should be noted that the 
serum levels of AA and GA observed in animals exposed to AA are in the same range 
of concentrations used in this study. In fact, a single oral dose of 50 mg/kg AA in mice 
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produced peak serum concentrations of AA and GA of approximately 450 and 200 µM, 
respectively [35] and a repeat dosing through drinking water of approximately 1 
mg/kg/day, produced steady state serum concentrations of approximately 500 nM in rats 
for both AA and GA [36]. 
The data concerning the levels of N7-GA-Gua after exposure to AA showed that 
this adduct was only detected for doses higher than 1 mM, but at very low levels (Table 
IIII.3). Since the V79 cells used in our study are essentially devoid of CYP2E1 activity, 
the low levels of N7-GA-Gua stemming from AA exposure might be related to either 
residual metabolism of AA in V79 cells or to a small extent of spontaneous non-
enzymatic oxidation to GA, under the aerobic conditions used for the incubations [13]. 
In cells treated with GA, the measurement of the N7-GA-Gua levels was much 
more dose-sensitive than the determination of the cytogenetic end-points evaluated in 
this study. In fact, N7-GA-Gua was detected for concentrations as low as 1 µM GA at 
two different exposure periods. However, the detection of N3-GA-Ade was only 
possible for exposure to doses higher than 250 µM, which is consistent with the data 
previously reported by Gamboa da Costa et al. [16]. In that study, the levels of N7-GA-
Gua in mice treated with AA were found to be considerably higher than those of N3-
GA-Ade, and a similar result was obtained from in vitro incubations of GA with DNA. 
The levels of N7-GA-Gua in V79 cultures, corresponding to parallel cultures of the CAs 
and SCEs assays (18 and 29 h, respectively), were within the same range. Since the 
half-life of N7-GA-Gua in DNA was determined to be 42 h at 37 ºC [16] a 
depurination-related decrease in adduct levels between the 18- and 29-h incubation 
periods would not be expected to exceed 16%, which is consistent with our 
observations. Moreover, the absence of a net increase in the levels of N7-GA-Gua at 29 
h further suggests that the GA concentrations in the incubation media might be 
essentially depleted at 18 h, presumably through hydrolysis. Likewise, considering that 
the half-life of N3-GA-Ade in DNA was estimated to be 14 h at 37 ºC [16], and 
assuming no mechanisms involved other than spontaneous depurination, a decrease of 
approximately 42% in the N3-GA-Ade levels would be expected in the 11-h period 
separating the 18 and 29-h incubations. This is compatible with the apparent decrease in 
adduct levels observed for N3-GA-Ade at 29 h. 
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This study shows that GA induced SCEs, in a linear dose-response manner, with 
a 10-fold increase being observed at 1 mM GA (Table III.2). Moreover, GA was 
approximately two orders of magnitude more potent than AA, for which SCEs were 
only induced at the highest dose tested (2 mM). The DNA adducts investigated in the 
present work are depurinating lesions, known to be formed upon direct reaction of GA 
with DNA, even at low GA concentrations [16]. The fact that there is an excellent 
correlation (r = 0.987; P = 1.25 x 10
-12
) between the levels N7-Gua-GA in the GA- and 
AA-treated cells and the extent of SCE induction strongly suggests that the metabolism 
of AA to GA and the ensuing formation of depurinating DNA lesions [8, 9] is 
responsible for the SCE induction.  
The repair of the lesions induced by GA was recently associated with the small 
patch of base excision repair pathway [33]. In addition, the authors also noted that GA 
is a strong inducer of single strand breaks (SSB). It is well known that base excision 
repair can lead to the formation of DNA breaks [37]. Likewise, depurination produces 
abasic sites that can initiate DNA breaks [37]. Therefore, DNA breakage may to some 
extent explain the higher clastogenic effect of GA, compared with AA. 
DNA breaks can also be repaired by homologous recombination. This type of 
repair is important for double strand break repair in late S and in G2 phases of the cell-
cycle [38]. However, in the case of an unrepaired SSB, conversion into a double strand 
break can occur. This event may take place during replication, collapsing the replication 
fork and leaving one free DNA end that is a substrate for homologous recombination 
[39]. This newly created double-strand break may initiate a SCE by homologous 
recombination after two subsequent mitotic steps. There is growing evidence that SCEs 
are formed from persisting SSB; for example, cells deficient in SSB repair have 
increased levels of SCEs [39]. It should be stressed that while only a moderate increase 
in clastogenicity was observed with GA, compared to AA, there were substantial 
differences (two to three orders of magnitude) in the levels of N7-GA-Gua between 
cells treated with equimolar doses of AA and GA. Thus, while there appears to be a 
causal relationship between depurinating adduct levels and SCEs/cell, other 
mechanisms must be involved in the induction of the other cytogenetic end points 
measured in this study. For example, while GA should be intrinsically less reactive than 
AA with free radicals, due to the absence of the olefinic double bond, it is still a potent 
electrophile that may contribute to glutathione depletion, thus increasing vulnerability 
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of the cells to oxidative damage, as suggested for AA [31]. Additionally, 
nondepurinating GA adducts (e.g., N1-GA-dA), and depurinating and nondepurinating 
adducts from direct reaction of AA with DNA [30] might play a role in the cytogenetic 
responses. 
In summary, these results are consistent with the conclusion that the induction of 
SCEs by AA is associated with the metabolism of AA to GA and subsequent formation 
of depurinating DNA adducts. Other mechanisms, however, must be involved in the 
formation of CAs. The elucidation of these mechanisms warrants further investigation.  
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Chapter 4 
 
 
 
 
 
 
Cytotoxicity and chromosomal aberrations induced by acrylamide in 
V79 cells: Role of glutathione modulators. 
 
 
 
 
This chapter was adapted from: 
 
“Cytotoxicity and chromosomal aberrations induced by acrylamide in V79 cells: Role 
of glutathione modulators.” Oliveira NG, Pingarilho M, Martins C, Fernandes AS, Vaz 
S, Martins V, Rueff J and Gaspar JF. Mutation Research (2009) 676: 87-92. 
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Abstract  
 
Acrylamide (AA) is a suspected human carcinogen found to be generated during 
the heating of carbohydrate-rich foodstuffs. AA exhibits ‘Michael-type’ reactivity 
towards reduced glutathione (GSH), resulting in vivo in the urinary
 
excretion of 
mercapturic acid conjugates. GSH is a key factor for mammalian cell homeostasis, with 
diverse functions that include, among others, the conjugation of electrophilic 
compounds and the detoxification of products generated by oxidative stress. Therefore, 
studies focusing on the modulation of GSH are of great importance for the 
understanding of the mechanisms of AA induced toxicity. This report addresses this 
issue by analyzing cytotoxicity (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) reduction assay) and clastogenicity (chromosomal 
aberrations) as endpoints in V79 cells exposed to AA. The experiments described herein 
include the evaluation of the effect of buthionine sulfoximine (BSO), an effective 
inhibitor of GSH synthesis, GSH-monoethyl ester (GSH-EE), a compound that is taken 
up by cells and intracellularly hydrolysed to GSH, and also GSH exogenously added to 
culture medium. Pre-treatment with BSO increased the cytotoxicity and the frequency 
of aberrant cells excluding gaps (ACEG) induced by AA. While pre-treatment with 
GSH-EE did not modify the cytotoxicity or the frequency of ACEG induced by AA, co-
treatment with AA and GSH decreased both parameters, rendering the cells less prone 
to the toxic effects of AA. In vitro studies in a cell-free system, using 
monochlorobimane (MCB), a fluorescent probe for GSH, were also performed in order 
to evaluate the role of AA in GSH depletion. The results obtained showed that 
spontaneous conjugation of AA with GSH in the extracellular medium is involved in the 
protection given by GSH. In summary, these results reinforce the role of GSH in the 
modulation of the cytotoxic and clastogenic effects induced by AA, which may be 
relevant in an in vivo exposure scenario.  
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4.1. Introduction 
 
Acrylamide (AA) is a suspected human carcinogen generated during the heating 
of carbohydrate-rich foodstuffs, predominantly from the precursor asparagine [1]. 
Acrylamide toxicity to mammalian cells has been described and characterized in the last 
few years using different approaches [2, 3].  
AA is metabolized to glycidamide (GA) by an epoxidation reaction, presumably 
mediated by cytochrome P450 2E1 (CYP2E1) [4, 5]. This metabolic conversion appears 
to be critical for the genotoxicity of AA [2, 3, 6, 7]. Recently, we have also found that 
AA, compared to GA, is clearly less cytotoxic and genotoxic, as evaluated by different 
endpoints [8]. In fact, either the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) reduction assay or the DNA damage endpoints studied, viz 
chromosomal aberrations (CAs), sister-chromatid exchanges (SCEs) and glycidamide-
DNA adducts (GA-DNA adducts), showed that GA unequivocally possesses more 
toxicity than AA. However, while the importance of GA is nowadays convincing, 
further studies focusing on the metabolic fate of AA are still needed for a better 
mechanistic understanding of its toxicity. The modulation of reduced glutathione (GSH) 
status could give additional insight into this matter. GSH has several crucial roles in 
mammalian cell including, among others, the conjugation of electrophilic compounds 
and the detoxification of products generated by oxidative stress [9]. Both GSH functions 
can indeed be important for mitigation of AA toxicity in an in vivo exposure scenario. 
In fact, besides the possibility of AA being an oxidative stress inducer [10-13], this 
compound is efficiently conjugated with reduced glutathione (GSH) [3, 14]. The α,ß-
unsaturated carbonyl group of AA allows
 
its ‘Michael-type’ reactivity toward GSH, 
resulting in the urinary
 
excretion of mercapturic acid conjugates [3]. The conjugates of 
GSH with AA have been quantified in humans and their importance reported. In fact, 
toxicokinetic studies in humans have shown that ~60%
 
of AA can be recovered in the
 
urine [15], essentially in the form of GSH conjugates [16]. GA is also conjugated with 
GSH, but the ratio of glycidamide-GSH to acrylamide–GSH conjugates excreted in 
human urine is
 
only
 
~0.1 [15].  
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In this report, we describe the evaluation of the effect of the GSH modulators 
buthionine sulfoximine (BSO), a specific inhibitor of GSH synthesis, and GSH-
monoethyl ester (GSH-EE), a compound that is taken up bycells and intracellularly 
hydrolysed to GSH. While BSO pre-treatment effectively reduces the endogenous 
content in GSH [17], the pre-loading of mammalian cells with GSH-EE has proven to 
significantly increase GSH intracellular content [18]. In this work, we performed cell 
viability studies, using the MTT reduction assay and also evaluated the levels of 
chromosomal damage by use the chromosomal aberrations assay in V79 Chinese 
hamster fibroblasts. In addition, the simultaneous treatment of AA with exogenously 
added GSH was studied using the same endpoints. In this co-treatment protocol the 
effect of GSH is essentially extracellular, since this compound does not easily enter the 
cells [19]. In view of this, we have performed in vitro studies in a cell-free system, 
using monochlorobimane (MCB), a fluorescent probe for GSH [20], in order to evaluate 
the depletion of GSH in the presence of AA and thus the role of the spontaneous, non-
enzymatic conjugation of AA with GSH. 
 
 
4.2. Materials and methods 
 
4.2.1. Chemicals 
 
L-Glutathione reduced (GSH; CAS registry number 70-18-8), glutathione 
reduced monoethyl ester (GSH-EE; CAS registry number 92614-59-0), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), trypsin, newborn 
calf serum, Ham’s F-10 medium, phosphate buffered saline pH 7.4 (PBS), mitomycin 
C, and penicillin-streptomycin solution were purchased from Sigma-Aldrich (St. Louis, 
MO). Dimethylsulphoxide (DMSO), ethanol, methanol, acetic acid, potassium chloride, 
sodium chloride, and Giemsa dye were obtained from Merck (Darmstadt, Germany). 
Colchicine, monochlorobimane (MCB), L-buthionine sulphoximine (BSO; CAS 
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registry number 83730-53-4), and acrylamide (AA; CAS registry number 79-06-1,  
99.5 % pure) were purchased from Fluka (Buchs, Switzerland).  
 
4.2.2. MTT reduction assay 
 
Cytotoxicity assay was carried out in V79 cells, cultured as described in Capter 
3 (3.2.2). The MTT assay was performed according to Martins et al. [8], as described in 
Chapter 3 (3.2.3). Ten-hour cultures, growing in 96-well microplates, were incubated 
with BSO (0.1 mM) or GSH-EE (1.0 and 2.5 mM) for a period of 14 h. Afterwards, the 
medium was removed, the cells were washed with culture medium, and exposed to AA 
(2.0 and 4.0 mM) for 24 h. In the co-incubation experiments, cells exposed to AA (0.5-
6.0 mM) were simultaneously incubated with GSH (1.0 mM). After 24 h of incubation, 
the cells were washed and MTT (0.5 mg/ml) was added to each well. The cells were 
grown for a further period of 3 h and the assay was carried out as described in the 
previous chapter. Absorbance values presented by V79 cell cultures without the 
addition of AA, BSO, GSH-EE or GSH, i.e. control cultures, correspond to 100% of 
cell viability. At least two independent experiments were performed. Eight individual 
cultures were used in each independent experiment.  
 
 
4.2.3. Chromosomal aberrations assay 
 
The chromosomal aberrations assay was performed as described previously [8, 
21] and as described in Chapter 3 (3.2.4). V79 cells (24-h cultures) were exposed to 2.0 
mM AA for a period of 16 h. BSO (0.1 mM) and GSH-EE (1.0 mM) were added 14 h 
before the incubation with AA. In the co-incubation experiments, cells were 
simultaneously exposed to AA and GSH (1.0 and 3.0 mM). Mitomycin C (0.75 µM) 
was used as the positive control. After the treatments, the assay was carried out as 
described in the previous chapter. Two independent experiments were performed except 
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for the co-treatment of AA with GSH 1.0 mM. In this case four independent 
experiments were performed. 
For each independent experiment, 100 well-spread metaphases were observed 
using a 1250x magnification on a light microscope. Scoring of the different types of 
aberrations was performed according to published criteria [22, 23]. For the 
quantification of the DNA damage induced by AA, the index %ACEG (percent of 
aberrant cells excluding gaps) was used. This index represents the frequency of 
metaphases containing chromosomal aberrations excluding gaps and constitutes the 
standard indicator for the chromosomal aberrations assay. The types of aberrations 
considered for this index were: breaks (chromatid and chromosome), dicentric 
chromosomes and rings, chromatid-type rearrangements (triradial, quadriradial), other 
complex rearrangements and multi-aberrant cells (MA, cells with more than 10 
aberrations, including heavily damaged pulverized cells). 
 
 
4.2.4. GSH conjugation assay 
 
The conjugation studies of AA with GSH were carried out in 96-well black 
microplates using an in vitro cell-free assay based on the MCB fluorimetric method [20, 
24]. MCB is a probe that reacts with GSH generating an adduct (MCB-GSH conjugate) 
that can be detected by fluorimetry [20]. 
To each well was first added PBS, and afterwards AA (up to 6.0 mM, final 
concentration) and/or GSH (up to 1.0 mM, final concentration). The microplates were 
placed in an incubator at 37 ºC, protected from the light for a period of 1 h or 24 h. 
Afterwards, MCB solution (stock solution of 10 mM in absolute ethanol and diluted 10x 
with PBS) was added to each well at a final concentration of 100 µM. Control 
experiments were performed with AA and GSH without any incubation. The plates 
were then placed in an incubator with shaker for 30 min at 37 ºC (100 rpm, protected 
from light) and then fluorescence was measured in an Anthos Zenyth 3100 multimode 
detection microplate reader (λexc= 405 nm , λem = 465 nm).  
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The results were expressed either in fluorescence intensity using relative 
fluorescence units (RFU) after the subtraction of the background fluorescence or 
normalized in terms of free GSH (%), i.e. the mean value of fluorescence (RFU) 
observed in GSH alone plus MCB wells corresponded to 100%. For each experimental 
point four wells were used in each independent experiment. At least two independent 
experiments were carried out.  
 
4.2.5. Statistical analysis 
 
The Kolmogorov-Smirnov test was used to test the normality of continuous 
variables (% cell viability, %ACEG). For the variables with a normal distribution the 
homogeneity of the variances was evaluated using the Levene test, and the differences 
in the mean values of the results observed in cultures treated with AA versus AA+GSH 
modulators were evaluated by the Student t-test. For non normal variables the Mann-
Whitney was used. The levels of significance considered were P<0.05, and P<0.01. All 
analyses were performed with the SPSS statistical package (version 15, SPSS Inc. 
Chicago Il., USA). 
 
 
4.3. Results  
 
4.3.1. MTT reduction assay 
 
The results from a set of cell-based experiments using the MTT reduction assay 
are presented in Fig. 4.1. These experiments were performed in order to evaluate the 
effect of GSH modulators on the viability of V79 cells treated with AA.  
Fig. 4.1.A presents the effect of the depletion of intracellular GSH by pre-
incubation of V79 cells with BSO. BSO alone slighlty reduced cell viability compared 
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with that of control cells (Fig. 4.1.A). The viability of AA-treated V79 cells decreased 
as a function of AA concentration (Fig. 4.1.A). The pre-incubation with 0.1 mM BSO 
caused an additional decrease in viability of 35% at 4 mM of AA (P<0.05).  
The effect of the pre-treatment with GSH-EE on the viability of V79 cells 
exposed to AA is shown in Fig. 4.1.B. In these experiments, two concentrations of 
GSH-EE were used (1.0 and 2.5 mM). GSH-EE alone at 1.0 mM concentration was not 
cytotoxic, but the high concentration (2.5 mM) caused a decrease in cell viability of 
about 17%. The cell viability in AA-treated cultures was not significantly altered in the 
presence of both 1.0 and 2.5 mM concentrations of GSH-EE.  
Cell viability data corresponding to simultaneous treatment of V79 cells with 
AA and GSH are presented in Fig. 4.1.C. A slight decrease in cell viability was 
observed for GSH alone (1.0 mM). Co-treatment with AA (0.5-6.0 mM) and GSH (1.0 
mM) consistently enhanced the viability of V79 cells when compared with AA 
treatment alone. In fact, absolute increases in cell viability of approximately 15-20 % 
were observed for AA concentrations of 2.0 mM (P<0.05), 4.0 mM (P<0.05) and 6.0 
mM (P<0.01) in the presence of GSH (Fig. 4.1.C.).  
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Fig. 4.1. Effect of glutathione modulators on cell viability presented by V79 fibroblasts 
exposed to acrylamide (AA, 24 h incubation) using the MTT reduction assay (% MTT 
reduction). (A) Effect of BSO (0.1 mM) pre-treatment (14 h). Results are expressed as 
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mean values and SD from three independent experiments (*P<0.05 when compared 
with the same concentration of AA in the absence of BSO). (B) Effect of GSH-EE (1.0 
and 2.5 mM) pre-treatment (14 h). Results are expressed as mean values and SD from 
two independent experiments. (C) Effect of GSH (1.0 mM) co-incubation (24 h). 
Results are expressed as mean values and SD from three independent experiments 
(*P<0.05 and ** P<0.01 when compared with the same concentration of AA in the 
absence of GSH).  
 
 
4.3.2. Chromosome aberration assay 
 
The results from the CAs assay in V79 cells exposed to AA are presented in Fig. 
4.2. Considering all four independent CA experiments, AA at 2.0 mM significantly 
increased the frequency of ACEG from ~1% to ~12 % (P<0.05). While pre-treatment 
with BSO (0.1 mM) caused an increase of the genotoxicity of AA by a factor of 1.5 (not 
significant), pre-treatment with GSH-EE had no effect on the frequency of ACEG 
induced by AA (Fig. 4.2.A).  
The effect of GSH co-treatment (1.0 mM) on the %ACEG induced by AA is 
depicted in Fig. 4.2.B. The presence of GSH 1.0 mM led to a decrease of about 25% in 
the clastogenicity of AA (not significant). GSH 3.0 mM markedly reduced AA-induced 
ACEG by more than 50%, and this effect almost reached statistical significance 
(P=0.06). As depicted in Fig. 4.2.B, there is a consistent trend in the decrease of ACEG 
induced by AA as a function of GSH concentration. 
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Fig 4.2. Effect of glutathione modulators on the induction of chromosomal aberrations 
by acrylamide (2.0 mM) in V79 cells. (A) Effect of BSO (0.1 mM) or GSH-EE (1.0 
mM) pre-treatment (14 h). Results are expressed as mean values and SD from two 
independent experiments. (B) Effect of GSH (1.0 and 3.0 mM) co-incubation (24 h). 
Results are expressed as mean values and SD from two (GSH 3.0 mM) or four (GSH 
1.0 mM) independent experiments. 
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4.3.3. GSH conjugation assay 
 
The results from cell-free experiments performed in order to evaluate the 
spontaneous non-enzymatic conjugation of AA with GSH are presented in Fig. 4.3. Fig. 
4.3.A shows the fluorescence curve of the conjugate GSH-MCB for increasing 
concentrations of GSH, up to 1.0 mM, presenting a clear dose-response and an increase 
in the intensity of the fluorescence. The pre-treatment by 0.5 mM AA for 1 h (37 ºC) 
with the same concentrations of GSH did not change the intensity of the fluorescence 
observed (Fig. 4.3.A).  
Fig. 4.3.B shows the effect of 1-h pre-treatment with GSH (0.5 mM) with 
increasing concentrations of AA, up to 4.0 mM. The results expressed in terms of free 
GSH (%) show a slight conjugation of GSH at different concentrations of AA, which 
was only evident for the higher concentrations of AA. A control experiment was 
performed in the same conditions with the purpose of evaluating the immediate 
conjugation of AA with GSH (without pre-incubation). Under these circumstances no 
spontaneous conjugation was found (data not shown). 
The effect of 24-h pre-treatment of GSH (1.0 mM) with increasing 
concentrations of AA, up to 6.0 mM is presented in Fig. 4.3.C. The conjugation 
observed was much more pronounced than for 1-h incubation (Fig. 4.3.B). At the higher 
concentrations of AA (4.0 and 6.0 mM) the GSH-MCB fluorescence was very low 
(<3%), which means that almost all the GSH was involved in the conjugation with AA. 
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Fig. 4.3. In vitro non-enzymatic GSH conjugation studies with acrylamide (AA) using the 
fluorimetric monochlorobimane (MCB) assay. (A) Dose-effect curves of GSH-MCB 
fluorescence intensity presented by GSH alone or GSH incubated 1 h with AA (0.5 mM). 
Results are expressed as mean values and SD of fluorescence intensity (Relative Fluorescence 
Units -RFU) from two independent experiments. (B) Dose-effect curve of free GSH (%) 
observed upon incubation of GSH (0.5 mM) during 1 h with different concentrations of AA. 
Results are normalized in terms of the GSH-MCB fluorescence, considering 100% the 
fluorescence presented by GSH alone plus MCB. Results are expressed as mean values and SD 
from three independent experiments. (C) Dose-effect curve of free GSH (%) observed upon 
incubation of GSH (1.0 mM) during 24 h with different concentrations of AA. Results are 
normalized in terms of the GSH-MCB fluorescence, considering 100% the fluorescence 
presented by GSH alone plus MCB. Results are expressed as mean values and SD from two 
independent experiments.  
 
 
4.4. Discussion 
 
Recently, we have shown that the induction of sister chromatid exchanges and 
the levels of G7-GA-DNA adducts were found to be two-to-three orders of magnitude 
lower in AA-treated V79 cells than in GA exposed cells [8]. However, AA cytotoxicity 
as assessed by the MTT assay and clastogenicity in terms of %ACEG were only about 
twofold lower when compared with those seen with GA [8]. In view of these clear 
different effects it seemed important to evaluate the role of GSH modulators in AA-
induced toxicity using the aforementioned endpoints of cell viability and clastogenicity 
in the same cell line. The V79 cells are essentially devoid of CYP2E1 activity [5, 25], 
being thus adequate for this study, since only negligible amounts of GA are expected to 
be formed. 
In this work, different approaches for the modulation of GSH status were used. 
First, the effect of endogenous depletion of GSH was studied. Typically, GSH depletion 
has been carried out by use of BSO, an effective inhibitor of GSH synthesis [17]. In our 
experimental protocol, V79 cells were incubated with BSO 0.1 mM for a period that 
approximately corresponds to the duration of one cell cycle (14 h). This concentration 
of BSO has proven to deplete the GSH content in V79 cells [26]. Other authors using 
even lower concentrations of BSO also reported marked reductions in the GSH levels in 
this cell line [27, 28]. In our experiments, BSO treatment alone was associated with 
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relatively low toxicity leading to a slight decrease in cell viability (Fig. 4.1.A) and to a 
slight increase in the frequency of ACEG (Fig. 4.2.A). 
Several reports have shown the sensitization potential of GSH depletion for the 
toxicity of physical and chemical agents (reviewed in [29]). As far as AA is concerned, 
there are few reports focusing on its toxicity in cultured mammalian cells depleted of 
GSH. Park et al. [30] found that BSO increased the percent of morphologically 
transformed colonies of Syrian hamster embryo cells induced by AA. Recently, other 
authors described increases in the cytotoxicity of AA in HepG2 cells pre-treated with 
BSO [12], and others reported enhanced DNA damage as measured by the comet assay 
in V79 cells pre-treated with BSO [31]. Our results show that the depletion of GSH 
significantly decreased the viability of AA-treated cells supporting the role of 
endogenous GSH in the mitigation of the toxic effects triggered by this agent. The 
clastogenicity of AA was also further enhanced in the presence of BSO. However, this 
~1.5 fold increase observed was not significant, which may suggest that, at least in 
some extent, AA-related cytotoxicity and clastogenicity could be achieved by different 
mechanisms. 
Intracellular GSH enrichment by means of pre-treatment with GSH-EE is a 
common procedure to evaluate the potential protective effect of GSH towards the 
toxicity of a given xenobiotic agent. Wellner et al [18] showed that the increase in GSH 
became effective after ~4 h of pre-incubation with GSH-EE and that the GSH content 
increased either with the duration of the pre-treatment period (up to 24 h) or with the 
concentration of GSH-EE. In our study, we selected a pre-incubation period of 14 h and 
two concentrations of GSH-EE, 1.0 mM and 2.5 mM. Longer periods of incubation and 
higher concentrations of GSH-EE were avoided in order to minimize the possibility of 
toxicity due to GSH-EE per se. In contrast to several reports focusing on the 
cytoprotective effects of GSH-EE [18, 29, 32-35] there are also some published data 
where the pre-incubation with GSH-EE did not protect cells against a toxic insult [36-
39].  
As far as we know there are no previous reports on the effect of GSH-EE against 
the toxicity induced by AA. The results obtained in this study were consistent with 
respect to both the cytotoxicity and the clastogenicity endpoint, and fail to show a 
protective effect of GSH-EE. These results may suggest that the intracellular 
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concentration of GSH is not the limiting factor for the detoxification of AA in V79 
cells, although other issues including the extrusion of GSH-EE as well as some toxicity 
derived from GSH-EE pre-treatment could be involved. In fact, it has been previously 
reported that the hydrolysis of the ethyl esters of GSH produces ethanol [18]. This 
occurrence may be related to the cytotoxicity sometimes associated with GSH 
monoesters [35, 40], although some authors attribute the toxicity to impurities present in 
GSH-EE (reviewed in [33]). In this study, we have also observed a modest cytotoxic 
effect (Fig. 4.1.B) for the higher concentration of GSH-EE (2.5 mM).  
While the pre-treatment with GSH-EE readily increases the intracellular 
concentration of GSH to values significantly above physiological values [32, 40], the 
incubation with GSH generally leads to small increases in intracellular GSH [32] and 
therefore can give additional information on extracellular protective effects by GSH. 
The results presented here show that exogenously added GSH can effectively reduce the 
cytotoxicity (Fig. 4.1.C) and the induction of chromosomal aberrations (Fig. 4.2.C) by 
AA. In order to evaluate the effect of a potential conjugation of AA with GSH in the 
extracellular medium we studied in a set of cell-free experiments the intensity of 
fluorescence of the conjugate GSH-MCB after incubation of AA with GSH. There are 
only some reports on the conjugation of AA with GSH in in vitro cell-free systems [41]. 
The experiments herein described with the MCB probe show that the spontaneous 
conjugation of AA is favoured when AA concentrations are higher than GSH 
concentrations. Also, these results show that this spontaneous conjugation is clearly 
time-dependent since 1-h incubation barely decreased the percentage of free GSH when 
compared to a 24-h incubation period.  
The cytotoxicity data from Fig. 4.1.C were obtained in experimental conditions 
(concentration, incubation period, temperature) comparable to those used in the 
conjugation studies (Fig. 4.3.C). These results show a marked decrease in free GSH 
after 24-h incubation, supporting the notion that spontaneous conjugation with AA may 
be implicated in the reduction of the cytotoxicity of AA when GSH is simultaneously 
added to the culture medium. However, we should also consider that GSH could be 
responsible for the scavenging of reactive oxygen species that could be formed by AA 
in mammalian cells. In fact, some reports have suggested that AA induces oxidative 
stress in cell-based and animal models [10-13]. 
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It is also interesting to mention that the increase in the viability of V79 cells co-
treated with AA and GSH corresponds roughly to 20% in terms of absolute cell viability 
irrespective of the concentration level. In contrast, the in vitro data from the MCB 
experiments show a clear dose-response decrease in the percentage of free GSH. This 
apparent lack of correlation may be explained by mechanistic differences between cell-
free and cellular systems, since AA is taken up by the cultured cells, and is thus less 
available for extracellular conjugation with GSH and more prone to exert its toxic 
effects intracellularly. 
In summary, the results presented here reinforce the role of GSH in the 
modulation of the cytotoxic and clastogenic effects induced by AA. The protection 
afforded by GSH could be achieved by different mechanisms, including the conjugation 
with AA and also by an antioxidant-based mechanism. Since GSH is considered to be a 
key protective factor for mammalian cells and its content may vary at cellular level and 
also according to patho-physiological conditions, these results may be relevant for an in 
vivo AA exposure scenario. 
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Chapter 5 
 
 
Induction of sister chromatid exchange by acrylamide and glycidamide 
in human lymphocytes: Role of polymorphisms in detoxification and 
DNA-repair genes in the genotoxicity of glycidamide 
 
 
This chapter was adapted from: 
 
“Induction of sister chromatid exchange by acrylamide and glycidamide in human 
lymphocytes: Role of polymorphisms in detoxification and DNA-repair genes in the 
genotoxicity of glycidamide.” Pingarilho M, Oliveira NG, Martins C, Gomes BC, 
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Doerge D, Rueff J and Gaspar JF.   
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Abstract  
 
Acrylamide (AA) is a probable human carcinogen generated in carbohydrate-
rich foodstuffs upon heating. Glycidamide (GA), formed via epoxidation, presumably 
mediated by cytochrome P450 2E1, is considered to be the active metabolite that plays a 
central role in the genotoxicity of AA. The aim of this work was to evaluate the 
cytogenetic damage induced by AA and GA in cultured human lymphocytes by use of 
the sister chromatid exchange (SCE) assay and the levels of specific glycidamide-DNA 
adducts,
 
namely N7-(2-carbamoyl-2-hydroxyethyl)guanine (N7-GA-Gua) and
 
N3-(2-
carbamoyl-2-hydroxyethyl)adenine (N3-GA-Ade). Furthermore, this report addresses 
the role of individual genetic polymorphisms in key genes involved in detoxification 
and DNA-repair pathways (BER, NER, HRR and NHEJ) on the induction of SCE by 
GA. While AA induced the number of SCE/metaphase only slightly, especially for the 
highest concentration tested (2000 µM), GA markedly induced SCEs in a concentration-
dependent manner up to concentrations of 750 µM, leading to an increase in SCEs of up 
to about 10-fold compared with controls. A linear dose-response was observed between 
the GA concentrations (up to 750 μM) and the level of N7-GA-Gua, with this adduct 
been detected at the lower studied dose (10 μM). AA-induced DNA adducts were not 
found at any concentration studied. By combining DNA damage in GA-treated 
lymphocytes and data on polymorphisms, associations between the induction of SCEs 
with GSTP1 (Ile105Val) and GSTA2 (Glu210Ala) genotypes are suggested.  
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5.1. Introduction 
 
Acrylamide (AA) is a well-known industrial chemical classified as a probable 
human carcinogen by IARC since 1994 [1]. Until 2002 AA was regarded only as an 
industrial or occupational genotoxicant. In fact, AA has been used to manufacture 
polymers, as additives for water treatment, as flow control agent in oil recovery, in pulp 
and paper processing, in mining and mineral processing and in laboratory gels. The 
foremost routes of exposure were considered to be dermal absorption and inhalation of 
aerosols in the workplace [2, 3].  
In 2002 it was shown that AA can be formed during heating via the Maillard 
reaction between asparagine and reduced sugars in processed food [4-7]. Moreover, 
there is evidence that the major contribution for acrylamide-Hb adducts in 
occupationally non-exposed subjects is originated from acrylamide formation during 
cooking and food preparation [8]. AA can be found in commonly consumed foods and 
beverages, such as processed cereals, French fries, potato chips and coffee. Average 
daily intake of AA was estimated to be about 0.5-1.0 µg/Kg bw in adults and up to 2-
fold higher in 13 year-old children with a normal western diet [9].  
The metabolism of AA occurs via conjugation with reduced glutathione (GSH) 
resulting in the urinary excretion of a mercapturic acid conjugate, or through 
epoxidation presumably mediated by cytochrome P450 (CYP2E1) to yiel the genotoxic 
epoxide glycidamide (GA). GA can be metabolized via conjugation with GSH or 
undergo hydrolysis of the epoxide group by epoxide hydrolase (EPHX) to form 
glyceramide, which is also excreted in urine [6, 10, 11]. 
The alpha/ beta-unsaturated double bond of AA is responsible for much of its 
reactivity, being involved in Michael-type reactions. In fact, the beta-carbon of AA can 
react with nucleophiles [2], leading to formation of protein adducts (e.g. AA-Hb 
adducts). In addition, the biological activity of AA is also mediated by its metabolite 
GA. Besides generating protein adducts, GA has high affinity to DNA, giving rise to 
DNA-adducts. Conversely, AA has a rather weak capacity to bind DNA [2]. 
Recently, a number of GA-DNA adducts have been characterized including the 
N7-(2-carbamoyl-2-hydroxyethyl)guanine (N7-GA-Gua, Fig. 5.1), N3-(2-carbamoyl-2-
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hydroxyethyl)adenine (N3-GA-Ade, Fig. 5.1), and N1-(2-carboxy-2-hydroxyethyl)-2’-
deoxyadenosine (N1-GA-dA) [12]. 
 
 
 
 
 
 
Figure 5.1 - Chemical structures of N7-(2-carbamoyl-2-hydroxyethyl)guanine (N7-GA-
Gua) and N3-(2-carbamoyl-2-hydroxyethyl)adenine (N3-GA-Ade). 
 
Long-term studies in rodent models have shown that AA is carcinogenic at 
different organ-sites [6]. However, no consistent evidence of an increased cancer risk 
was found among workers exposed to AA. Moreover, the association of the increased 
risk for human cancer with dietary consumption of AA is still a matter of discussion [3, 
6]. While some studies have found significant associations between oral exposure to AA 
and cancer, others failed to prove such a relationship. For instance, a recent study by 
Wilson et al [13] found no association between acrylamide and breast cancer. However, 
with high acrylamide consumption a greater risk for endometrial and possibly ovarian 
cancer was observed. Similar findings were reported by Hogervorst et al [14] whereas 
Olesen et al found a positive association with estrogen-positive breast cancer [15]. In 
view of the conflicting results in the epidemiological studies it is crucial to develop 
valuable toxicological biomarkers to be associated with the information in food-
frequency questionnaires (FFQ) in order to improve the assessment of carcer risk upon 
oral consumption of AA. 
In this context, the primary aim of the present report is to assess the usefulness 
of sister chromatid exchange (SCE) as a cytogenetic toxicological biomarker in human 
lymphocytes exposed in vitro to AA and GA and compare this end-point results with 
the extent of GA-DNA adducts formation. Moreover, this study aims to identify 
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possible associations of SCE with biomarkers of susceptibility concerning individual 
genetic polymorphisms in detoxification and DNA-repair genes. The polymorphisms 
herein studied comprise genes associated with metabolism, specifically glutathione S-
transferases (GSTM1, GSTT1, GSTP1, GSTA2) and EPHX1. Moreover, this study is 
focused on polymorphisms in DNA-repair genes from the base-excision repair (BER), 
nucleotide-excision repair (NER), homologous recombination repair (HRR) and non-
homologous end-joining repair (NHEJ) pathways, which could be critical in the repair 
of GA-induced DNA lesions. 
 
 
5.2. Materials and Methods 
 
5.2.1. Chemicals 
Acrylamide (AA; CAS registry number 79-06-1, ≥99.5% pure) was purchased 
from Fluka (Buchs, Switzerland) and glycidamide (CAS Registry Number 5694-00-8, 
>98.5% pure, containing ~1% AA) was obtained from Toronto Research Chemicals 
(North York, Ontario, Canada). Fetal calf serum, Ham’s F-10 medium, penicillin-
streptomycin solution, L-glutamine, phosphate-buffered saline pH 7.4 (PBS), methanol, 
acetic acid, Hoechst 33258, 5-bromo-2’-deoxyuridine (BrdU), mitomycin C, ethidium 
bromide and colchicine were purchased from Sigma–Aldrich (St. Louis, MO, USA). 
Potassium chloride and Giemsa dye was acquired from Merck (Darmstadt, Germany). 
Phytohemagglutinin (PHA) was purchased from Gibco (Grand Island, NY, USA) and 
heparin was acquired to B. Braun (Lisbon, Portugal). 
 
 
5.2.2. Blood samples collection 
Peripheral blood samples were obtained from 13 healthy donors (8 female and 5 
male, mean ages 28.1 ± 4.3). The samples were collected under sterile conditions by 
venipuncture in heparinized tubes, coded and analyzed under blind conditions. 
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All donors were informed about the aim and experimental details of the study 
and an informed consent was obtained from all participating subjects prior to the start of 
the study. Each participant completed one standardized questionnaire about health 
history, lifestyle, alcohol consumption, medication usage, family history of cancer, 
exposure to indoor/outdoor pollutants, and dietary habits. All individuals were all non-
smokers. Ethical approval for this study was obtained from the institutional Ethical 
Board of the Faculty of Medical Sciences. 
 
 
5.2.3. Lymphocytes culture 
The lymphocytes cultures were set up by adding 0.5 ml of whole blood to 4.5 ml 
of Ham’s F-10 medium supplemented with 24 % fetal calf serum, 100 IU/ml penicillin, 
100 μg/ml streptomycin, 1 % L-glutamine, and 50 IU/ml heparin. Lymphocytes were 
stimulated with 1.5 % (v/v) of PHA and incubated at 37 ºC for 72 h in an atmosphere 
containing 5 % CO2. 
 
 
5.2.4. Sister chromatid exchange assay 
Firstly, different concentrations of AA and GA up to 2000 µM (dissolved in 
PBS, pH 7.4) were evaluated in order to characterize the dose-response pattern of both 
chemicals. For this purpose 24-h cultures of lymphocytes from two donors were treated 
with AA or GA and two independent experiments were performed for each donor. From 
the dose-response curve of GA, the concentration of 250 µM was chosen to be further 
assayed in all the donors (two replicate cultures).  
For both studies, after 46 h incubation with AA or GA in the presence of BrdU 
(final concentration of 10 µM), lymphocytes were washed with fresh culture medium 
and colchicine (0.6 µg/ml) was added. The lymphocytes were then incubated for a 
further 1.5h. Differential staining of BrdU-substituted sister chromatids was performed 
according to the fluorescence-plus-Giemsa method [16], as described in Chapter 3 
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(3.2.5). The frequency of SCE in each metaphase (SCE/metaphase) was scored in 30 
second-division metaphases, whenever possible, for each concentration in each 
experiment. Mitomycin C (0.75 µM) was used as positive control. 
 
 
5.2.5. Mitotic index 
The mitotic index (MI) was carried out as a measure of the cell proliferation. 
This index can be defined as MI = (no. of cells in division / total no. of cells) x 100 [17]. 
To determine this index, 1000 lymphocytes were scored for each experiment and the 
number of metaphases recorded. 
 
 
5.2.6. DNA adducts 
 
5.2.6.1. Chemical exposure and DNA extraction.  
Twenty-four hour cultures growing in culture tubes, were exposed to different 
concentrations of AA (0–1000 μM) and GA (0–2000 μM) during 22 hour period 
(corresponding to parallel cultures of the SCE assay, already explained in Chapter 
5.2.4). The lymphocytes were washed with PBS, and the cell suspensions were 
immediately stored at 20 ºC. DNA was extracted as described in Chapter 3 (3.2.6.1).  
 
 
5.2.7. DNA quantification.  
Quantification of DNA was carried out using a Pico-Green dsDNA quantitation 
kit as described in Chapter 3 (3.2.6.2). The yield of DNA extracted from each cell 
suspension was in the range of 20–40 μg, in accordance with the manufacturer’s 
standard yields of DNA for lymphocytes cells. 
 
 
136 
 
5.2.8. Quantification of DNA adducts.  
GA-DNA adducts, specifically N7-GA-Gua and N3-GA-Ade, were released 
from the DNA by neutral thermal hydrolysis and quantified by high-performance liquid 
chromatography coupled with tandem mass spectrometry, essentially as described in 
Gamboa da Costa et al [12] as described in Chapter 3 (3.2.6.3). 
 
 
5.2.9. Genotyping  
 
5.2.9.1. Detoxification pathways 
Genotyping of GSTM1 and GSTT1 for gene deletions were carried out by a 
multiplex PCR as described by Lin et al. [18] with minor modifications described in 
Costa et al [19]. After electrophoretic separation the amplified products were visualized 
in 2 % agarose gel stained with ethidium bromide (2.0 g/ml). 
The genotyping of GSTP1 Ile105Val (rs1695), EPHX1 Tyr113His (rs1051740) 
and His139Arg (rs2234922) and GSTA2 Glu210Ala (rs6577) was conducted with the 
polymerase chain reaction and restriction fragment length polymorphisms (PCR-RFLP). 
GSTP1 Ile105Val genotyping was performed according to Gaspar et al [20], EPHX1 
Tyr113His and His139Arg polymorphisms were determined as described by Teixeira et 
al [21] and GSTA2 Glu210Ala polymorphisms were determined according to published 
procedures [22, 23] with minor modifications. For the EPHX1 genotypes, in codons 113 
and 139, individuals were classified according to the expected activity on the basis of 
their genotypes as: low activity: His/His–His/His; His/His–His/Arg; Tyr/His–His/His; 
His/His–Arg/Arg; medium activity: Tyr/Tyr–His/His; Tyr/His–His/Arg; Tyr/His–
Arg/Arg; high activity: Tyr/Tyr–Arg/Arg; Tyr/Tyr–His/Arg [22, 24]. 
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5.2.9.2. DNA repair Pathways 
The genotyping of XRCC2 Arg188His (rs3218536), XRCC3 Thr241Met 
(rs861539) was performed by means of PCR-RFLP according to Bastos et al [25]. XPC 
Lys939Gln (rs2228001) and Ala499Val (rs2228000) polymorphisms were also 
conducted by means of PCR-RFLP and the primers sequences and PCR product for the 
polymorphic sites of these genes are shown in Table V.1. For these polymorphisms the 
nucleotide change resulted in either gain or loss of a restriction site, which therefore 
allowed the common and variant alleles to be discriminated by RFLP after appropriate 
enzyme digestion (see Table V.2). 
APEX Asp148Glu (rs1130409; C___8921503_10), ERCC1 Gln504Lys 
(rs3212986; C__2532948_10), ERCC2 Lys751Gln (rs13181; C___3145033_10), 
ERCC4 Arg415Gln (rs1800067; C___3285104_10), ERCC5 Cys529Ser (rs2227869; 
C___15956775_10) and His1104Asp (rs17655; C___1891743_10), ERCC6 
Gln1413Arg (rs2228529; C__16171343_10) and Arg1230Pro (rs4253211; 
C__25762749_10), GSTA2 Pro110Ser (rs2234951; C__12027714_50) and Ser112Thr 
(rs2180314; C__22275149_30), Ku80 Ex21-238G➝A (rs2440; C___3231046_20); 
Ex21+338T➝C (rs1051677; C___8838367_1_), Ex21-352C➝A (rs6941; 
C__8838374_10), Ex21+466A➝G (rs1051685; C___8838368_1_), LIG4 Thr9Ile 
(rs1805388; C__11427969_20), MUTYH Gln335His (rs3219489; C__27504565), NBS1 
Glu185Gln (rs1805794; C__26470398_10), OGG1 Ser326Cys (rs1052133; 
C___3095552_1_), PARP1 Val762Ala (rs1136410; C___1515368_1_), PARP4 
Gly1280Arg (rs13428; C___8700143_10) and Pro1328Thr (rs1050112; 
C___8700142_10), RAD23B Ala249Val (rs1805329; C__11493966_10), RAD51 
5’UTR (rs1801321; C__7482700_10), XRCC1 Arg194Trp (rs1799782; 
C__11463404_10) and Gln399Arg (rs25487; C____622564_10) and XRCC4 It7G>A 
(rs1805377; C__11685997_10) and Thr134Ile (rs28360135; C25618660_10) 
polymorphisms were genotyped by Real-Time PCR (AB7300), using TaqMan SNP 
Genotyping Assays from Applied Biosystems, according to the manufacturer’s 
instructions and previous studies from our group [23, 25-27]. DNA samples were 
quantified with PicoGreen dsDNA Quantification Reagent (Molecular Probes, Eugene, 
Ore., USA) according to the manufacturer’s recommendations. The SNP genotyping 
assay information for BER and NER polymorphisms is summarized in Table V.3. 
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Genotype determinations were carried out twice (all samples for multiplex and 
PCR-RFLP and 20 % of samples for Real-Time PCR) in independent experiments and 
all the inconclusive samples were reanalyzed. 
 
 
5.2.10. Statistical Analysis 
For the concentration-response curves of AA and GA, regression analyses were 
performed using the Graphpad Prism v.5 software. The non-parametric Mann-Whitney 
(for 2 groups comparisons) and Kruskal-Wallis (for more than 2 groups comparisons) 
tests were used to evaluated the association of different genotypes with the frequency of 
GA-induced SCE after subtracting the background values. The level of significance 
considered was p≤0.05. All analyses were performed with the SPSS statistical package 
(version 17, SPSS Inc., Chicago, IL, USA). 
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Table V.1. Primer sequences, melting temperature (Tm), GC content and PCR product 
for XPC polymorphisms. 
Primer Sequences Tm 
GC 
content 
PCR 
product (bp) 
XPC Lys939Gln 
Forward 5´- ACC AGC TCT CAA GCA GAA GC- 3' 58º C 55% 
281 
Reverse 5' -CTG CCT CAG TTT GCC TTC TC- 3´ 56º C 55% 
XPC Ala499Val 
Forward 5´- TAA GGA CCC AAG CTT GCC CG- 3' 51º C 60% 
152 
Reverse 5' –CCC ACT TTT CCT CCT GCT CAC AG - 3´ 52º C 56% 
 
 
 
Table V.2. – Restriction enzymes used to digest the different PCR products and the 
respectively digestion time, temperature and restriction patterns for XPC 
polymorphisms. 
Polymorphism and effect on 
restriction enzyme site 
Digestion time and 
temperature 
Restriction patterns after enzyme 
digestion 
XPC Lys939Gln 
 
2 h 37ºC 
Lys/Lys : 281 bp 
C→A, create one Pvu II site Lys/Gln : 281 bp + 150 bp + 131 bp 
 Gln/Gln : 150 bp +131 bp 
XPC Ala499Val 
 
16-18 h 37ºC 
Ala/Ala: 152 bp 
C→T, create one Sac II site Ala/Val: 152 bp + 131 bp + 21 bp 
 Val/Val: 131 bp + 21 bp 
 
 
Table V.3. Single Nucleotide Polymorphisms genotyping assay information for BER and NER pathways. 
Repair Pathway Gene SNP region Amino Acid Exchange dbSNP ID ABI ID 
BER 
APEX   Asp148Glu rs1130409 C__8921503_10 
OGG1 Ex6-315C>G Ser326Cys rs1052133 C___3095552_1_ 
PARP1 Ex17+8T>C Val762Ala rs1136410 C__1515368_1 
 
PARP4 Ex31+172G>C Gly1280Arg rs13428 C__8700143_10 
  
Ex31+316C>A Pro1328Thr rs1050112 C__8700142_10 
  XRCC1 Ex10-4A>G Gln399Arg rs25487 C____622564_10 
 
ERCC2 Ex23+61A>C Lys751Gln rs13181 C___3145033_10 
 
 
ERCC5 Ex15-344G>C His1104Asp rs17655 C___1891743_10 
NER 
 
ERCC6 Ex21+176A>G Gln1413Arg rs2228529 C__16171343_10 
 
Ex18-90G>C Arg1230Pro rs4253211 C__25762749_10 
  RAD23B Ex7+65C>T Ala249Val rs1805329 C__11493966_10 
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5.3. Results 
 
5.3.1. GA markedly increases the formation of SCE in human lymphocytes 
The cytogenetic response in terms of SCE was firstly evaluated in stimulated 
lymphocytes from whole blood cultures of two healthy individuals. Different 
concentrations of AA and GA (up to 2000 µM) were used. The individual 
concentration-response curves for SCE/metaphase obtained for both compounds are 
presented in Fig. 5.2. The MI was evaluated as a measure of cell proliferation associated 
with the cytogenetic end-point and both AA and GA decreased the MI. However, the 
anti-proliferative effect was more pronounced for GA (data not shown). For the 
concentration of 750 µM, GA decreased the MI to about 29 % of the MI observed in 
non-treated controls, and a MI of zero was found for 2000 µM. This cytotoxic effect 
precludes the assessment of SCE frequency for GA concentrations ≥ 1000 µM. For AA, 
a smaller anti-proliferative effect was noted. However, at a very high concentration of 
AA (2000 µM) the MI decreased to ~13% of controls (data not shown).  
Fig. 5.2. Sister chromatid exchanges (SCE/metaphase) induced by acrylamide (AA) and 
glycidamide (GA) in cultured lymphocytes from two donors. Results are expressed as 
the mean values ± SD from two independent experiments. 
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With regards to the induction of SCE, regression analyses performed on the 
concentration-response curves indicated slopes that were significantly different from 
zero for AA (slope 0.0022, donor 1; 0.0019 donor 2; p<0.01) and GA (slope 0.074, 
donor 1; 0.052, donor 2; p<0.01). These results suggest that AA causes a concentration-
dependent increase in SCE, although with a much lower response compared to GA. In 
fact, AA increased the levels of SCE/metaphase by about 1.5-1.8 fold. This slight 
increase was particularly observed for the high concentration tested (2000 µM). 
Conversely, GA was far more genotoxic than AA at all concentrations tested (up to 750 
µM), increasing the level of SCE in about 10-fold when compared with control cultures.  
 
 
5.3.2. GA-induced SCE show inter-individual variability  
 
Based on the concentration-response curve of GA (Fig. 5.2), the concentration of 
250 µM was selected to be used for the SCE assay on samples from all 13 individuals. 
This concentration was chosen since it led to a clear genotoxic response of 
approximately 4.5-fold when compared with non-treated control lymphocytes. 
Moreover, this concentration caused a decrease of the MI to ~ 62 % of that observed in 
non-treated controls, which is acceptable for evaluation of chemically-induced 
chromosome damage [17]. The effect of 250 µM of GA (46 h-exposure) for each donor 
in terms of SCE/metaphase is depicted in Fig. 5.3 (A). The collective average values 
and respective standard deviations (SD) for all donors are presented in Figure 5.3 (B). 
The mean level of SCE/metaphase obtained for the lymphocytes of all individuals 
whose blood was exposed in vitro to 250 µM of GA was 27.2 ± 3.8 while this was 6.6 ± 
1.1 for the controls. This represents a significant 4.1-fold increase in number of 
SCE/metaphase after treatment with GA, compared with the control (p<0.001). The 
results obtained for blood from individual donors treated with GA (Fig 5.3.A) show the 
extent of inter-individual variability in terms of SCEs results. In fact, the lymphocytes 
from donors 2, 5 and 9 clearly responded to GA insult to a lesser extent than did donor 
6, 8 and 10.  
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Fig. 5.3. Sister chromatid exchanges (SCE/metaphase) induced by glycidamide (GA) in 
cultured lymphocytes from 13 donors. (A) Individual frequencies of SCE/metaphase (B) 
Collective average values of SCE/metaphase. Results are expressed as mean values±SD. 
 
 
5.3.3. DNA-adducts levels induced by AA and GA 
 
The cytogenetic response in terms of DNA adducts (N7-GA-Gua and N3-GA-
Ade) was firstly evaluated in stimulated lymphocytes from whole blood culture of two 
healthy individuals. Different concentrations of AA and GA (up to 2000 µM) were 
used. The levels of individual GA-DNA adducts obtained are presented in Table V.4. 
AA adducts were not found at any concentration studied. However, a linear dose-
response was observed between the levels of GA exposure and the level of N7-GA-Gua 
adduct up to GA 750 µM, being this adduct detected at the lower dose studied (10 μM). 
A high increased in adducts levels were detected for higher doses studied (1000 and 
2000 μM) for both donors. GA adducts were not detected in non treated control samples 
in any of the experiments. 
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Table V.4. Levels of GA-DNA adduct (N7-GA-Gua and N3-GA-Ade) in lymphocytes 
treated with different concentrations of AA and GA (0-2000 µM) for a 46-hour period 
for two different donors. 
Test compound Donor 1 Donor 2 
 
N7-GA-Gua/ 
10
6
 nucleotides 
N3-GA-Ade/ 
10
6
 nucleotides 
N7-GA-Gua/ 
10
6
 nucleotides 
N3-GA-Ade/ 
10
6
 nucleotides 
     
Acrylamide (M)     
0 <LOD <LOD <LOD <LOD 
100 <LOD <LOD <LOD <LOD 
250 <LOD <LOD <LOD <LOD 
500 <LOD <LOD <LOD <LOD 
750 <LOD <LOD <LOD <LOD 
1000 <LOD <LOD <LOD <LOD 
2000 <LOD <LOD <LOD <LOD 
     
Glycidamide (M)     
0 <LOD <LOD <LOD <LOD 
10 1.8 <LOD 1.3 <LOD 
25 4.7 <LOD 4.3 <LOD 
100 18.1 <LOD 26.8 <LOD 
250 46.6 <LOD 55.7 <LOD 
500 86.5 <LOD 79.3 <LOD 
750 98.2 <LOD 93.7 <LOD 
1000 630.2 <LOD 603.6 6.20 
2000 874.2 11.4 1051.9 <LOD 
Note. The LOD for N7-GA-Gua and N3-GA-Ade, when assaying 5 µg of DNA, was 0.1 
adducts/10
6
 nucleotides. 
 
N3-GA-Ade, was also analyzed, but only detected for GA treated lymphocytes 
and for the highest concentrations studied (1000 and 2000 µM for donor 2 and 1, 
respectively). Further studies must be done in order to clarify these results. For AA 
treated lymphocytes and for the rest of concentrations, DNA adduct levels were near or 
below the limit of detection. 
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Fig. 5.4. Correlation between N7-GA-Gua adduct levels and SCE in lymphocytes 
exposed to glycidamide (100–750 µM) for two independent donors. Results for 
SCE/Metaphase are expressed as average values from two independent experiments. 
 
The levels of N7-GA-Gua adducts were compared with the levels of SCEs in 
AA and GA exposed cultures. A strong linear correlation between the levels of GA 
exposure and the level of N7-GA-Gua adducts obtained were observed (Figure 5.4) for 
both donors (r=0.994 and r=0.977). 
 
 
5.3.3. Role of genetic polymorphisms in induction of SCE by GA 
 
The inter-individual variability described above in terms of GA-induced SCE 
could be related with different polymorphisms in detoxification and DNA- repair genes 
(Tables V.1 and V.2, respectively). In view of this, the different donors were genotyped 
for detoxification (GSTM1, GSTT1, GSTP1, GSTA2 and EPHX1) and DNA-repair 
polymorphisms. For DNA repair, different genes involved in BER (APEX1, MUTYH, 
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OGG1, PARP1, PARP4, and XRCC1), NER (ERCC1, ERCC2, ERCC4, ERCC5, 
ERCC6, RAD23B and XPC), HRR (NBS, RAD51, XRCC2 and XRCC3) and NHEJ 
(Ku80, Lig4 and XRCC4) pathways were also analyzed in order to find out possible 
associations with GA-induced SCE.  
 
Table V.5. Sister-chromatid exchanges induced in vitro by glycidamide, considering 
different genotypes in detoxification genes  
Detoxification pathway Genotypes N SCE/metaphase ± SD P value 
GST GSTM1    
 Null 6 21.1 ± 3.9   
 Positive 7 20.1 ± 2.3  N.S.
(b) 
 GSTT1    
 Null 2 18.5 ± 3.3   
 Positive 11 20.9 ± 3.0 N.S.
(b)
 
 GSTP1 (Ile105Val)    
 Ile/Ile 4 23.1 ± 3.0   
 Ile/Val 6 20.1 ± 2.2  N.S.
(a) 
 Val/Val 3 18.0 ± 2.4  N.S.
(a)
 
 Ile/Val+Val/Val 9 19.4 ± 2.4  0.050
(b)
 
 GSTA2 (Pro110Ser)    
 Pro/Pro 13  20.6 ± 3.0   
 Pro/Ser 0 -----  
 Ser/Ser 0 -----  
 GSTA2 (Ser112Thr)    
 Ser/Ser 4 20.0 ± 1.9   
 Ser/Thr 6 22.1 ± 3.5  N.S.
(a)
 
 Thr/Thr 3 18.3 ± 2.1  N.S.
(a)
 
 Ser/Thr+Thr/Thr 9 20.8 ± 3.5  N.S.
(b)
 
 GSTA2 (Glu210Ala)    
 Glu/Glu 11 21.3 ± 2.7   
 Glu/Ala 2 16.7 ± 0.7  0.026
(b)
 
 Ala/Ala 0  ---  
EPH EPHX1 (Tyr113His + His139Arg)    
 Low activity 7 20.8 ± 3.7   
 Medium activity 2 19.0 ± 2.6  N.S.
(a)
 
 High activity 3 21.8 ± 1.8  N.S.
(a)
 
N.S. non significant p-value; (a) Kruskal-Wallis Test; (b) Mann-Whitney Test 
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Table V.6. Sister-chromatid exchanges induced in vitro by glycidamide, considering 
different genotypes in DNA repair genes 
REPAIR PATHWAY Genes N SCE/metaphase ± SD P value 
BER XRCC1 (Arg194Trp)    
 Arg/Arg 13 20.6 ± 3.0  
 Arg/Trp 0  -----  
 Trp/Trp 0  -----  
 XRCC1 (Gln399Arg)    
 Arg/Arg 5 20.1 ± 2.9  
 Arg/Gln 8 20.9 ± 3.2 N.S.
(b)
 
 Gln/Gln 0  -----  
 OGG1 (Ser326Cys)    
 Ser/Ser 5 20.8 ± 1.8  
 Ser/Cys 8 20.4 ± 3.7 N.S.
(b)
 
 Cys/Cys 0  -----  
 PARP1 (Val762Ala)    
 Val/Val 7 20.6 ± 2.7  
 Val/Ala 6 20.6 ± 3.6 N.S.
(b)
 
 Ala/Ala 0  -----  
 PARP4 (Pro1328Thr)    
 Pro/Pro 9 20.8 ± 3.5  
 Pro/Thr 3 19.7 ± 2.1 N.S.
(a)
 
 Thr/Thr 1 21.0 N.S.
(a)
 
 Pro/Thr+Thr/Thr 4 20.0 ±1.9 N.S.
(b)
 
 APEX1 (Asp148Glu)    
 Glu/Glu 3 19.2 ± 2.6  
 Glu/Asp 7 19.9 ± 2.4 N.S.
(a)
 
 Asp/Asp 3 23.4 ± 3.6 N.S.
(a)
 
 Glu/Asp+Asp/Asp 10 21.0 ± 3.1 N.S.
(b)
 
 MUTYH (Gln335His)    
 Gln/Gln 8 20.6 ± 3.6  
 Gln/His 3 19.3 ± 1.9 N.S.
(a)
 
 His/His 2 22.2 ± 1.7 N.S.
(a)
 
 Gln/His+His/His 5 20.4 ± 2.2 N.S.
(b)
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Table V.6. Continued 
REPAIR PATHWAY Genes N SCE/metaphase ± SD P value 
NER ERCC2 (Lys751Gln)    
 Lys/Lys 3 18.9 ± 3.9  
 Lys/Gln 7 20.2 ± 2.1 N.S.
(a)
 
 Gln/Gln 3 23.1 ± 3.5 N.S.
(a)
 
 Lys/Gln+ Gln/Gln 10 21.1 ± 2.8 N.S.
(b)
 
 ERCC1 (Gln504Lys)    
 Gln/Gln 8 20.3 ± 2.8   
 Gln/Lys 4 19.5 ± 1.6 N.S.
(a)
 
 Lys/Lys 1 27.1
 
N.S.
(a)
 
 Gln/Lys + Lys/Lys 5 21.0 ± 3.7 N.S.
(b)
 
 ERCC4 (Arg415Gln)    
 Arg/Arg 9 20.6 ± 3.2  
 Arg/Gln 3 21.8 ± 1.8 N.S.
(a)
 
 Gln/Gln 1 16.2 N.S.
(a)
 
 Arg/Gln + Gln/Gln 4 20.4 ± 3.2 N.S.
(b)
 
 ERCC5 (His1104Asp)    
 His/His 8 19.9 ± 2.5  
 His/Asp 5 21.6 ± 3.8 N.S.
(b)
 
 Asp/Asp 0 -----  
 His/Asp + Asp/Asp  -----  
 ERCC5 (Cys529Ser)    
 Cys/Cys 12 20.6 ± 3.2  
 Cys/Ser 1 20.4 N.S.
(b)
 
 Ser/Ser 0  -----  
 ERCC6 (Arg1230Pro)    
 Pro/Pro 11 20.3 ± 3.2  
 Pro/Arg 2 22.2 ± 1.7 N.S.
(b)
 
 Arg/Arg 0  -----  
 ERCC6 (Gln1413Arg)    
 Arg/Arg 8 21.2 ± 3.6  
 Arg/Gln 5 19.5 ± 1.7 N.S.
(b)
 
 Gln/Gln 0  -----  
 RAD23B (Ala249Val)    
 Ala/Ala 9 19.8 ± 2.8  
 Ala/Val 4 22.4 ± 3.2 N.S.
(b)
 
 Val/Val 0  -----  
 XPC (Ala499Val)    
 Ala/Ala 0  -----  
 Ala/Val 6 21.9 ± 3.3  
 Val/Val 7 19.4 ± 2.4 N.S.
(b)
 
 XPC (Lys939Gln)    -----  
 Lys/Lys 7 20.2± 2.4  
 Lys/Gln 6 21.0 ± 3.8 N.S.
(b)
 
 Gln/Gln 0  -----  
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Table V.6. Continued 
REPAIR PATHWAY Genes N SCE/metaphase ± SD P value 
HRR RAD51 (5’UTR)    
 G/G 5 19.5 ± 2.9  
 G/T 8 21.2 ± 3.1 N.S.
(b)
 
 T/T 0 -----  
 NBS (Glu185Gln)    
 Glu/Glu 7 21.5 ± 3.2  
 Glu/Gln 4 19.5 ± 3.4 N.S.
(a)
 
 Gln/Gln 2 19.6 ± 1.7 N.S.
(a)
 
 Glu/Gln + Gln/Gln 6 19.5 ± 2.7 N.S.
(b)
 
 XRCC3 (Thr241Met)    
 Thr/Thr 3 22.2 ± 5.6  
 Thr/Met 7 20.0 ± 2.3 N.S.
(a)
 
 Met/Met 3 20.2 ± 1.6 N.S.
(a)
 
 Thr/Met + Met/Met 10 20.1 ±2.0 N.S.
(b)
 
 XRCC2 (Arg188His)    
 Arg/Arg 11 20.5 ± 3.1  
 Arg/His 2 20.9 ± 3.6 N.S.
(b)
 
  His/His 0  ------  
NHEJ XRCC4 It7G>A    
 G/G 8 21.1 ± 3.1  
 G/A 5 19.7± 3.1 N.S.
(b)
 
 A/A 0   
 XRCC4 Thr134Ile    
 Ile/Ile 13 20.6 ± 3.0  
 Ile/Thr 0  -----  
 Thr/Thr 0  -----  
 Lig4Thr9Ile    
 Thr/Thr 10 20.9 ± 3.1  
 Thr/Ile 3 19.3 ± 2.7 N.S.
(b)
 
  Ile/Ile 0  -----  
 Ku80Ex21-238G>A    
 G/G 5 21.3 ± 1.5  
 G/A 4 21.0 ± 5.2 N.S.
(a)
 
 A/A 4 19.3 ± 1.8 N.S.
(a)
 
 G/A+A/A 8 20.1 ± 3.7 N.S.
(b)
 
 Ku80Ex21+338T>C    
 T/T 10 20.8 ± 3.3  
 T/C 3 19.7 ± 2.2 N.S.
(b)
 
 C/C 0  -----  
 Ku80Ex21-352C>A    
 C/C 10 20.8 ± 3.3  
 C/A 3 19.7 ± 2.2 N.S.
(b)
 
 A/A 0  -----  
 Ku80Ex21+466A>G    
 A/A 10 20.7 ± 3.0  
 A/G 3 20.2 ± 3.7 N.S.
(b)
 
 G/G 0  -----  
N.S. non significant p-value; (a) Kruskal-Wallis Test; (b) Mann-Whitney Test 
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The genotypic distribution of the polymorphisms involved in detoxification 
pathways and its association with the levels of GA-induced SCE is presented in Table 
V.5. In this table, as in Table V.6, the values of GA-induced SCE correspond to the 
SCE observed in GA-treated cultures (250 µM) after subtracting the respective 
background of SCE in non-treated controls. GSTM1 and GSTT1 deletion 
polymorphisms did not influence the level of SCEs induced by GA. Conversely, for 
GSTP1 Ile105Val, lymphocytes from wild-type individuals have a higher level of GA-
induced SCE than those with at least one variant allele (p=0.050, Table V.5). With 
respect to GSTA2, three SNPs (Pro110Ser, Ser112Thr, Glu210Ala), all non-
synonymous were analyzed. For GSTA2 Glu210Ala polymorphism, no homozygous 
donor for the variant allele was present in our study group. For this SNP, the level of 
SCE was lower for lymphocytes of heterozygous individuals (Glu/Ala) when compared 
with wild-type homozygous individuals (Glu/Glu) (p=0.026). For the Ser112Thr SNP 
no significant associations were found with SCE data (Table V.5). With regards to the 
third SNP, i.e.,GSTA2 Pro110Ser polymorphism, the analysis of a possible association 
was precluded since all donors had the wild type genotype. EPHX1 genotypes 
(Tyr113His and His139Arg) were also analyzed and individuals were classified 
according to the expected activity of the correspondent enzyme [22, 24]. These SNPs 
did not show any influence on the level of SCEs induced by GA.  
For DNA repair, the distribution of genotypic frequencies related with repair 
pathways (BER, NER, HRR and NHEJ) and its association with SCE levels is presented 
in Table V.6. For the DNA-repair pathways studied, i.e. BER (6 genes), NER (7 genes), 
HRR (4 genes) and NHEJ (3 genes), no associations with the level of GA-induced SCEs 
were found. 
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5.4. Discussion 
 
The development of predictive biomarkers for cancer-risk assessment is a 
challenging issue in food toxicology. The SCE test is well-known for its sensitivity to 
detect chemical genotoxicants [28]. The usefulness of SCE to evaluate genotoxicity of 
AA and GA has been previously shown in mammalian cells [29-31]. However, in vitro 
studies using human cells are still lacking. These studies are of utmost importance to 
predict the potential importance of SCE formation as a valuable cytogenetic 
toxicological biomarker to be used in the assessment of human risk from exposure to 
AA. Therefore, in the present work, the levels of SCEs induced by AA and GA were 
evaluated in human lymphocytes.  
PHA-stimulated lymphocytes from whole blood cultures were used throughout 
this report. This “whole blood” approach has been followed by other authors [32-34] 
and may be considered more closely related to the physiological situation than isolated 
lymphocyte cultures, since it encompasses the influence of other factors, such as red 
blood cells [35], platelets and plasma. 
In this study, a slight induction of SCE by AA was found, which was specially 
associated with the very high and cytotoxic concentration of 2000 µM. In contrast, GA 
markedly increased the frequency of SCE in a concentration-dependent manner. This is 
in agreement with our previous study [31], which reported a much higher genotoxic 
potential of GA when compared with AA, using the same end-point in V79 cells. In 
addition, the same trend was observed in a recent study from our group, carried out in 
human whole blood leukocytes analyzed with the comet assay [36].  
Additionally, data concerning the levels of DNA-adducts after exposure to AA 
showed that no DNA-adducts were detected at any concentration studied. In spite of 
AA-induced DNA adducts not have been detected in the present work, it is important to 
note that AA highly reacts with protein, specifically haemoglobin, originating 
haemoglobin adducts [2, 37]. The concentration of haemoglobin adducts reflects the 
internal doses of AA and GA and this type of adducts are biomarkers for the biological 
effect [38]. Moreover, several authors have reported positive results of haemoglobin 
adducts of AA and GA as biomarker of AA exposure [39-42]. On the other hand, our 
results showed that the major adduct analyzed in human lymphocytes was N7-GA-Gua, 
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formed by reaction of the DNA with the epoxide metabolite glycidamide. N7-GA-Gua 
was detected for concentrations as low as 10 µM GA.  
Furthermore, N3-GA-Ade was also analyzed but data showed that was formed in 
much lower amounts and only for the highest concentration studied (1000 and 2000 
µM). Similar results were found for DNA adducts measured in liver, brain and testes of 
rats administered with single oral doses of acrylamide [43, 44]. 
The cytogenetic end-point evaluated by sister chromatid exchange in stimulated 
lymphocytes exposed to GA, was compare in same conditions with N7-GA-Gua DNA-
adducts obtained. The results showed a strong correlation between these two end-points 
(Figure 5.4). This correlation is consistent with a mechanism involving the formation of 
GA-DNA adducts on the induction of SCEs in human lymphocytes after exposure to 
GA [12] and already suggested by our group in a previous study [31]. 
In view of this clear genotoxicity of GA, in contrast to AA, the further step of 
this study was to evaluate the inter-individual response to a GA concentration of 250 
µM and to associate it with polymorphisms in detoxification and DNA-repair genes. 
Although this concentration is much highter than human dietary exposure levels, it was 
clearly genotoxic for human lymphocytes, without a marked cytotoxicity. Therefore, it 
enabled us to distinguish differences among individuals. This approach is crucial not 
only for a thorough understanding of the usefulness of SCE frequency as a cytogenetic 
biomarker in risk assessment, but also for the identification of genotypes that potentially 
modulate the genotoxic damage in an AA-exposure scenario.  
The induction of SCE by the metabolite GA revealed inter-individual variability 
(Fig. 5.2.A). The heterogeneity in terms of DNA damage, among individuals with 
different genotypes, has been described for other xenobiotics and the association with 
detoxification genes has been reported [32, 45]. The metabolic fate of GA has been 
extensively reviewed [5, 6]. GA is detoxified by conjugation with glutathione via GSTs, 
or can be hydrolyzed by EPHX [11, 46]. Therefore, the possible association between 
inter-individual variations in GA-induced DNA damage and polymorphisms in the 
genes GSTM1, GSTT1, GSTP1, GSTA2 and EPHX1 was further analyzed. The SCEs 
results from this study suggest that GSTP1 (Ile105Val) and GSTA2 (Glu210Ala) 
polymorphisms may influence the detoxification capacity of GA.  
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The GSTP1 enzyme is the major GST enzyme in blood and metabolizes several 
diol-epoxides of polycyclic aromatic hydrocarbons (PAH) [10]. The GSTP1 isoenzyme 
with valine in position 105 has a higher efficiency for conjugation of PAH diol-
epoxides [47]. Our results indicate a lower level of cytogenetic damage in lymphocytes 
from individuals presenting at least one variant allele for GSTP1 suggesting that a 
higher conjugation efficiency of GA with GSH could be achieved for the variant forms 
of GSTP1. A similar study by Teixeira et al [21] reported that SCE frequencies 
presented by plastic workers with low exposure to styrene were also related with the 
GSTP1 (Ile105Val) polymorphism. Styrene is a small molecule that undergoes 
metabolization to styrene-7,8-oxide, a low molecular weight epoxide comparable in size 
to GA. Moreover, the detoxification of toluene di-isocyanate seems to be affected by 
GSTP1 105Val variant allele [48]. 
With regards to GSTA2, there is lack of data on the role of genetic 
polymorphisms associated with exposure to environmental genotoxicants. GSTA2 is 
predominantly expressed in the liver, the major site for detoxification of drugs and 
xenobiotics [23, 49]. In this study, the heterozygous genotype of GSTA2 (Glu210Ala) 
SNP showed a decrease in SCE levels versus wild-type individuals (Glu/Glu). This 
result suggests the possible involvement of GSTA2 in detoxification of GA. The alpha-
class GSTs has commonly been described as one of the most versatile GST classes, 
since it is responsible for detoxification of a heterogeneous group of compounds [23]. In 
this context, Ketterer et al, pointed out a role for GSTA2 genotypes in the detoxification 
of small molecules like cumene hydroperoxide [49, 50]. Previous studies have reported 
that for the polymorphisms Ser112Thr and Glu210Ala the respective amino acid 
residues are not at the active site of GSTA2. However, while in the case of Ser112Thr 
polymorphism the amino acid change did not show an important effect in protein 
structure, for the Glu210Ala a slight effect in protein function may be observed [49], 
which may explain the differential results obtained in our study where no differences 
were found for the Ser112Thr polymorphism. In respect to Pro110Ser polymorphism, 
which may have some impact on rigidity of the active site [49], no individuals displayed 
the variant genotype, precluding any analysis.  
GSTT1 and GSTM1 enzymes are involved in the metabolism of epoxides and 
are mainly expressed in liver and blood [10]. Our results show that deletions in the 
genes GSTT1 and GSTM1 do not seem to affect the levels of SCEs. This is in 
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accordance with previous reports [10, 51] that addressed the involvement of GSTT1 and 
GSTM1 in the toxicokinetics of AA in terms of haemoglobin (Hb)-adducts, concluding 
that these enzymes do not seem to play a major role in the AA and GA conjugation with 
glutathione. In contrast, a recent study from Duale et al [52] suggested a possible 
involvement of both GSTM1 and GSTT1. These conflicting results clearly anticipate the 
need for further studies focusing on GSTs with the use of additional toxicological 
biomarkers.  
The same is valid for the genetic polymorphisms of EPHX1 for which some 
association has been recently reported in terms of urinary acrylamide metabolites from 
workers exposed to acrylamide [53]. EPHX1 catalyzes the hydrolysis of reactive 
epoxides to their corresponding dihydrodriols, playing an important role in their 
detoxification. EPHX1 is probably involved in the metabolism of GA to a less reactive 
and more soluble glyceramide. EPHX1 is expressed in all tissues, including white blood 
cells [10, 52, 54]. The data reported here did not show any effect of EPHX1 
detoxification in relation to GA-induced SCE. Our results are in accordance with 
Paulson et al [10] who previously showed that the chemical inhibition of EPHX1 had 
no significant effect in the Hb-adducts levels after exposure to AA and GA.  
DNA-repair polymorphisms that modulate DNA repair capacity may influence 
the individual susceptibility to DNA-damaging agents and, therefore, modify cancer 
risk. In fact, polymorphic variants in DNA-repair genes have been associated with 
susceptibility for several types of DNA lesions and cancer risk [55]. However, the 
overall data presented here did not show relevant associations between SCE levels and 
individual genetic polymorphisms in DNA-repair genes.  
In summary, our results show that AA only slightly induced SCEs at a very high 
concentration. Conversely, GA is clearly genotoxic to cultured human lymphocytes, 
highlighting the importance of this metabolite. It was also demonstrated that SCE 
frequency constitutes a sensitive and reliable endpoint to evaluate DNA damage, being 
a valuable cytogenetic biomarker that could be used, along with other cytogenetic 
biomarkers (e.g. micronuclei, chromosomal aberrations), to evaluate genotoxic effects 
in an AA-exposure scenario.  
Although these results are based on a small number of blood donors, this 
exploratory study points out to a possible role for GSTP1 Ile105Val and GSTA2 
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Glu210Ala on the modulation of the genotoxicity induced by GA. These data provide a 
further step towards the development of potential susceptibility biomarkers for AA and 
GA. However, for more conclusive results, studies involving a larger number of 
individuals should be performed and other polymorphisms and combinations of 
polymorphisms regarding genes involved in GA detoxification and DNA repair should 
be further evaluated. 
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Genetic polymorphisms in detoxification and DNA repair genes and 
susceptibility to glycidamide-induced DNA damage. 
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Abstract  
Acrylamide (AA) is a probable human carcinogen formed in carbohydrate-rich 
foodstuffs upon heating. Glycidamide (GA), the AA metabolite formed by epoxidation 
is considered the ultimate genotoxic agent. In this study, the in vitro genotoxic potential 
of AA and GA in human whole blood leukocytes was compared using the alkaline 
comet assay. Although AA did not induce DNA damage in the concentrations tested (up 
to 1000 µM), GA markedly increased the %Tail DNA at concentrations ≥ 250 µM 
(p<0.005). Further, this study addressed the role of genetic polymorphisms in key genes 
involved in metabolism and DNA repair pathways (BER, NER, HRR and NHEJ) on 
GA-induced genotoxicity assessed by the alkaline comet assay. The results obtained 
suggested associations between DNA damage and polymorphisms of BER (MUTYH 
Gln335His and XRCC1 Gln399Arg) and NER (XPC Ala499Val and Lys939Gln) genes, 
either alone or in combination. 
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6.1. Introduction 
 
Acrylamide (AA) is a suspected human carcinogen classified as a probable 
human carcinogen by IARC [1]. AA is an important industrial monomer mainly used 
for the production of polyacrylamides since the mid-1950s. These compounds gained 
importance in many field application, namely in wastewater treatment, as flocculants 
for clarifying drinking-water, as flow control agents in oil-well operations and in gels 
used for laboratory techniques [2-6].  
Acrylamide is also a component of tobacco smoke (1-2 µg/cigarette) and is 
used in cosmetic additives, including creams, body lotions and shampoos [2]. Further, 
the general population is exposed to varying amounts of AA via diet [4, 7]. In fact, AA 
may be generated from food components during heat treatment as a result of the 
Maillard reaction between an amino acid, primarily asparagine (the major amino acid 
in potatoes and cereals) and reducing sugars, such as glucose [8]. The extent of AA 
formation strongly depends on the heating conditions and type and concentration of 
certain foodstuffs [9]. AA is found at relatively high concentrations (micrograms to 
milligrams per kilogram) in common food items such as French fries, potato crisp, 
crisp bread, bread, coffee and cookies [10-12]. Average intake was estimated to be in 
the range of 0.3 to 0.8 µg AA/Kg body weight (bw)/d for developed countries, 
corresponding to aproximately 21-26 µg/day for a 70-Kg person, although in children 
the oral exposure may be two- to threefold highter [2]. 
Concerns on the health risks of AA for the general population have been raised, 
since AA is a known rodent neurotoxicant and multisite carcinogen [13, 14]. In fact, 
chronic studies in rodent models demonstrated that AA is carcinogenic at different 
organ sites, including the mammary gland [6, 7]. AA is metabolized to the epoxide 
derivative glycidamide (GA), presumably mediated by cytochrome P450 2E1 and 
postulate to be the ultimate metabolite that plays a critical role in AA-induced 
genotoxicity [15-17]. While AA possesses high capacity to bind proteins, GA has a 
high affinity to bind DNA, generating  DNA-adducts [2]. In this context, different 
DNA adducts have been quantified, being N7-(2-carbamoyl-2-hydroxyethyl)guanine 
(N7-GA-Gua), the predominant adduct [18-20].  
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Epidemiological data in human populations exposed to AA are conflicting with 
respect to cancer risk assessment [21-25]. Genetic variability in metabolism 
(detoxification) and DNA repair genes might influence individual susceptibility to 
cancer [26, 27]. It is therefore important to correlate genetic polymorphisms with DNA 
damage using adequate biomarkers of genotoxicity. 
Primary DNA damage in human cells may be evaluated by the single-cell gel 
electrophoresis (SCGE) or comet assay, a simply, sensitive, versatile, rapid and 
economic method [28]. The comet assay, under alkaline conditions, detects single- and 
double-strand breaks, incomplete repair sites, alkali-labile sites and DNA cross-linking 
in any eukariotic cell population [29]. The aim of this study was to assess the in vitro 
genotoxicity of AA and GA in human peripheral blood leukocytes (PBL) using the 
comet assay. Further, this study aimed to identify possible associations between DNA 
damage and biomarkers of susceptibility concerning individual genetic polymorphisms 
in key metabolism and repair genes.  
 
 
6.2.Materials and Methods 
 
6.2.1.Chemicals 
Acrylamide (AA; CAS registry number 79-06-1, ≥99.5% pure) was purchased 
from Fluka (Buchs, Switzerland). Glycidamide (CAS Registry Number 5694-00-8, 
>98.5% pure, containing ~1% AA) was obtained from Toronto Research Chemicals 
(North York, Ontario, Canada). Fetal calf serum (FCS), Ham’s F-10 medium, 
penicillin-streptomycin solution, phosphate-buffered saline pH 7.4 (PBS), Na2EDTA, 
Trizma base, Triton X-100, low melting point (LMP) agarose and ethidium bromide 
were purchased from Sigma–Aldrich (St. Louis, MO, USA). Dimethyl sulfoxide 
(DMSO), ethanol, sodium chloride and sodium hydroxide were acquired from Merck 
(Darmstadt, Germany). Agarose multi-purpose, used as normal melting point (NMP) 
agarose, was obtained from Bioline (London, UK). Heparin was acquired from B. 
Braun (Lisbon, Portugal). 
 
165 
 
 
6.2.2. Blood Sample Collection 
Peripheral blood samples were obtained from 25 healthy donors (18 female and 
7 male, mean ages 27.1 ± 4.5). Samples of 10 ml were collected under sterile conditions 
by venipuncture in heparinized tubes. All samples were coded and analyzed under blind 
conditions. All donors were informed about the aim and experimental details of the 
study and an informed consent was obtained from all participating subjects prior to the 
start of the study. Each participant completed one standardized questionnaire about 
health history, lifestyle, alcohol consumption, medication usage, family history of 
cancer, exposure to indoor/outdoor pollutants and dietary habits. Donors were all 
nonsmokers. Ethical approval for this study was obtained from the institutional Ethical 
Board of the Faculty of Medical Sciences of New University of Lisbon. 
 
6.2.3. Comet assay 
The comet assay was performed under alkaline conditions essentially according 
to the procedures of Singh et al.[30] and Busto et al, [31] with minor modifications. 
Nonstimulated whole blood (125 µl) was suspended in 1125 µl of Ham’s F-10 medium 
supplemented with 24 % (v/v) of FCS, 1% (v/v) antibiotics (final concentrations of 100 
UI/mL penicillin G and 100 μg/mL streptomycin), 1% (v/v) L-glutamine and 1% (v/v) 
heparin in a 10 ml sterile tube. Blood cultures were then exposed to different 
concentrations of AA or GA, ranging from 10 to 1000 µM and incubated for 1 hour at 
37 ºC. Afterwards, cells were washed twice with fresh culture medium and then 
collected by centrifugation (1200 x g for 5 min). Seven microliters of cell suspension 
were ressuspended in 70 µl of 0.5 % LMP agarose in PBS (pH=7.4) and dropped onto a 
frosted slide precoated with a layer of 1 % NMP agarose. Slides were placed at 4 ºC for 
20 min and allowed to solidify. Cover slips were then removed and slides immersed in a 
4 ºC freshly prepared lysing solution (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Trizma 
base, 1% Triton X-100, 10 % DMSO, pH=10) overnight in the dark. After lysis, slides 
were washed twice with ice-cold bidistilled water for 10 min and then slides were 
randomly placed on a horizontal electrophoresis tank at 4 ºC. The tank was filled with 
freshly made alkaline electrophoresis solution (1mM EDTA, 300 mM NaOH, pH≥13) 
to cover the slides. The slides were left in electrophoresis solution for 20 min in the dark 
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to allow DNA unwinding and alkali-labile sites expression. Electrophoresis was carried 
out for 20 min at 25 V (1.0 V/cm) and 300 mA. The slides were washed gently thrice at 
5-min intervals with a neutralizing buffer (400 mM Tris, pH=7.5) to remove excess 
alkali and reagents. After neutralization, slides were passed through 50, 70 and 100 % 
solutions of ethanol for 5 min each, drained, stained with 100 µl of ethidium bromide 
solution (20 µg/ml), and covered with cover slips. Slides were stored at 4 ºC in 
humidified containers until analysis. Two independent experiments were conducted in 
duplicate for the dose-response curve (four slides per data point) and two replicate 
blood cultures were carried out for each donor.  
The comets were observed at a 400 x magnification with a fluorescent 
microscope (Leica DMLB 100S) equipped with an excitation filter of 530-545 nm and a 
suppressor filter of 610-675 nm. Fifty individual cells from each slide were randomly 
analyzed, giving a total of 200 cells analyzed per data point. The percentage of DNA in 
Tail (% Tail DNA) of comets was measured to assess the extent of DNA damage.  
Image analysis was performed using the Tri Tek Comet Score
TM
 v 1.5, using a 65 
% cutoff. The median of the % DNA in Tail was used as representative value for each 
subject, and the media of medians was used for statistical analysis [32]. 
 
6.2.4. DNA extraction 
Genomic DNA was obtained from 250 µl of whole blood using a commercially 
available kit, according to the manufacturer instructions (QIAamp DNA extraction kit; 
Qiagen, Hilden, Germany). Each DNA sample was stored at –20 C until analysis. 
 
6.2.5. Genotyping  
This study included polymorphisms in genes associated with metabolism, 
specifically glutathione S-transferases (GSTM1, GSTT1, GSTP1, GSTA2) and EPHX1. 
In addition, polymorphisms in DNA repair genes from the base excision repair (BER), 
nucleotide excision repair (NER), homologous recombination repair (HRR) and non-
homologous end-joining repair (NHEJ) pathways were studied. 
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6.2.5.1. Detoxification pathways 
GSTM1 and GSTT1 genotyping for gene deletions were carried out by a 
multiplex PCR as described by Lin et al. [33] with minor modifications described in 
Costa et al [26] and as described in Chapter 5 (5.2.9.1).  
The genotyping of GSTP1 Ile105Val (rs1695), EPHX1 Tyr113His (rs1051740) 
and His139Arg (rs2234922), GSTA2 Glu210Ala (rs6577), were determined by 
polymerase chain reaction (PCR) and restriction fragment length polymorphisms 
(RFLP), as described in Chapter 5 (5.2.9.1). 
 
6.2.5.2. DNA repair pathways 
The genotyping of XRCC2 Arg188His (rs3218536), XRCC3 Thr241Met 
(rs861539) and XPC Lys939Gln (rs2228001) and Ala499Val (rs2228000) were 
determined by polymerase chain reaction (PCR) and restriction fragment length 
polymorphisms (RFLP) as described in Chapter 5 (5.2.9.2).  
APEX Asp148Glu (rs1130409), ERCC1 Gln504Lys (rs3212986), ERCC2 
Lys751Gln (rs13181), ERCC4 Arg415Gln (rs1800067), ERCC5 Cys529Ser 
(rs2227869) and His1104Asp (rs17655), ERCC6 Gln1413Arg (rs2228529) and 
Arg1230Pro (rs4253211), GSTA2 Pro110Ser (rs2234951) and Ser112Thr (rs2180314), 
Ku80 Ex21-238G➝A (rs2440); Ex21+338T➝C (rs1051677), Ex21-352C➝A (rs6941), 
Ex21+466A➝G (rs1051685), LIG4 Thr9Ile (rs1805388), MUTYH Gln335His 
(rs3219489), NBS1 Glu185Gln (rs1805794), OGG1 Ser326Cys (rs1052133), PARP1 
Val762Ala (rs1136410), PARP4 Gly1280Arg (rs13428) and Pro1328Thr (rs1050112), 
RAD23B Ala249Val (rs1805329), RAD51 5’UTR (rs1801321), XRCC1 Gln399Arg 
(rs25487) and XRCC4 It7G>A (rs1805377) and Thr134Ile (rs28360135) 
polymorphisms were genotyped by Real-Time PCR (AB7300), using TaqMan SNP 
Genotyping Assays from Applied Biosystems, according to the manufacturer’s 
recommendations and to previous reports from our group [34-37] with minor 
modifications and as described in Chapter 5 (5.2.9.2). Genotype determinations were 
carried out twice (all samples for multiplex and PCR-RFLP and 20% of samples for 
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Real-Time PCR) in independent experiments and all the inconclusive samples were 
reanalyzed. 
 
6.2.6. Statistical analysis 
The Kolmogorov-Smirnof test was used to verify the normality of the 
continuous variables (% Tail DNA). For the variables with a normal distribution the 
homogeneity of the variances was evaluated using the Levene test and the association of 
% Tail DNA (value obtained subtracting the tail DNA percent value for background) 
and the different genotypes obtained was evaluated by Student’s t-test. The level of 
significance considered was p≤0.05. All analyses were performed with the SPSS 
statistical package (version 17, SPSS Inc., Chicago, IL, USA). 
 
 
6.3. Results: 
 
The concentration-response profile of AA and GA in terms of DNA damage was 
evaluated by the comet assay in PBL from one healthy individual, and the results are 
depicted in Figure 6.1. For AA, no marked changes in % Tail DNA were found for the 
concentrations studied (10-1000 µM). Conversely, GA elevated the % Tail DNA in a 
concentration-dependent manner for concentrations ranging from 10 to 1000 µM, and 
this rise was more pronounced and significant for concentrations higher than 250 µM. 
GA at 1000 µM increased the % Tail DNA approximately 4.4-fold compared to 
controls. Based on the concentration-response curve of GA, the concentration of 250 
µM was selected to be used in the comet assay to all 25 individuals. This concentration 
provided sufficient sensitivity to discriminate between individual responses, increasing 
the % Tail DNA in about 2.6 fold in relation to control PBL (Figure 6.1). 
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Figure 6.1. Percent DNA in Tail (%Tail DNA) induced by AA and GA in whole blood 
leucocytes from a healthy donor. Results are expressed as the mean ± SD from two 
independent experiments  
 
The individual effects of 250 µM of GA in terms of % Tail DNA obtained for 
the 25 individuals are presented in Figure 6.2 (A). The collective average values and 
respective SD are presented in Figure 6.2 (B). The mean level of % Tail DNA was 11.4 
± 4.9 for untreated PBL of all donors, while it rose 1.7-fold after 1 h of exposure to GA 
to a mean value of 19.0 ± 6.0 %. From Fig 6.2, it is also clear that the results obtained 
for individual donors treated with GA showed interindividual variability. In fact, some 
donors displayed a much more pronounced response (e.g. donors 1 and 23) to GA insult 
than other donors (e.g. 11 and 12), that only numerically increased the % Tail DNA.  
p=0.00
3 
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Figure 6.2. Percent DNA in Tail (% Tail DNA) induced by GA in whole blood 
leukocytes for 25 healthy donors. (A) Individual values of % Tail DNA. Results are 
expressed as mean ± SD from two replicates. (B) Collective values of % Tail DNA. 
Results are expressed as mean values ± SD. 
 
This variability in terms of GA-induced % Tail DNA may be correlated with 
different polymorphisms in detoxification and repair genes. In this context, the study 
subjects were therefore characterized with respect to genetic polymorphisms in 
detoxification (GSTM1, GSTT1, GSTP1, GSTA2 and EPHX1), and DNA repair 
pathways genes. Among these repair pathways, genes from BER (XRCC1, OGG1, 
PARP1, PARP4, APEX1 and MUTYH), NER (ERCC2, ERCC1, ERCC4, ERCC5, 
ERCC6, RAD23B and XPC), HRR (RAD51, NBS, XRCC3 and XRCC2) and NHEJ 
(XRCC4, Lig4 and Ku80) were evaluated. Afterwards, genotyping data was integrated 
with the GA-induced % Tail DNA obtained from the comet assay, in order to establish 
possible associations between those polymorphisms and DNA damage.  
The genotypic distribution of polymorphisms involved in metabolism and repair 
pathways and its association with the levels of GA-induced % Tail DNA are presented 
in Tables VI.1 to VI.5. In these tables, the values of GA-induced % Tail DNA were 
calculated by subtracting the % Tail DNA value for the non treated controls 
(background) from the % Tail DNA value observed in GA treated cultures (250 µM). 
In relation to the metabolism polymorphisms studied involved in the 
detoxification of xenobiotics, no significant correlations between GA-induced %Tail 
DNA values and genotypic frequencies of polymorphisms were observed (Table VI.1). 
[GA]=2
50µM 
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The same was noted for the haplotypes generated from GSTA2 polymorphisms 
Pro110Ser, Ser112Thr and Glu210Ala (data not shown). 
Polymorphisms in DNA repair pathways included 6 genes involved in BER 
(Table VI.2). However, it is important to note that PARP4 polymorphisms Pro1328Thr 
and Gly1280Arg are in linkage disequilibrium. In view of this only PARP4 Pro1328Thr 
was studied. It was noted that for MUTYH Gln335His there was a marked increase in 
GA-induced % Tail DNA in homozygous individuals for variant genotype (11.9 ± 
1.8%) when compared with heterozygous individuals (6.1 ± 1.7%). However, in relation 
to other BER SNP studied, no significant associations were found.  
In order to further characterize the influence of BER in GA-induced 
genotoxicity, the combination of different polymorphisms of this pathway was also 
included in this study. This approach allowed the identification of haplotypes 
potentially associated with DNA damage induced by GA (Table VI.6). These 
haplotypes included XRCC1 Gln399Arg and MUTYH Gln335His. A significant rise in 
GA-induced % Tail DNA was obtained for ArgArg+ArgGln/HisHis (11.9 ± 1.8%) 
compared with ArgArg+ArgGln/GlnGln+GlnHis (7.0 ± 4.5%) and with 
GlnGln/GlnGln+GlnHis (4.3±1.2%). 
The NER polymorphisms per se did not present any significant association with 
GA-induced DNA damage (Table VI.3). However, haplotypes generated from XPC 
Ala499Val and Lys939Gln (Table VI.7) showed a significant association when 
comparing AlaVal/LysGln with ValVal/LysGln (2.8 ± 3.7% vs. 9.1± 3.3%, p<0.05). 
Other associations between SNPs of a single gene of this pathway (e.g. ERCC5 
Asp1104His and Cys529Ser polymorphisms) did not reveal any significant association 
(data not shown).  
For the other DNA repair pathways studied, that is HRR (four genes) and NHEJ 
(three genes) no statistically significant associations were found between the genotyping 
frequencies and the GA-induced % Tail DNA (Tables VI.4 and VI.5). In addition, no 
marked associations were found for NHEJ haplotypes and DNA damage attributable to 
GA (data not shown).  
 
172 
 
Table VI.1. Percent DNA in Tail (%Tail DNA) induced by GA in whole blood leukocytes 
from 25 healthy individuals considering different genotypes of genes involved in 
metabolism. 
Detoxification pathway Genotypes N % Tail DNA ± SD 
GST GSTM1   
 Positive 13 8.9 ± 4.6  
 Null 12 6.3 ± 4.0  
 GSTT1   
 Positive 22 7.3 ± 4.6  
 Null 3 9.8 ± 3.1  
 GSTP1 (Ile105Val)   
 Ile/Ile 12 8.1 ± 5.5  
 Ile/Val 11 7.0 ± 3.7  
 Val/Val 2 8.0 ± 0.0  
 Ile/Val + Val/Val 13 7.2 ± 3.4  
 GSTA2 (Pro110Ser)   
 Pro/Pro 23  7.5 ± 4.4  
 Pro/Ser 2  8.9 ± 6.3  
 Ser/Ser 0  --- 
 GSTA2 (Ser112Thr)   
 Ser/Ser 7 7.7 ± 5.4 
 Ser/Thr 11 6.6 ± 4.6  
 Thr/Thr 7 9.1 ± 3.2  
 Ser/Thr + Thr/Thr 18  7.6 ± 4.2  
 GSTA2 (Glu210Ala)   
 Glu/Glu 21 8.0 ± 4.7  
 Glu/Ala 4 5.6 ± 2.3  
 Ala/Ala 0  --- 
EPH EPHX1 (Tyr113His + His139Arg)   
 Low activity 12 7.9 ± 5.0  
 Medium activity 6 6.3 ± 1.9  
 High activity 6 8.0 ± 5.5  
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Table VI.2. Percent DNA in Tail (%Tail DNA) induced by GA in whole blood leukocytes 
from 25 healthy individuals considering different genotypes of genes involved in BER 
pathway. 
 
Genotypes N % Tail DNA ± SD 
XRCC1 (Gln399Arg)   
Arg/Arg 10 9.6 ± 5.0 
Arg/Gln 13 6.6 ± 3.9 
Gln/Gln 2 4.3 ± 1.2 
Arg/Gln + Gln/Gln 15 6.3 ± 3.7 
OGG1 (Ser326Cys)   
Ser/Ser 11 8.8 ± 4.0 
Ser/Cys 14 6.6 ± 4.7 
Cys/Cys 0  ----- 
PARP1 (Val762Ala)   
Val/Val 19 8.2 ± 3.8 
Val/Ala 5 5.7 ± 7.1 
Ala/Ala 1 5.5 
Val/Ala + Ala/Ala 6 5.7 ± 6.4 
PARP4 (Pro1328Thr)   
Pro/Pro 12 7.7  ± 4.6 
Pro/Thr 12 7.0 ± 4.4 
Thr/Thr 1 13.4 
Pro/Thr+Thr/Thr 13 7.4 ± 4.6 
APEX1 (Asp148Glu)   
Glu/Glu 8 7.7  ± 4.4 
Glu/Asp 12 8.2  ± 4.9 
Asp/Asp 5 6.0  ± 4.2 
Glu/Asp + Asp/Asp 17 7.5 ± 4.7 
MUTYH (Gln335His)   
Gln/Gln 14 7.1 ± 5.3 
Gln/His 7 6.1 ± 1.7
 
His/His 4 11.9 ± 1.8*
 
Gln/His+His/His 11 8.2 ± 3.3 
Note. Asterisk indicates significant at p<0.001 compared to homozygous variant genotypes with 
heterozygous genotypes. 
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Table VI.3. Percent DNA in Tail (%Tail DNA) induced by GA in whole blood leukocytes 
from 25 healthy individuals considering different genotypes of genes involved in NER 
pathway. 
Genotypes N % Tail DNA ± SD 
ERCC2 (Lys751Gln)   
Lys/Lys 8 8.2± 4.2 
Lys/Gln 13 6.5 ± 3.5  
Gln/Gln 4 10.0 ± 7.5  
Lys/Gln+ Gln/Gln 17 7.3 ± 4.7  
ERCC1 (Gln504Lys)   
Gln/Gln 17 8.1 ± 4.9  
Gln/Lys 6 7.3 ± 2.9  
Lys/Lys 2 4.4 ± 5.9 
Gln/Lys + Lys/Lys 8 6.6 ± 3.6 
ERCC4 (Arg415Gln)   
Arg/Arg 20 7.1 ± 4.3 
Arg/Gln 3 10.8 ± 7.0 
Gln/Gln 2 7.6 ± 0.7 
Arg/Gln + Gln/Gln 5 9.5 ± 5.3 
ERCC5 (His1104Asp)   
His/His 15 7.9± 4.9 
His/Asp 9 7.2 ± 4.2 
Asp/Asp 1 5.5 
His/Asp + Asp/Asp 10 7.1 ± 4.0 
ERCC5 (Cys529Ser)   
Cys/Cys 24 7.4 ± 4.5 
Cys/Ser 1 10.9 
Ser/Ser 0  ----- 
ERCC6 (Arg1230Pro)   
Pro/Pro 22 7.3 ± 4.5 
Pro/Arg 3 9.6 ± 4.6 
Arg/Arg 0 ----- 
ERCC6 (Gln1413Arg)   
Arg/Arg 17 7.6 ± 4.4 
Arg/Gln 6 7.5 ± 5.9 
Gln/Gln 2 7.6 ± 0.7 
Arg/Gln + Gln/Gln 8 7.5 ± 5.0 
RAD23B (Ala249Val)   
Ala/Ala 19 7.1 ± 4.1 
Ala/Val 6 9.1± 5.6 
Val/Val 0 ----- 
XPC (Ala499Val)   
Ala/Ala 2 6.9 ± 4.3 
Ala/Val 10 6.6 ± 6.0 
Val/Val 13 8.4 ± 3.2 
Ala/Val + Val/Val   
XPC (Lys939Gln)   
Lys/Lys 11 7.4 ± 5.4 
Lys/Gln 12 8.0 ± 4.0 
Gln/Gln 2 6.2 ± 2.6 
Lys/Gln + Gln/Gln 14 7.8 ± 3.8 
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Table VI.4. Percent DNA in Tail (%Tail DNA) induced by GA in whole blood 
leukocytes from 25 healthy individuals considering different genotypes of genes 
involved in HRR pathway. 
Genotypes N % Tail DNA ± SD 
RAD51 (5’UTR)   
G/G 6 10.4 ± 5.7 
G/T 11 6.9 ± 4.7 
T/T 8 6.4 ± 2.3 
G/T + T/T 19 6.7 ± 3.8 
NBS (Glu185Gln)   
Glu/Glu 15 7.3 ± 4.6 
Glu/Gln 8 7.7 ± 5.0 
Gln/Gln 2 9.2 ± 1.8 
Glu/Gln + Gln/Gln 10 8.0 ± 4.5 
XRCC3 (Thr241Met)   
Thr/Thr 6 5.8 ± 3.7 
Thr/Met 13 7.9 ± 4.4 
Met/Met 6 8.6 ± 5.7 
Thr/Met + Met/Met 19 8.1 ± 4.7 
XRCC2 (Arg188His)   
Arg/Arg 22 7.0 ± 4.5 
Arg/His 3 11.6 ± 1.5 
His/His 0   ----- 
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Table VI.5. Percent DNA in Tail (%Tail DNA) induced by GA in whole blood 
leukocytes from 25 healthy individuals considering different genotypes of genes 
involved in NHEJ pathway. 
 Genotypes N % Tail DNA ± SD 
 XRCC4 Asn298Ser   
 Asn/Asn 17 8.4 ± 4.7 
 Asn/Ser 8 5.9 ± 3.6 
 Ser/Ser 0  ------ 
 XRCC4 Thr134Ile   
 Ile/Ile 24 7.8 ± 4.5 
 Ile/Thr 1 3.5  
 Thr/Thr 0  ----- 
 Lig4Thr9Ile   
 Thr/Thr 19 8.2 ± 4.7 
 Thr/Ile 6 5.7 ± 3.4 
 Ile/Ile 0  ------ 
 Ku80Ex21-238G>A   
 G/G 12 7.4 ± 4.2 
 G/A 8 6.6 ± 4.4 
 A/A 5 9.8 ± 5.5 
 G/A+A/A 13 7.8 ± 4.9 
 Ku80Ex21+338T>C   
 T/T 20 7.8 ± 4.6 
 T/C 4 6.7 ± 5.4 
 C/C 1 7.2  
 T/C+C/C 5 6.8 ± 4.6 
 Ku80Ex21-352C>A   
 C/C 20 7.8 ± 4.6 
 C/A 4 6.7 ± 5.4 
 A/A 1 7.2  
 C/A+A/A 5 6.8 ± 4.6 
 Ku80Ex21+466A>G   
 A/A 20 7.8 ± 4.7 
 A/G 5 6.8 ± 4.0 
 G/G 0  ----- 
 
 
 
Table VI.6. XRCC1 Gln399Arg and MUTYH Gln335His association and DNA damage 
 
 
 
XRCC1Gln399Arg / MUTYHGln335His 
 ArgArg+ArgGln/GlnGln+GlnHis ArgArg+ArgGln/HisHis* GlnGln/GlnGln+GlnHis** Gln/Gln/His/His 
%Tail DNA ±SD (n) 7.0 ± 4.5 (19) 11.9 ± 1.8 (4) 4.3 ± 1.2 (2) n.d. 
Note. Asterisk indicates significant difference at p=0.05 compared with ArgArg+ArgGln/GlnGln+GlnHis; Double asterisk indicates significant difference at 
p<0.05 compared with ArgArg+ArgGln/HisHis; n.d. non detected 
 
 
Table VI.7 XPC haplotypes and DNA damage 
 
 XPCAla499Val / XPCLys939Gln 
 AlaAla/LysLys AlaVal/LysLys AlaVal/LysGln* ValVal/LysLys ValVal/LysGln ValVal/GlnGln 
%Tail DNA ±SD (n) 6.9 ± 4.3 (2) 7.6 ± 6.2 (8) 2.8 ± 3.7 (2) 6.7 (1) 9.1 ± 3.3 (10) 6.2 ± 2.6 (2) 
Note Asterisk indicates significant difference at p<0.05 when compared AlaVal/LysGln with ValVal/LysGln 
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6.4. Discussion: 
 
Acrylamide is a public health concern in terms of cancer risk assessment 
justifying the need of reliable toxicological biomarkers. In this context, the comet assay 
is actually an emerging tool to properly assess primary DNA damage either in vitro or 
in vivo. Using this methodology, the in vitro genotoxic potential of AA and GA was 
characterized by the % DNA in Tail in peripheral blood leukocytes from healthy donors.  
Acrylamide 1-h exposure did not alter DNA damage at any concentration level 
tested up to 1 mM. Our results are in agreement with Baum et al [38], who also did not 
find AA genotoxicity in the comet assay with human blood cells at 1-4 h of incubation. 
In addition, Hansen et al. [39] reported an absence of AA-induced DNA damage up to 5 
mM in human peripheral PBL at 2 h. However, other studies with HepG2 [40, 41], V79 
cells and Caco-2 cells [9] detected significant increases in DNA damage but only at 
very high concentrations of AA (millimolar range). In contrast, Blasiak et al [42] 
showed significant DNA damage in isolated human lymphocytes exposed to AA at low 
concentrations, reinforcing the need for further evaluation of AA in human cells using 
different experimental conditions and protocols. In contrast to the use of isolated human 
lymphocytes, the present report was carried out using whole blood, an approach that can 
be considered more closely related to the physiological situation, since it takes into 
account the influence of other factors, such as red blood cells, platelets and plasma [43, 
44]. Another important feature when whole blood is used is that AA reacts with 
haemoglobin forming Hb adducts [2], rendering AA less available to a potential cellular 
damaging effect.  
There are convincing data showing that GA acts as the ultimate genotoxic agent 
in AA exposure. Our results using the comet assay revealed that GA indeed produced 
significant increases in terms of %Tail DNA, at concentrations starting from 250 µM. 
These results are in agreement with the data published by Baum et al [38] who observed 
that GA induced DNA damage for concentrations of 300 µM and highter. In addition, 
the results presented here are generally in accordance with other investigations that also 
found DNA damage for GA in the comet assay, although for higher GA concentrations 
(≥ 500 µM) in human lymphoblastoid TK6 cells [45] and isolated lymphocytes [39].  
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The results from our study also demonstrated that PBL from healthy donors 
respond differently in vitro to a given genotoxic concentration of GA. This is an 
important point that has not yet been fully addressed. The heterogeneity of the response 
observed in the comet assay using whole PBL from different donors may be in part 
attributed to individual genome sensitivity [46]. A plausible explanation for the 
interindividual variability noted herein may rely on individual genetic polymorphisms 
associated with detoxification and repair pathways that are likely to influence the levels 
of DNA damage after exposure to GA.  
With respect to the detoxification polymorphisms in GSTs and EPHX1 no 
relevant associations with GA-induced DNA damage were found. For a definitive 
conclusion further studies need to be performed using different endpoints of DNA 
damage, namely the induction of sister chromatid exchanges, which were shown to 
correlate with GA-DNA adducts [20]. 
The predominant adduct N7-GA-Gua is promutagenic since it might undergo 
spontaneous depurination [19, 47, 48]. The abasic site thus generated is likely to 
promote incorporation of deoxyadenosine during DNA replication, leading to G→T 
transversions [47]. DNA repair is therefore essential for the understanding of GA-
induced genotoxic effects, for which a number of different primary lesions are present, 
including GA adducts, abasic sites and DNA breaks [20, 49]. Johansson et al using 
DNA repair deficient cell lines, suggested that the repair of the lesions induced by GA 
involves BER (short patch) and HRR, but not NER [49].  
Concerning the BER pathway, MUTYH gene encodes a glycosylase involved in 
the repair of DNA damage resulting from the oxidation of guanine nucleotides. 
MUTYH protein can prevent transversions of a G:C base pair with a T:A base pair, 
resulting from the oxidation product of guanine that mispairs to adenine [50]. There is 
scarce information on the formation of reactive oxygen species by GA, although for AA 
some reports suggest the involvement of oxidative stress [40, 51]. Our results suggest 
that MUTYH (Gln335His) influences the genotoxicity induced by GA, since variant 
individuals presented higher levels of DNA damage. Further studies should be 
performed to clarify this point.  
XRCC1 has multiple roles in repairing DNA base damage and single-strand 
DNA breaks. Although XRCC1 does not have a known enzymatic activity, there is 
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evidence suggesting that it may act as a nucleating factor by bringing different BER 
components together at the site of action [52]. The importance of XRCC1 Gln399Arg 
polymorphism was previously identified in occupational studies using the comet assay. 
Studies performed with welders [53], and healthy Japanese workers [54] associated with 
higher DNA damage with XRCC1 variant allele. However, conflicting results have also 
been published (e.g. fruit growers exposed to pesticides) [55].  
Our results suggested a significant interaction between XRCC1 Gln399Arg and 
MUTYH Gln335His polymorphisms, as PBL from individuals with the haplotype 
ArgArg+ArgGln/HisHis were more prone to DNA damage than those with 
ArgArg+ArgGln/GlnGln+GlnHis and with GlnGln/GlnGln+GlnHis. In view of this 
MUTYH and XRCC1, seem to be involved in the genotoxicity induced by GA. Overall, 
our results emphasize that the BER pathway may be operative in the repair of lesions 
generated by GA. However, as a consequence of sample size, further confirmations 
need to be made in a larger population.  
Data presented here also suggest an association of global genome NER pathway, 
specifically XPC, and GA-induced DNA damage. XPC is involved in DNA damage 
recognition, and in DNA repair initiation. The binding of XPC to damaged DNA is the 
rate-limiting step for NER [56]. Several epidemiological studies have been carried out 
to evaluate the association of XPC polymorphisms with cancer risk at different organ 
sites and in diverse populations (reviewed in [56]). Further, a study performed by Wang 
et al [57] suggested that the polymorphisms of XPC genes might modulate the 
genotoxicity by PAH in coke oven workers. Our results suggest that XPC 
Ala499Val/Lys939Gln diplotype, might be associated with DNA damage induced by 
GA.  
Overall, this study shows that GA, but not AA, increases DNA damage as 
measured by the comet assay. Using this methodology, the interindividual variation 
observed in terms of GA-induced genotoxicity might be associated with polymorphic 
genes involved in BER and NER pathways. Further studies should be performed to 
reinforce these findings, including a larger number of individuals with different 
genotypes. Further, functional studies are required in order to understand the underlying 
mechanisms of the variability in the GA-induced DNA damage. 
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7.1. Concluding remarks and future prospects 
 
Acrylamide is a well-known industrial chemical classified as probable human 
carcinogen by IARC since 1994 [1] presented in stuff foods [2]. This carcinogen can be 
formed by Maillard reaction between primarily the amino acid asparagine and reducing 
sugars in food processing upon heating [3, 4]. Furthermore, AA can be found in 
commonly consumed foods and beverages, such as processed cereals, French fries, 
potato chips and coffee [2]. The average daily intake of AA was estimated to be about 
0.5-1.0 µg/Kg bw in adults and up to 2-fold in 13 year-old children with a normal 
western diet [2]. This has raised concerns about the positive health risks of AA for the 
general population, even more because AA is a known rodent carcinogen [5]. 
Furthermore, the association of the increased risk of human cancer with AA dietary 
consumption is still a matter of discussion [5, 6]. 
AA can be metabolized by cytochrome P450 (CYP2E1) to the genotoxic 
epoxide glycidamide (GA), the ultimate genotoxin. However, the mechanisms of 
genotoxicity of AA- and GA- dependent in mammalian cells are not yet fully 
understood. In view of this, the evaluation of DNA damage induced by these two 
compounds is of major importance. With this purpose, we resorted to the use of distinct 
assays: chromosomal aberrations (CAs), sister chromatid exchange (SCEs), 
quantification of DNA adducts and comet assay in V79 Chinese hamster cells and in 
human lymphocytes. 
V79 cells are a well established mammalian cell line widely used in cytotoxicity 
and genotoxicity studies. These cells are very important in present study as they do not 
express detectable levels of CYP2E1, the recognized cytochrome P450, responsible for 
AA epoxidation [7, 8]. These cells revealed to be an adequate model to properly address 
the mechanisms of genotoxicity by AA and GA. However, the use of human cells is 
obviously more suitable for human risk assessment, and also provides the possibility to 
address inter-individual variation in terms of DNA damage and the association with 
individual susceptibility. The use of human cells from whole blood samples was chosen 
in this work since it is considered to be more closely related to the physiological 
situation than isolated lymphocytes, including the influence of others factors, such as 
red blood cells, platelets and plasma [9]. 
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In view of that, the cytotoxicity of AA and GA in V79 cells, evaluated by the 
MTT reduction assay, was performed. The results showed that both AA and GA 
induced dose-dependent cell death, being GA clearly more cytotoxic than AA for all the 
concentrations studied, which is in agreement with data reported by others groups, using 
different cell survival end points [10, 11]. 
The clastogenicity of these compounds were then analyzed by CAs assay in V79 
cells. The results suggested that both AA and GA induced CAs, especially chromatid 
breaks and gaps. AA and GA increased the % ACEG mainly for the higher 
concentration studied (1000 and 2000 µM, for GA and AA, respectively). 
The genotoxicity of AA and GA were also analyzed by SCEs assay in V79 cells 
and in stimulated human lymphocytes. The results concerning SCE formation in V79 
cells clearly showed that GA consistently induced SCEs for concentrations above 10 
µM, increasing the background levels of SCEs by about 10-fold to levels of about 60 
SCE/cell for the highest concentration tested. On the other hand, for AA-exposed 
cultures, a significant increase in SCE/cell was observed only at a very high 
concentration level (2000 µM). The induction of SCE in lymphocytes revealed results 
that are in agreement with the previous one obtained in V79 cells, since the induction of 
SCEs by AA was slight and specially associated with the very high and cytotoxic 
concentration of 2000 µM and that GA markedly induced SCE in a dose-response 
manner (up to 750 µM). These results reinforce the knowledge that GA is far more 
genotoxic than AA and also highlight the high sensitivity of SCE to be used as a 
toxicological biomarker in an AA exposure scenario.  
The levels of N7-GA-Gua and N3-GA-Ade were also measured in V79 cells and 
in stimulated lymphocytes exposed to AA and GA. Data showed that AA exposure in 
V79 cells lead to very low levels of N7-GA-Gua, which were only observed for 
concentrations higher than 1000 µM. These low levels of N7-GA-Gua stemming from 
AA exposure might be related to either residual metabolism of AA in V79 cells or to a 
small extent of spontaneous nonenzymatic oxidation to GA, since V79 cells are 
essentially devoid of CYP2E1. On the other hand, GA showed to be a potent inducer of 
N7-GA-Gua with linear dose-response dependence. The detection of this adducts was 
observed for doses as low as 1 µM and 10 µM of GA, respectively in V79 cells and in 
lymphocytes. The second more frequent adduct, N3-GA-Ade was only detected at very 
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high GA concentrations precluding the interest of its quantification in human dietary 
studies. It is recognized that compounds that form DNA adducts are also strong SCEs 
inducers. Our results showed, in fact, a very strong correlation between the levels of 
N7-GA-Gua and SCE/cell for both cell types. This finding is very important in terms of 
the understanding of the mechanisms involved in DNA damage signaling and repair. 
These results suggested that the metabolism of AA to GA and the ensuing formation of 
depurinating DNA lesions [12, 13] are responsible for SCE induction. 
In view of these showed clearly differences between AA and GA genotoxicity, it 
seemed important to clarify the genotoxicity mechanisms induced by AA per se. The 
modulation of reduced glutathione (GSH) status could give additional insight into this 
matter, as GSH is a key factor for mammalian cells homeostasis, with diverse functions 
that include, among others, the conjugation of eletrophilic compounds, including AA 
and GA, and the detoxification of products generated by oxidative stress. For this 
purpose the cytotoxicity was analyzed by the MTT assay and clastogenicity evaluated 
by CAs. This study evaluated the effect of GSH modulators, including the evaluation of 
the effect of buthionine sulfoximine (BSO), of GSH-monoethyl ester (GSH-EE) and 
also of GSH endogenously added to culture medium in V79 cells. BSO treatment alone 
was associated with relatively low toxicity leading to a slight decrease in cell viability 
and a moderate increase in the frequency of ACEG. In order to evaluate the potential 
protective effect of GSH towards AA toxicity, the intracellular GSH enrichment was 
performed by pre-treatment with GSH-EE. The results obtained fail to show the 
protective effect of GSH-EE. Co-treatment with GSH exogenously added to the culture 
medium revealed a protective effect either in terms of cytotoxicity or clastogenicity 
induced by AA. This effect could be a consequence of the spontaneous conjugation of 
AA with GSH in the extracellular medium. In this sense, the evaluation of the potential 
conjugation of AA with GSH in the extracellular medium was performed. With this 
purpose, we studied in a set of cell free experiments the intensity of fluorescence of the 
conjugate GSH-monochorobimane (MCB), a fluorescent probe for GSH, after 
incubation of AA with GSH. These results showed that spontaneous conjugation of AA 
is favored when AA concentrations are higher than GSH concentrations and that 
spontaneous conjugation is clearly time-dependent (1-h incubation decreased the 
percentage of free GSH when compared with a 24-h incubation period). The results 
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presented here reinforce the role of GSH in the modulation of the cytotoxic and 
clastogenic effects induced by AA. 
The “single cell gel electrophoresis” or comet assay was also performed to study 
the genotoxicity of AA and GA in human cells. We compared the DNA damage 
potency of AA and its metabolite GA in the comet assay using human leukocytes 
(whole blood samples) and the results revealed that AA was not genotoxic up to 1000 
µM, while GA showed to significantly increase % Tail DNA at concentrations starting 
from 250 µM. 
Both SCE and comet assay showed some extent of inter-individual variability 
that could be related with different polymorphisms in detoxification and DNA repair 
genes. In view of this, the different donors were genotyped for detoxification (GSTM1, 
GSTT1, GSTP1, GSTA2 and EPHX1) and DNA repair genes involved in BER (APEX1, 
MUTYH, OGG1, PARP1, PARP4, and XRCC1), NER (ERCC1, ERCC2, ERCC4, 
ERCC5, ERCC6, RAD23B and XPC), HRR (NBS, RAD51, XRCC2 and XRCC3) and 
NHEJ (Ku80, Lig4 and XRCC4) pathways. These polymorphic genes were analyzed in 
order to find out possible associations between genotypes and GA-induced SCE 
frequency and % Tail DNA.  
By combining DNA damage, assessed by SCE assay, in GA-treated 
lymphocytes and polymorphisms data, associations between the induction of SCEs and 
GSTP1 (Ile105Val) and GSTA2 (Glu210Ala) genotypes are suggested, but not the other 
polymorphic genes associated with DNA repair pathways. Moreover, our results 
suggested associations between DNA damage, assessed by the alkaline comet assay, 
and polymorphisms of BER (MUTYH Gln335His and XRCC1 Gln399Arg) and NER 
(XPC Ala499Val) genes, either alone or in combination. Further studies should be 
performed in order to evaluate other polymorphisms and different combinations of 
polymorphisms. These future studies necessarily need larger population samples and 
will be important to reinforce these findings and understand the underlying mechanisms 
of variability in GA-induced DNA damage. 
The overall results showed that GA is far more genotoxic than AA in all the 
endpoints studied and in both types of cell models used. All biomarkers developed in 
the framework of this study revealed to be adequate to understand the mechanisms 
triggered upon AA or GA exposure. Nonetheless, the use of specific N7-GA-Gua a GA-
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DNA adduct revealed to be of utmost importance in terms of toxicological significance 
in view of the high sensitivity, being much relevant its quantification in cultured cells 
exposed to GA at concentrations as low as 1 µM. Taken together the results from this 
thesis strongly point out that GA, the epoxide metabolite of AA is the responsible for 
the genotoxic effects of AA. 
In the future it would be important to validate these results with a group of 
young Portuguese individuals, taking into account the amount of foodstuff consumed 
containing AA. This study is already being performed by us and shall evaluate the 
results obtained in a food frequency questionnaire and the basal levels of DNA damage 
in this group using the cytogenetic biomarkers (SCEs, CAs, comet assay and DNA-
adducts) validated in this work. 
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Resumo  
 
A acrilamida (AA) é um composto químico, utilizado principalmente como 
agente floculante no processo de depuração de água potável e tratamento de águas 
residuais urbanas e industriais, e como agente de controlo de fluxo em operações em 
poços de petróleo. Por outro lado, a AA é utilizada em engenharia civil, em fundações, 
como constituinte da argamassa utilizada na construção e reparação de esgotos, túneis e 
barragens. A AA é ainda utilizada na estabilização de solos, síntese de corantes, 
produção de materiais de embalagem, co-polímeros para lentes de contacto, cosméticos, 
e em muitos laboratórios de biologia molecular e engenharia genética na preparação de 
géis de electroforese. 
A AA foi classificada como potencial carcinogéneo para os humanos, pela IARC 
(International Agency for Research on Cancer), com base em resultados obtidos em 
estudos com animais. Estudos de carcinogenicidade em ratos mostraram que a AA 
aumenta o número de tumores em diferentes órgãos, incluindo a glândula mamária. Foi 
também demostrado que a AA é neurotóxica em humanos e em experiências com 
animais, e que apresenta propriedades mutagénicas em células somáticas e germinais. A 
AA absorvida pode ser oxidada ao seu metabolito epóxido glicidamida (GA) através do 
citocromo P450 2E1, podendo ambas, AA e GA, ser conjugadas com o glutationo 
reduzido (GSH), originando conjugados de ácido mercaptúrico, que serão eliminados 
pela urina. A GA, por sua vez, pode também ser conjugada com a epóxide hidrolase, 
originando a gliceramida. Tanto a AA como a GA podem ligar-se a macromoléculas, 
tais como a hemoglobina e o DNA originando aductos específicos. Estes aductos podem 
ser usados como biomarcadores de dose efetiva de exposição à AA e GA.  
Durante a década de 90 pensava-se que o homem estava exposto à AA apenas 
através da exposição ocupacional, e também apenas em pequenas quantidades através 
do consumo de água potável refinada com poliacrilamida, ou ainda pela inalação do 
fumo de tabaco. No entanto, alguns estudos verificaram a existência de níveis elevados 
de aductos de AA-hemoglobina em indivíduos não expostos, o que provocou uma forte 
preocupação em termos de risco para a saúde humana, principalmente porque foram 
descobertos níveis relativamente elevados de AA em diversos alimentos ricos em amido 
quando sujeitos a elevado tratamento térmico. Os referidos produtos alimentares, além 
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de serem consumidos em larga escala, são especialmente consumidos por crianças e 
jovens, sendo que nos mesmos se incluem por exemplo as batatas fritas, “snacks”, 
cereais de pequeno-almoço, bolachas e café, tendo sido estimado que a dose total diária 
de AA ingerida por adulto tendo como base uma dieta ocidental normal, se encontra na 
ordem dos 1 µg/Kg por peso corporal, podendo ser 2 a 3 vezes superior em crianças e 
adolescentes.  
Desde 2002 as investigações sobre a presença de AA nos alimentos, e as 
possíveis consequências para a saúde pública têm-se sucedido e vários progressos têm 
sido alcançados. No entanto, até à data os resultados são escassos tendo em conta os 
mecanismos de genotoxicidade da AA e GA. Por esse motivo, o objectivo desta tese 
centra-se na avaliação das consequências genéticas da exposição à AA e GA, 
recorrendo ao uso de linhas celulares e de linfócitos humanos. 
Neste estudo procedeu-se inicialmente à avaliação da citotoxicidade e das lesões 
de DNA induzidas pela AA e GA em células de hamster Chinês V79, uma linha celular 
deficiente em CYP2E1, de modo a prevenir a conversão de AA a GA (Capítulo3). Para 
avaliar a citoxicidade recorreu-se ao ensaio do MTT para concentrações compreendidas 
entre 0.1 e 10 mM. A AA mostrou ser menos citotóxica do que a GA para todas as 
concentrações testadas, apresentando baixos níveis de sobrevivência (<5%) para 
concentrações elevadas de GA (≥ 4mM) e de AA (10 mM). 
De modo a avaliar a genotoxicidade e a clastogenicidade da AA e GA em 
células de mamífero, recorreu-se à utilização de dois testes citogenéticos diferentes: o 
teste das aberrações cromossómicas (CAs), e o teste da troca de cromátides irmãs 
(SCEs). Os resultados obtidos no teste das CAs em células V79, mostraram claramente 
que tanto a AA como a GA, são compostos clastogénicos induzindo a formação de 
aberrações cromossómicas, com uma dependência dose-resposta, especialmente 
observada para as concentrações mais elevadas (1000 µM e 2000 µM). No entanto, para 
concentrações equimolares a GA mostrou ser mais clastogénica do que a AA. Através 
dos resultados obtidos no teste da troca de cromátides irmãs, na mesma linha celular, 
pode-se afirmar que a GA é um potente indutor de SCEs para concentrações igual ou 
superiores a 10 µM, com uma clara relação dose-resposta, aumentando a frequência 
basal de troca de cromátides irmãs em cerca de 10 vezes, para níveis de 
aproximadamente 60 SCE/célula para a concentração mais elevada (1000 µM). Em 
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contrapartida, a AA demonstrou ser um fraco indutor de SCEs, observando-se apenas 
um aumento no nível de lesão para a concentração mais elevada (2000 µM). Os 
resultados no geral, para todas as doses testadas, mostraram que a GA é mais citotóxica 
e clastogénica do que a AA em células V79. Este estudo demonstrou também a elevada 
sensibilidade do ensaio da troca de cromátides irmãs, de modo a poder ser utilizado 
como biomarcador toxicológico no caso de um cenário de exposição à AA. 
No âmbito desta tese efetuou-se também a quantificação de aductos específicos 
de DNA, nomeadamente N7-(2-carbamoil-2-hidroxietil)guanina (N7-GA-Gua) e N3-(2-
carbamoil-2-hidroxietil)adenina (N3-GA-Ade) em células V79. Os resultados 
mostraram que a exposição à AA origina níveis muito baixos de aductos N7-GA-Gua, 
os quais foram apenas observados para concentrações superiores a 1000 µM. Estes 
baixos níveis de aductos que são provenientes da exposição à AA devem estar 
relacionados com a oxidação não enzimática espontânea da AA a GA, uma vez que as 
células V79 são deficientes em CYP2E1. No entanto, a GA mostrou ser um potente 
indutor de N7-GA-Gua, apresentando uma dose-resposta linear, sendo a detecção deste 
aducto observada para concentrações tão baixas como 1 µM. O segundo aducto mais 
frequente, N3-GA-Ade foi apenas detectado para concentrações muito elevadas de GA, 
limitando o seu interesse em estudos sobre dieta humana. Adicionalmente, observou-se 
que as concentrações de GA e os níveis de N7-GA-Gua apresentam uma relação dose-
resposta linear. Obteve-se também uma óptima correlação entre os níveis de N7-GA-
Gua e o nível de SCE/célula (r=0.987; p=1.25x10
-12
). 
Durante este trabalho procurou-se também compreender os mecanismos da 
genotoxicidade induzida pela AA. Para tal estudaram-se os mecanismos de modulação 
do glutationo reduzido (GSH), o qual possui vários papéis importantes nas células de 
mamífero, incluindo a conjugação com compostos electrofílicos e a destoxificação de 
produtos obtidos por stress oxidativo. Deste modo, foram efetuados ensaios onde se 
averiguou o efeito da deplecção intracelular de GSH (pré-incubação com butionina 
sulfoximina, BSO), o efeito do enriquecimento intracelular com GSH (pré-incubação 
com GSH-monoetil estér, GSH-EE) e o papel do GSH adicionado extracelularmente 
(através da co-incubação com GSH) em células V79 (Capítulo 4). Com este objectivo, 
avaliaram-se diferentes parâmetros, tais como a citotoxicidade (ensaio do MTT) e a 
clastogenicidade (ensaio das ACs). Nos ensaios das células V79 expostas a AA e com 
pré-incubação com BSO, verificou-se um decréscimo na viabilidade celular e um 
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aumento na fequência das aberrações cromossómicas excluindo gaps (ACEG). Por 
outro lado, através da pré-incubação com GSH-EE não se verificaram alterações 
significativas na percentagem de sobrevivência das células V79 expostas à AA, nem na 
frequência de ACEG. Por fim, no co-tratamento com GSH adicionado exogenamente ao 
meio de cultura, verificou-se um efeito protectivo tanto em termos de viabilidade celular 
quer em termos de clastogenicidade induzidas pela AA. Este efeito pode ser 
consequência da conjugação expontânea da AA com GSH no meio extracelular. Deste 
modo, foi posteriormente avaliado o potencial de conjugação da AA com o GSH com 
base no teste da fluorescência do monoclorobimano (MCB), uma sonda fluorescente 
que se liga ao GSH. Os resultados mostraram que a conjugação expontênea da AA é 
favorecida quando existem concentrações superiores de AA em relação ao GSH e que 
esta conjugação expontânea é claramente dependente do tempo de exposição (1h de 
exposição diminuiu a percentagem de GSH livre quando comparado com o período de 
24h de exposição). Globalmente, os resultados obtidos reforçaram o papel do GSH na 
modulação da citotoxicidade e clastogenicidade induzidas pela AA. 
Apesar do uso das células V79 ser adequado como modelo para inferir sobre a 
genotoxicidade induzida pela AA e GA, o passo seguinte deste trabalho envolveu o 
estudo em células humanas. A utilização deste tipo de células é obviamente mais 
adequado para a avaliação de risco, permitindo também a possibilidade de investigar a 
variabilidade individual em termos de lesão de DNA, e a sua correlação com a 
susceptibilidade de cada individuo. Para tal recorreu-se à colheita de sangue periférico 
de dadores saudáveis, não sujeitos a medicação e não fumadores. Os dadores foram 
devidamente informados sobre o âmbito do estudo, e um consentimento informado foi 
assinado pelos mesmos, antes de se ter procedido ao início dos trabalhos. Cumprirá 
também salientar o facto de ter sido obtida uma aprovação do estudo pelo Comité de 
Ética da Faculdade de Ciências Médicas da Universidade Nova de Lisboa. No referido 
estudo recorreu-se ao uso de células humanas provenientes de sangue total, uma vez que 
é considerado ser mais aproximado da situação fisiológica do que o uso de linfócitos 
isolados, pois tem em conta a influência de outros factores, tais como glóbulos 
vermelhos, plaquetas e plasma.  
Deste modo, linfócitos estimulados com fitohemaglutinina foram expostos a 
diferentes concentrações de AA e GA e as lesões de DNA quantificadas através do 
ensaio das SCEs e dos níveis de aductos de DNA (Capítulo 5). A partir destes estudos e 
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em relação ao ensaio das SCEs, observou-se mais uma vez que a GA é muito mais 
genotóxica do que a AA, aumentando a GA o nível de SCEs em cerca de 10 vezes, 
quando comparada com o controlo, o que está de acordo com os resultados previamente 
obtidos com células V79. Por outro lado, a AA só induziu SCE para a concentração 
mais elevada (2000 µM). Do mesmo modo, a quantificação de aductos de DNA, 
nomeadamente N7-GA-Gua e N3-GA-Ade, efectuados em linfócitos estimulados, 
originaram resultados coerentes com os obtidos em células V79. Os resultados obtidos 
mostram uma dose-resposta linear entre os níveis de N7-GA-Gua e as concentrações de 
GA estudadas (até 750 µM), tendo sido este aducto detectado para a menor dose 
estudada (10 µM). O aducto (N7-GA-Gua) determinado em linfócitos expostos à GA 
apresentou uma correlação directa entre os níveis de aductos e a frequência de SCEs, tal 
como anteriormente já se tinha verificado em células V79. 
Por outro lado, foi também avaliado o potencial de lesão do DNA da AA e GA 
em leucócitos humanos, recorrendo-se à técnica do ensaio do cometa alcalino (Capítulo 
6). Os resultados mostraram que a GA aumentou significativamente a % de DNA na 
cauda do cometa, para concentrações superiores a 250 µM, enquanto a AA não 
provocou lesões de DNA significativas para as concentrações estudadas (até 1000 µM). 
Com base nas curvas dose-resposta obtidas para o ensaio das SCEs e do cometa 
alcalino, a concentração de 250 µM de GA foi escolhida para ser posteriormente 
utilizada em ensaios com vários indivíduos, tanto no que diz respeito às SCEs (13 
indivíduos) como ao ensaio do cometa (25 individuos). Ambos os ensaios mostraram 
alguma variabilidade inter-individual que poderá estar relacionada com os diferentes 
polimorfismos envolvidos na destoxificação e nas vias de reparação de DNA.  
Deste modo, o presente estudo teve também como objectivo a identificação de 
possíveis associações entre as lesões de DNA induzidas pela AA e GA quantificadas 
através dos ensaios das SCEs e do ensaio do cometa, e biomarcadores de 
susceptibilidade, considerando os polimorfismos genéticos individuais envolvidos nas 
vias de destoxificação (GSTM1, GSTT1, GSTP1, GSTA2 e EPHX1), e nas vias de 
reparação de DNA (Capítulo 5 e 6). No que diz respeito à reparação de DNA, foram 
estudados diferentes genes envolvidos na via de reparação por excisão de bases (BER), 
tais como APEX1, MUTYH, OGG1, PARP1, PARP4, e XRCC1, na reparação por 
excisão de nucleótidos (NER), tais como ERCC1, ERCC2, ERCC4, ERCC5, ERCC6, 
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RAD23B e XPC, na via de reparação por recombinação homóloga (HRR), tais como 
NBS, RAD51, XRCC2 e XRCC3, e na via de reparação por recombinação não homóloga 
(NHEJ), tais como Ku80, Lig4 e XRCC4.  
O nível de lesão de DNA determinado pela frequência de SCEs induzidas pela 
GA, aponta para uma modulação pelos polimorfismos do GSTP1 (Ile105Val) e do 
GSTA2 (Glu210Ala), mas não por outros polimorfismos associados com as vias de 
reparação de DNA. Por outro lado, os resultados obtidos com base no ensaio do cometa 
alcalino sugerem associações entre as lesões de DNA e polimorfismos da via BER 
(MUTYH Gln335His e XRCC1 Gln39Arg) e da via NER (XPC Ala499val e 
Lys939Gln), considerando os genes isoladamente ou combinados. No entanto, mais 
estudos devem ser efetuados contemplando uma maior amostragem de indivíduos 
saudáveis de modo a consolidar os resultados obtidos e compreender os mecanismos 
envolvidos nas diferenças individuais de resposta a genotóxicos. 
Os resultados globais mostraram que a GA é de facto mais genotóxica do que a 
AA, tendo como referência todos os ensaios efectuados bem como os vários tipos de 
células estudadas. Adicionalmente, todos os resultados apontam fortemente para que a 
GA, o metabolito epóxido da AA, seja o principal responsável pelos efeitos genotóxicos 
da AA. É de salientar também, que apesar dos vários tipos de ensaios utilizados neste 
trabalho terem demonstrado ser adequados para a compreensão dos mecanismos 
envolvidos na exposição à AA e GA, a quantificação de aductos de DNA por exposição 
à GA, nomeadamente N7-GA-Gua, mostrou ser aquele que revela maior robustez em 
termos de avaliação toxicológica devido à sua elevada sensibilidade. Assim sendo, este 
biomarcador de dose-efectiva pode e deve ser usado em estudos epidemiológicos em 
complementaridade com os questionários de frequência alimentar. Adicionalmente este 
trabalho permitiu tirar conclusões acerca da variabilidade da susceptibilidade individual 
relativa à destoxificação e reparação das lesões de DNA provocadas pela exposição a 
estes xenobióticos alimentares. 
 
